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INTRODUCTION 
Skin is the barrier that protects the body against infection and dehydration. After a skin injury, 
wound healing process rapidly occurs to restore the skin integrity. Healing requires a well-
orchestrated integration of biological events that lead to tissue repair. Wound healing is 
characterized by four overlapping phases: coagulation, inflammation, migration/proliferation 
and remodeling. In tissues with preexisting pathophysiological abnormalities such as chronic 
wounds, parts of the wound can be stuck in different phases as their progression does not 
occur in synchrony.1  
Cutaneous chronic wounds are characterized by the absence of healing six weeks after 
the injury. More than 6 million persons in the United States are affected by these pathologies; 
in France they are 1.5 million.2 The most prevalent cutaneous chronic wounds are venous, 
diabetic foot ulcers (Figure 1) and bedsores. The number of affected persons is expected to 
increase in the next years as the European population ages and more people develop diabetes 
related to overweight and obesity.3  
 
Figure 1. Diabetic foot ulcers are characterized by impaired wound healing of skin.  This 
sometimes leads to infection and leg amputation. It is a major complication of diabetes 
mellitus because they occur in 15% of all patients with diabetes. 
 
To correct impaired wound healing, it is necessary to treat the underlying disease. 
Meanwhile, the local treatment of the wound is crucial to prevent infection, to control the 
removal of exudates and to create the right environment to allow for skin wound healing. The 
classical treatment is the debridement of the wound bed to remove necrotic tissue.4 This 
procedure is followed by the wound compression with sterile gauze.5 Another technique is the 
negative wound pressure therapy. Sometimes, these techniques are not effective enough and 
require the application of a wound dressing.  
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Initially wound dressings had a passive and protective role in the healing process. 
Further on, bioactive dressings consisting of cellularized scaffolds were designed as skin 
substitutes. A typical example is the Apligraf® dressing, consisting of collagen matrices 
associated with living fibroblasts and keratinocytes (Figure 2).6 These cells produce a panel 
of growth factors that can promote tissue repair. Nowadays research orientation is towards 
medicated dressings based on the integration of active biomolecules within scaffolds in 
order to tune cell phenotype towards migration, differentiation or modulation of 
inflammation. First efforts in this direction were done using proteins as therapeutic 
molecules.7 However, despite the effort in the development of drug delivery systems, protein 
therapies suffer from high cost, rapid diffusion and degradation of biomolecules. Gene 
therapy represents a promising alternative as it overcomes the concerns about the protein 
stability and affords a sustained delivery of biomolecules.8 Gene delivery into cells makes 
them produce therapeutics molecules that can act locally, limiting possible side effects.9  
 
 
 
 
Figure 2: The Apligraf® skin substitute used in the treatment of diabetic foot ulcers associate 
a matrix, made of collagen with fibroblasts and keratinocytes cells.  
 
Success of gene delivery depends on the development of an efficient delivery vector 
that permits the penetration of genes into the cells as well as their protection against 
endosomal degradation. Viruses are the most efficient vectors to transfect cells but they suffer 
from safety concerns such as immunogenicity or oncogenicity.10 Among the non-viral 
vectors, polyethyleneimine (PEI) has attracted a lot of interest as it is able to compact large 
DNA sequences, permits DNA penetration into cells thanks to its positive charge and is able 
to escape from the endosome.11 However, as its transfection efficiency and cytotoxicity are 
strongly correlated, efforts have been made to explore the possibility of tuning PEI properties 
by chemical modification12 or complexation with nanoparticles13 to shield its positive charge.  
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In this context, silica nanoparticles (SiNPs) possess several attractive characteristics 
such as suitable cytocompatibility, large surface area, tunable size/shape and versatile 
bioconjugation chemistry14 making them ideal drug delivery vehicles15 and gene transfection 
agents.16 Nevertheless, bare SiNPs, being plain or mesoporous, cannot be used alone as gene 
carriers as they bear a negative charge near neutral pH and are unable to compact DNA, 
thereby preventing its internalization. Hence conjugation of these particles with PEI appears 
as a promising method to design nanoscale hybrid gene carriers.17 
In this context, the present work aimed at designing novel medicated dressings 
allowing for the production of biomolecules favoring cutaneous wound repair within 
collagen scaffolds. Our strategy has relied on the use of PEI-conjugated silica 
nanoparticles as gene carriers to transfect fibroblasts cells immobilized with the 
scaffolds (Figure 3).  
Figure 3: Schematic overview of the project 
 
In the following pages, we first provide a literature survey of the biomedical and 
biological contexts of our work, introduce the main concepts and strategies of gene therapy 
and give the reader an overview of the past and current developments related to silica 
nanoparticles as drug delivery systems (Chapter I). 
We then describe our study of PEI-coated silica particles as vectors of a model 
plasmid to transfect 3T3 fibroblast cells first in 2D cultures and then in various 3D 
configurations (Chapter II). 
The encouraging outcome of this study led to us to explore further the transfection 
properties of PEI-SiNPs systems, by modifying the conjugation mode of the polymer on the 
silica surface. The ability of these hybrid nanocarriers to transfect human primary fibroblast 
and keratinocytes was also studied (Chapter III). 
!"#$%
&'($)%
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Finally, first attempts were made to use PEI-coated silica nanoparticles for the 
expression of the anti-inflammatory interleukin-10 protein by 3T3 cells and the inhibition of 
TNF-αa expression in macrophages (Chapter IV) 
A conclusion section gathers our main results, enlightening our contribution to the 
understanding of the mechanisms of gene transfection as mediated by silica nanoparticles, and 
provides some perspectives in the different fields relevant to this work.  
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CHAPITRE I 
Rappels bibliographiques 
 
Résumé 
Cette introduction bibliographique vise à rassembler l’état de l’art dans les trois grands 
domaines couverts par ce travail de thèse : les plaies chroniques de peau, la thérapie génique 
et les nanoparticules de silice comme vecteurs thérapeutiques. Dans une première partie, nous 
rappelons les évènements impliqués dans la cicatrisation des plaies cutanées et décrivons les 
phénomènes à l’origine des plaies chroniques. Le rôle particulier joué par les macrophages 
d’une part, et l’interleukin-10 (IL-10) d’autre part dans les processus de réparation cutanée est 
souligné. Les différents traitements actuellement utilisés ou à l’étude pour favoriser la 
cicatrisation sont ensuite présentés, mettant en lumière l’intérêt du développement actuel de 
pansements médicamenteux. Une deuxième partie est consacrée à la thérapie génique. Après 
une présentation des différentes formes de gènes thérapeutiques, la distinction entre vecteurs 
viraux et non-viraux est introduite et les défis rencontrés dans l’utilisation de ces derniers sont 
présentés. Le principe de matrices tri-dimensionnelles promouvant la transfection est enfin 
exposé. La dernière partie de ce chapitre offre un panorama des progrès réalisés ces dernières 
années dans la synthèse et la fonctionalisation de nanoparticules de silice à visée médicale, 
avec une attention particulière à leur application dans la délivrance de gène. La possibilité 
d’associer ces particules avec un polymère naturel biocompatible, le collagène, pour obtenir 
des biomatériaux nanocomposites est finalement présentée.  
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I-1. CHRONIC WOUNDS - A FAILURE TO HEAL 
I-1-1. Structure of human skin 
 
Figure I-1: Structure of the skin2 
The skin constitutes the largest organ in the body and possesses multiple functions in daily 
life. It not only acts as the barrier to hazardous substances but also plays indispensible roles in 
physical protection, temperature regulating, immune response, and sensory detection.  
Skin is composed with three layers: the epidermis, dermis and subcutaneous layer (Figure 
I-1). The epidermal barrier layer is ~ 0.1–0.2 mm in depth and tightly attached to the 
underlying dermis by a specialized basement membrane zone, consisting of several different 
types of collagen and laminin 5. This tissue is a stratified epithelium composed of several 
layers of keratinocytes (at least four). Some epidermal stem cells are present in the basal layer 
located on the basement membrane. They are responsible for the renewal of the epidermis by 
the generation of a differentiated cell and another stem cell. New cells continually move 
towards the surface while they are differentiating. They gradually die and become flattened 
and then die. Dead cells form the stratum corneum, an impermeable squamous epithelium. 
This layer gives properties of resistance against bacterial infection and prevents fluid and 
electrolyte loss.3 Other types of cells are found in the epidermis such as Langerhans cells or 
melanocytes. Langerhans cells belong to the immune system and act as antigen-presenting 
cells. Melanocytes synthesize melanin, molecule involved in the cutaneous photoprotection 
The dermis is a dense connective tissue which gives skin resistance and elasticity. This 
well-vascularized tissue feeds the epidermis by nutrient diffusion. Those blood vessels 
provide nourishment and waste removal for both dermal and epidermal cells. Some epidermal 
annexes are inserted dermis such as hair follicles, sweat glands and sebaceous glands. The 
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dermis also contains receptors for touch, temperature and pain. It varies in thickness 
depending on its site in the body (1-4 mm). The dermis consists of an extracellular matrix 
(ECM) in which several kinds of cells are encapsulated. Structural components of the 
extracellular matrix are collagen (type I, III and V), elastin, fibronectin, hyaluronic acid and 
proteoglycans. Furthermore, the ECM also mediates cell-matrix adhesion and transducer 
signals into cells.4 In addition, hair follicles, sweat glands, sebaceous glands, apocrine glands, 
lymphatic vessels and blood vessels are present in the dermis. Those blood vessels provide 
nourishment and waste removal for both dermal and epidermal cells. The dermis is composed 
of three major types of cells: fibroblasts, macrophages, and adipocytes (energy storing cells). 
Fibroblasts are the main type of cells of this tissue because they synthesize the whole 
macromolecules forming ECM and they continuously communicate with epidermis via 
soluble factors. Together with macrophages, they play important roles in wound healing, 
which will be described in detail in the following subsection.  
I-1-2. Process of wound healing 
I-1-2-1. Acute wounds 
Wound healing is a complex process that involves the simultaneous actuation of soluble 
mediators (i.e. growth factors and cytokines/chemokines), blood cells, ECM and parenchymal 
cells (Figure I-2). This process can be divided into several phases: homeostasis/inflammation, 
proliferation, and remodeling.6 These phases are not associated with specific period of time 
and may overlap:  
(i) Haemostasis and Inflammatory Phase (day 1-3) 
Immediately after an injury, the inflammatory and haemostasis phase occur to stop bleeding 
and combat the infection. First, a fibrin clot is formed around aggregated platelets in order to 
reestablish haemostasis (Figure I-2a). This clot serves as a temporary shield protecting the 
injured tissue and provides a matrix over and through which cells can migrate. Meanwhile, 
aggregated platelets secrete a wide range of mediators such as platelet-derived growth factor 
(PDGF) and TNF-β that recruit neutrophils and monocytes to the wound site, which then 
secrete proteinases and reactive oxygen species (ROS) to kill microorganism and clean up cell 
debris by phagocytosis. Other cells such as mastocytes migrate to the wound site, secrete 
histamine, thereby promoting inflammation. Two days after the injury neutrophils are 
progressively replaced by macrophages. These cells activated from monocytes, act as 
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biological bins as they digest cellular debris. They play a part in the early stage of wound 
healing by the expression of colony-stimulating factor (CSF), VEGF, TGF-β and PDGF. 
These mediators moderate the transition between the initial phase of inflammation and tissue 
repair. These cytokines play a role in cell migration, proliferation and ECM production. 
 
 
Figure I-2: The different phases of skin wound repair5 
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 (ii) Proliferation Phase (day 2-10) 
This phase consists of neoangiogenesis, granulation tissue formation, ECM deposition and re-
epithelialisation (Figure I-2b).139 After the destruction of the cutaneous tissue, the initial 
migration of keratinocytes operates from the wound borders and the hair follicles. They 
migrate on the fibrin clot made of fibrin and fibronectin and then proliferate, differentiate to 
form a novel epidermis.140 Re-epithelialization is favoured by the secretion of fibroblastic 
growth factors such as Keratinocyte Growth Factors (KGF) and Fibroblasts Growth Factor – 
10 (FGF-10).  
Fibroblasts begin to migrate into the wound by around day 3 after the injury, marking the 
start proliferation phase. The angiogenic factors, such as fibroblast growth factor (FGF), 
VEGF and PDGF induce angiogenesis by stimulating the production of basic fibroblast. The 
neovascularization arises in the wound by the end of the first week, and continue to grow until 
the wound is healed. In addition, growth factors released by platelets and secreted by 
macrophages during the first phase of healing have been sequestered in the provisional 
matrix. Thus these growth factors stimulate cells as they move into the wound. Fibroblasts 
start proliferating and secrete ECM macromolecules in the fibrin clot to form the granulation 
tissue. They mainly synthesize collagen III at this stage. After their migration, fibroblasts 
progressively differentiate into myofibroblasts. With this pro-fibrotic phenotype, they acquire 
contractile capabilities and biosynthetic activities with the aim of replacing the damaged 
tissue. At the end of the proliferative phase, the wound is closed thanks to the contraction by 
myofibroblasts. When the wound area is completely filled with new granulation tissue, 
angiogenesis stops and the apoptosis of many new vessels is then started.  
 (iii) Remodelling Phase  (several months) 
The last phase is characterized by the degradation of the previously formed granulation tissue 
and by dermis regeneration (Figure I-2c). Matrix formation requires the removal of 
granulation tissue with revascularization. A framework of collagen and elastin fibers replaces 
the granulation tissue. This framework is then saturated with proteoglycans and glycoproteins. 
This is followed by tissue remodeling involving the synthesis of new collagen mediated by 
TGF-β. Collagen remodeling during the transition from granulation tissue to scar is dependent 
on continued synthesis and catabolism of collagen. The degradation of collagen in the wound 
is controlled by several matrix metalloproteinases secreted by macrophages, epidermal cells, 
and endothelial cells, as well as fibroblasts. The final product of this phase is scar tissue. 
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Main sources and functions of cytokines and growth factors involved in wound healing are 
summarized in Table I-1. 
Name Sources Target Function 
EGF Platelets, Macrophages Fibroblasts Keratinocytes Re-epithelialization 
FGF-2 
Keratinocytes 
Mast Cells, Fibroblasts 
Endothelial cells 
Smooth muscle cells 
Chondrocytes 
Keratinocytes 
Fibroblasts 
Endothelial cell 
Granulation tissue formation 
Re-epithelialization 
Matrix formation and remodeling 
TGF-β 
Platelets, Keratinocytes 
Macrophages, Lymphocytes 
Fibroblasts 
Platelets, Keratinocytes 
Macrophages, Fibroblasts, 
Leukocytes,  
Endothelial cells, ECM 
Inflammation 
Granulation tissue formation 
Re-epithelialization 
Matrix formation and remodeling 
TNF-α Neutrophils Macrophages 
Epidermal, mesenchymal 
cells 
Inflammation 
Re-epithelialization 
PDGF 
Platelets, Keratinocytes 
Macrophages, Fibroblasts 
Endothelial cells 
Leukocytes, Macrophages, 
Fibroblasts 
Inflammation 
Granulation tissue formation 
Reepithelialization 
Matrix formation and remodeling 
VEGF 
Platelets, Neutrophils 
Macrophages, Fibroblast 
Endothelial cells 
Smooth muscle cells 
Endothelial cells, 
macrophages Granulation tissue formation 
IL-1 
Neutrophils 
Monocytes 
Macrophages 
Keratinocytes 
Endothelial cells, 
Macrophages, Leukocytes, 
Fibroblasts Keratinocytes, 
Inflammation 
Reepithelialization 
IL-6 Neutrophils Macrophages 
Endothelial cells, 
Macrophages, 
Kerotinocytes,Leukocytes 
Inflammation 
Reepithelialization 
IL-10 Leukocytes Leukocytes Anti-inflamamtion 
Table I-1: Cytokines and growth factors involved in wound healing7 
I-1-2-2. Chronic wounds 
Chronic skin ulcers are wounds that have failed to progress through the normal healing stages 
and enter a state of chronic and pathological inflammation.141 While acute wounds usually 
progress linearly through the different healing phases, chronic wounds do not follow this 
timeline, but are locked in one of the above-mentioned healing phases (Figure I-3)8.  
The most prevalent chronic wounds in the developed world are venous leg ulcers and 
diabetic foot ulcers. Venous leg ulcers (VLUs) result from hypertension or sustained 
ambulatory venous pressures as a consequence of a chronic venous insufficiency.142,143 
Hypertension leads to an infiltration of leukocytes into the dermis, which is responsible for 
inflammation.144 Diabetic foot ulcers are consequences of neuropathy or/and vascular disease 
related to diabetes.145 The major complications of chronic ulcers are microbiological 
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contamination and malignant transformation.146,147  In the case of FDUs, bacteriological 
infection can lead to gangrene and eventually leg amputation.148 Indeed, bacteria colonizing 
the wound produce a biofilm composed of a wide variety of polysaccharides, which is 
impervious to phagocytic cells and impermeable to antibiotics.10 Frustrated phagocytes 
release a plethora of proteases and toxic oxygen radials into the wound milieu making a bad 
situation worse as these agents destroy tissue cells, extracellular matrix, and growth factors in 
the wound. 
 
Figure 1-3: Acute wound and chronic wound undergoes different processes8 
 
The large amount of proteases and presence of reactive oxygen species, both produced 
by inflammatory cells is the main characteristic of chronic wounds. The presence of proteases 
in dermis leads to fibroblast senescence, poor vascularization and keratinocytes apoptosis. As 
a consequence, the protective barrier constituted by the epidermis is disrupted. As 
keratinocytes at the wound edge are unable to migrate into the wound bed, re-epithelialization 
is inhibited and wound closure impossible. Lastly, non-healing skin wounds are characterized 
by poor vascularization, with disturbance in blood vessel formation within the wound.149  Not 
surprisingly, such chronic wounds lack ingrowth of granulation tissue 
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I-1-3. Macrophages, target cells for chronic wounds treatment 
I-1-3-1. Role of macrophages in cutaneous wounds 
The macrophage is a prominent inflammatory cell in wounds, but its role in healing 
remains incompletely understood.11 Macrophages have various functions in wounds, 
including host defense, promotion/ resolution of inflammation, removal of apoptotic cells and 
necrotic tissues, support of cell proliferation and tissue restoration. The specific activities of 
macrophages concerning these functions in wound healing are summarized in Table 1-2.  
Although macrophages are beneficial for the repair of normal wounds, this pleotropic 
cell type may promote excessive inflammation or fibrosis under certain circumstances. 
Emerging evidence suggests that macrophage dysfunction is a component of the pathogenesis 
of non-healing and poorly healing wounds.12 Consequently, the macrophage is widely deemed 
as an attractive therapeutic target, both to reduce fibrosis and scarring, and to improve healing 
of chronic wounds. 
Wound healing process Activities of Macrophages  
Phagocytosis ROS, NO 
Debridement Collagenase, elastase 
Cell recruitment and activation 
Growth factors: PDGF, TGF, EGF, IGF 
Cytokines: TNF-α, IL-1, IL-6 
Fibronectin 
Matrix synthesis 
Growth factors: TGF, EGF, PDGF 
Cytokines: TNF-α, IL-1, IFN 
Enzymes: arginase, collagenase 
Prostaglandins 
NO 
Angiogenesis 
Growth factors: FGF, VEGF 
Cytokines: TNF 
NO 
Table I-2: Activities of macrophages in wound healing processes 
 
I-1-3-2. Recruitment and residence of macrophages 
Leukocytes (including monocytes, neutrophils, mast cells, etc) are present during each of the 
phases of wound repair, represented in Figure I-4, as haemostasis (yellow panel), early 
inflammation (light pink panel), late inflammation (dark pink panel) and resolution/ 
remodelling (blue panel). Specially, macrophages differentiated from monocytes, are first 
recruited by factors such as split products from coagulation cascade (e.g. degredaded ECM 
molecules), factors released from platelet degranulation and activated complement 
components. Later, much more macrophages infiltrate in response to chemotactic gradients in 
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the wound during inflammation phase.13 Finally, low numbers of resident macrophages are 
present during the lengthy remodeling phase whereas neutrophils and lymphocytes disappear. 
 
 
Figure I-4: Pattern of leukocyte infiltration into wounds11 
I-1-3-3. Plasticity of macrophages in wound healing 
Macrophages exist in different phenotypic states during wound healing process and can 
change their phenotype in response to environmental cues (Figure 1-5). Recent studies 
suggest the influence of these cells on each stage of repair varies with the specific phenotype. 
Macrophages are considered to have two phenotypes, namely M1 and M2 type. Recently, 
Mosser et al. came up a third phenotype- wound healing macrophages, which arise in 
response to IL-4.12  
(i) Classically activated macrophages (M1 type) arise in response to interferon-γ 
(IFNγ), which can be produced T helper 1 (TH1) cells, CD8+ T cells (not shown) and natural 
killer (NK) cells. In addition, TNF, produced by antigen-presenting cells (APCs) can also 
activate macrophages to M1. Moreover, in wound site, PDGF (released by platelets due to 
tissue damage) and bacteria (main component LPS shown in Figure 1-5B) will also lead to 
the transformation of tissue macrophages to M1 phenotype.150 
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Figure I-5: The macrophages activated by endogeneous factors (A) and exogeneous factors 
(B) 12 
(ii) Wound-healing (alternatively activated) macrophages arise in response to interleukin-4 
(IL-4) or interleukin-13 (IL-13), which can be produced during an adaptive immune response 
by TH2 cells or during an innate immune response by granulocytes. 
(iii) Regulatory macrophages (namely M2 type) are generated in response to various stimulis, 
including immune complexes, prostaglandins, G-protein coupled receptor (GPCR) 
ligands,glucocorticoids, apoptotic cells or IL-10. Their hallmark is the production of large 
quantities of IL-10, which inhibits the inflammatory hallmark is the production of large 
quantities of IL-10, which inhibits the inflammatory response. 
Each of these three populations has a distinct physiology. Classically activated macrophages 
have microbicidal activity, whereas regulatory macrophages produce high levels of IL-10 to 
suppress immune responses.  
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I-1-4. The IL-10 anti-inflammatory cytokine 
I-1-4-1. Production and function of IL-10 
As introduced above, macrophages play a key role in wound healing and they can be 
damaging if the response is excessive. Interleukin 10 (IL-10) is a cytokine that promotes 
macrophages toward an anti-inflammatory state (M2 phenotype) and therefore promotes 
wound healing.14 A good understanding in its molecular event about its production and 
functions will help better design of new strategies of wound treatment.  
IL-10 is produced by many cells of the innate and adaptive immune response, including 
macrophages, dendritic cells, B cells, and T cells.15 It plays a crucial role in preventing 
inflammatory and autoimmune pathologies. More specifically, it regulates and represses the 
expression of pro-inflammatory cytokines produced by innate cells such as macrophages and 
dendritic cells during the recovery phase of infections and reduces the tissue damage caused 
by these cytokines. Specially, IL-10 has multiple modulating effects on the macrophage 
population including the suppression of pro-inflammatory cytokines, and the promotion of 
macrophages towards the wound healing M2 phenotype. As demonstrated before, the shift in 
the balance from M1 to M2 populations is postulated to be essential since it occurs in tissues 
that undergo wound healing. 
IL-10 stimulation promotes arginase-1 expression in macrophages that suppresses pro-
inflammatory mediators by shunting metabolic pathways away from the production of nitric 
oxide (NO). Arginase-1 expressing macrophages have also been shown to suppress T-cell 
responses causing inflammation and fibrosis as well as producing components of the ECM. In 
addition to arginase-1 expression, M2 macrophages also express the mannose receptor, 
CD206, which has been used in conjunction with arginase-1 as a marker to identify M2 
macrophage subtypes. The mannose receptor facilitates phagocytosis of mannose N-linked 
glycoproteins that are found on a variety of microorganisms. Promoting IL-10 following 
tissue injury at strategically defined locations may therefore offer targeted therapeutic benefits 
by capitalizing on its inflammatory suppressing/ wound healing potential.  
I-1-4-2. IL-10 delivery as an anti-inflammation therapeutic strategy 
The bioactive half-life of IL-10 is dependent on the cellular microenvironment and ranges 
from minutes to hours in vivo. To date, investigations of IL-10 have been carried out using 
direct administration of the IL-10 protein or peptide fragmentswhich remains biologically 
 24 
active for a restricted period of up to 2.5 h in vivo. Efforts have been devoted to extending the 
bioavailability and bioactivity of IL-10.  
One strategy is to immobilize IL-10 to polymeric scaffolds for sustained release to 
neighboring tissues. In some cases, IL-10 is covalent bonded to the matrix to manipulate a 
cell population towards a wound healing (M2) phenotype in spatially confined regions and 
therefore offer novel and practical therapeutic approaches to promote wound healing. 16 Gene 
therapy represents an alternative to protein therapy as “fresh IL-10” could be continuously 
produced via cell transfection. Studies combing gene delivery and polymeric scaffold to 
improve efficacy17 and achieve long-term release18 of IL-10 to modulate inflammation have 
also been recently reported. 
I-1-5. Cutaneous wound treatment 
I-1-5-1. Treatment strategies 
 
Figure I-7: Global cutaneous wound care market in 2013 (http://www.mediligence.com) 
The classical treatment of chronic skin ulcers consists at first in a surgical debridment to 
remove necrotic tissue and exudates followed by a bandaging method to compress the wound. 
As shown in Figure I-7, this type of treatment accounts for almost half of current wound care 
market (45.6%). When wound healing is unsuccessful, different strategies have been 
evaluated to enhance and speed up wound closure. Protein therapy based on growth factors 
such as PDGF (Platelet Derived Growth Factor) and TGF-β1 (Transforming Growth Factor) 
takes up only 3.4% due to their instability in vitro and short half-life in vivo. Cell therapy is 
another effective treatment, however, the preparation and storage are challenging to current 
technological conditions.  
New and recent alternatives to conventional dressings have been developed to guarantee 
an optimal wound environment. In the following part, these dressings are introduced as non-
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medicated dressing and medicated dressing. As impaired wound healing such as Diabetic 
Foot Ulcers (DFU) involves multiple biochemical deficiencies19, a singular treatment 
modality is unlikely to be effective. Combination of different strategies is thus urgent to 
address the complex underlying pathology. 
I-1-5-2. Protein therapy 
As introduced before, the process of wound healing is driven by numerous cellular mediators, 
including eicosanoids, cytokines, nitric oxide, and various growth factors. The field of 
biologic wound products aims to accelerate healing by modulating these inflammatory 
mediators. So far, Granulocyte/macrophage colony-stimulating factor (GM-SCF), PDGF-BB, 
VEGF and bFGF are the most extensively studied proteins for wound treatment, especially 
for non-healing wounds.20 
Cytokines include chemokines, lymphokines, monokines, interleukins, colony-
stimulating factors, and interferons. These molecules regulate inflammation by influencing 
hematopoietic cells. GM-CSF has been most extensively studied, which can stimulate 
neutrophils, macrophages, keratinocytes, and fibroblasts and increase VEGF production, 
rendering it a very promising molecule in wound healing. There have been encouraging 
results in a prospective randomized control study involving patients with venous ulcers21, as 
well as studies on diabetic-foot ulcers22. Interleukins are still in preliminary studies, yet they 
have displayed positive effects in wound healing. For example, IL-19 has been found to be 
effective for wound closure by increasing fibroblast keratinocyte growth factor expression23. 
IL-10 has been intensively studied as a strong general inhibitor of immune response and 
inflammation.14 
Growth factors stimulate mainly fibroblasts and keratinocytes via transmembrane 
glycoproteins and are so far the most intensive studied and applied protein product in wound 
treatment. They are divided into five superfamilies, the most known being PDGF. 
Recombinant PDGF was studied in a series of 118 patients with DFUs by Steed and co-
workers.24 Patients were treated with rhPDGF or placebo for up to 20 weeks in randomized 
double-blind study. The rhPDGF group showed a significantly higher percentage of patients 
that achieved wound healing, 48% versus 25%, as well as a greater reduction in wound size. 
This study has led to FDA approval of rhPDGF for diabetic ulcers, which is now known as 
becaplermin (Regranex®). Additional studies have confirmed increased odds of wound 
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healing and decreased rates of amputation in diabetic foot ulcers, as well as accelerated 
wound healing in abdominal wound separation and irradiated wounds.  
Despite the effort in the development of drug delivery systems, protein therapies suffer 
from high cost, rapid diffusion, and degradation. For example, after intravenous injection, the 
half-life of basic fibroblast growth factor (bFGF) is 3 min and that of vascular endothelial 
growth factor (VEGF) is 50min. Instabilities of these proteins may also lead to the formation 
of immunogenic degradation products.25 A more promising approach is based on the 
integration of the bioactive proteins within a scaffold for long-term delivery. Such medicated 
dressings are introduced in the next section.  
I-1-5-3. Wound dressings 
Wound dressings can be made from natural (chitosan, hyaluronic acid, cellulose, alginate, 
collagen, fibrin) or synthetic (PVA, PEG, PVP, PU, PHEMA, poly(esters)) materials and 
processed in the form of films, foams, hydrocolloids and hydrogels. In general, wound 
dressings should provide a moist microenvironment, offer protection from further infections, 
remove wound exudates and promote tissue regeneration. To have a better efficacy, it is 
promising to integrate of active biomolecules (e.g. antibiotics, growth factors, cytokines) 
within dressings to tune cell phenotype toward migration, differentiation, or modulation of 
inflammation. Recent studies and commercial products are summarized based on material 
resources in Table I-3. 
(i) Non-medicated dressing: 
Hydrocolloids: they are composed with a semi-permeable film (for water and oxygen) and a 
layer of hydrophilic particles that usually made of proteins or polysaccharides. Hydrocolloids 
can absorb wound exudates and provide a moisted environment. They can be applied to 
granulating, epithelializing, and necrotic wounds, but can’t be used in case of severe 
infections because of macerates.  
Hydrogels: they are composed with hydrated polymers (> 20 wt %) and water. Advantages of 
hydrogels lie in flexibility, non-antigenicity and permeability to water, oxygen and 
metabolites. Therefore, they can maintain high level of moisture and promote wound 
debridement. Poor mechanical behavior is the main drawback of hydrogel-based dressings. 
Foams: foams are highly absorbent, cushioning, and protective to the wound site. As they 
don’t promote tissue repair and can be only used in the first stages of wound healing. 
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Films: Films are durable, easy to manipulate, adhesive, semipermeable to oxygen and water 
and impermeable to liquid and bacterias. Therefore, they can only use as protective dressings 
when there are few exudates present. 
(ii) Medicated dressings 
Dressings loaded with antimicrobials/antibiotics (to challenge biofilm formation in the wound 
site), platelet-derived substances, growth factors and peptides act to balance the biochemical 
events of inflammation in the chronic wound and to improve healing. These medicated 
dressing have therapeutic effects on the wounds and therefore release profile should be well 
tuned to fit the application purposes. Stability and burst releases of bioactive molecules are the 
main obstacles and sustained release over one week is often desirable to avoid frequent 
administration. In some cases, novel drug delivery system at micro- or nano-scale, including 
liposomes, polymeric or inorganic nanoparticles are integrated into the dressing scaffold to 
improve drug stability and release kinetics.  
The release of antibiotics can be controlled by swelling or degradable properties of the 
scaffold and in many cases the drug is released by diffusion. This problem of burst release is 
often solved by hydrophobic coatings on the dressing surface to inhibit drug diffusion. Fine 
tuning the physical (e.g. mechanical strength, porosity, degradation rate) and chemical (e.g. 
polymer modification, cross-linking) properties are proved to achieve desired drug release. 
Interestingly, pH-responsive polymers offer possibility for intelligent release due to the basic 
microenvironment of serious infections. More recently, the incorporation of nanoparticles into 
the scaffold has also emerged as a solution for sustained drug release.  
As introduced before, direct injection of therapeutic proteins (growth factors, cytokines) 
suffers from short effective time in vivo. Sophisticated delivery systems allowing long-term 
stability, controlled release and even multiple deliveries of proteins with independent release 
profile have been developed to favor wound healing. Proteins can be covalent or non-covalent 
bonded to the scaffold for immobilization. Moreover, the incorporation of growth factors 
during scaffold fabrication was found to have more controlled delivery kinetics.  
Novel methods for more efficient delivery involve micro- or nanotechnology in materials 
design. Proteins can be loaded in micro- or nanoparticles to improve stability and modify 
protein release profile. The incorporated micro- or nanoparticles also have the potential to 
improve mechanical strength of the scaffold.  
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Undergoing research Polymers  
Matrix Bioactive components 
Commercial 
dressing 
Chitosan-PEO nanofiber mat Ciprofloxacin Hydrochloride 
Moxifloxacin hydrochloride26 
Chitosan nanofibers Honey27 
Chitosan-crosslinked collagen aFGF28 
Chitosan and 
derivatives 
 
Chitosan, alginate and poly(r-
glutamic acid) hydrogel 
No therapeutics added29 
Kytocel® Gelling 
fiber dressing  
HA nanocapsule Polyhexanide30 
HA scaffold Autologous fibroblasts31 
Crosslinked HA fibrous 
membrane 
No therapeutics added32 
Cross-linked high/low Mw of 
HA foam 
Arginine and EGF33 
Hyaluronic acid(HA) 
and derivative 
HA gel (Vulcamin) Mixture of amino acids34 
Bionect® 
Cellulose dressing Silver nanoparticles35 
Collagen-oxidized 
regenerated cellulose foam 
No therapeutics added36 
Cellulose and 
derivatives 
 
Microbial-derived cellulose 
hydrogel 
Polyhexamethylasebiguanide37 
Regranex®Gel 
Aquacel® 
 
Alginate hydrogel ZnCO338 
Alginate gel coated with 
chitosan 
rhodamine B39 
Alginate 
Alginate hydrogel Phenytoin40 
MediHoney® 
Sorbalgon® 
Koltostat® 
TegadermTM high 
gelling 
Gelatin microspheres bFGF41 
Geltin-PLGA scaffold EGF42 
Concentrated collagen Ampicillin43 
Collagen sponge Model plasmid encoding for 
luciferase44 
Collagen matrix Glucose oxidase45 
Collagen/Gelatin 
Collagen-gelatin foam bFGF46  
Unite®Biomatrix 
BGC Matrix® 
Promogran® 
Prisma®Dermocol
/AgTM 
Fibracol® 
Fibrin scaffold  VEGF/bFGF-loaded PLGA 
nanoparticles 47  
Fibrin  
PEGylated fibrin gel Chitosan microspheres loaded 
with silver48 
Tisseel® 
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 Fibrin gel CD 34+ cells49  
Fibroin film Aloe vera extract50 Silk fibroin 
Fibroin fiber Silver51 
 
Dextran fibers Thrombin or antibiotics52 Dextran 
Dextran hydrogel No therapeutics added53 
 
Elastin film silver54 
Elastin-like peptides gel KGF55 
Elastin 
Elatin-silk fibroin scaffold No therapeutics added56 
 
Aminated-PVA hydrogel NO57 PVA 
Aminophenylboronic acid 
with PVA 
Ciprofloxacin58 
 
PCL-PEG copolymer rhEGF59 
PEG-PCL nanofibers EGF and bFGF60 
PEGylated fibers Rha FGF61 
PEG 
PEG PEI-Plasmid encoding bFGF 62 
 
PVP fibers Indomethacin63 PVP 
Poly (Vinyl methyl ether co-
maleic anhydride) and PVP 
NO64 
 
PHEMA PHEMA hydrogel NO65  
PLGA  film TiO2 nanoparticles66 
PCL nanofibers Curcumin67 
PLGA nanoparticles rhEGF68 
Poly (α-esters) 
PLA fibers bFGF69 
 
Table 1-3: Wound dressings in lab research and in the market 
I-1-5-4. Cell therapies 
 
Figure 1-8: Current strategies of cell therapies for wound repair 
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Wound healing requires the integration of cell migration and proliferation as well as 
extracellular matrix deposition, angiogenesis, and remodeling. Therefore, cell therapies is also 
widely applied in wound treatment, particularly in cases where host cells, due to disease, age, 
or excessive trauma, are unable to repair the defect or deficiency alone. Direct injection and 
fusion cell suspension has been proved unsuccessful.61 Current bioengineered skin substitutes, 
both biosynthetic skin substitutes and cultured autologous engineered skin, are available to 
provide temporary or permanent coverage, with the advantages of availability in large 
quantities and negligible risk of infection or immunologic issues. The main limitation of these 
products is high expense and storage conditions to preserve cell viability (generally at -80oC 
in liquid nitrogen). 
Apligraf® is composed of an epidermal layer of allogeneic neonatal keratinocytes and 
fibroblasts from neonatal foreskin. The cells are deposed on bilayered type I bovine collagen 
that is used as an adjunct covering to autograft, providing accelerated healing times. It is also 
used alone in chronic wound ulcers, showing decreased healing times when compared to 
controls. However, the chance of successful skin repair is less than 50%. In addition, 
Apligraf® has several drawbacks such as low resistance against degradation by proteases and 
weak persistence of fibroblasts within the normal collagen hydrogels. Recent studies on 
engineered hydrogels mimicking the extracellular matrix have provided significant insights 
into the designs of cell delivery systems. The matrix environment should provide directional 
cues to the transplanted cells in terms of adhesive ligands, integrin specificity, and a carefully 
engineered growth factor microenvironment. Future research is heading for dynamic or 
triggered changes in bioactivity, as well as multiple growth factor delivery for synergistic 
effects in directing cell fate for successful tissue repair.70 
 
I-2. GENE THERAPY – AN ALTERNATIVE STRATEGY FOR TISSUE 
ENGINEERING  
I-2-1. Introduction 
Gene therapy is the intentional modulation of gene expression in specific cells to treat 
pathological conditions. The European Medicines Agency (EMA) defines that a gene therapy 
medicinal product is a biological product which fulfils the following two characteristics: (a) it 
contains an active substance which contains or consists of a recombinant nucleic acid used in 
or administered to human beings with a view to regulating, repairing, replacing, adding or 
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deleting a genetic sequence; (b) its therapeutic, prophylactic or diagnostic effect relates 
directly to the recombinant nucleic acid sequence it contains, or to the product of genetic 
expression of this sequence.  
 
Figure I-9: Graphical presentation of different indications that have been addressed by gene 
therapy in clinical trials (n=2145), 2015, The Journal of Gene Medicine, Wiley and Sons 
(http://www.abedia.com/wiley/index.html) 
Since the first gene therapy trials in 1970s, two decades has seen more than 1700 
approved clinical trials worldwide. Although gene therapy was first conceived for genetic 
disorders, it has found broader applications for the treatment of severe diseases, with cancers 
being the major interest (64.2%), followed by infectious diseases (8%) and monogenic 
diseases (9.2%) (Figure I-9). Generally, gene therapy can be categorized into two categories- 
germ line gene therapy and somatic gene therapy. The difference between these two 
approaches is that in somatic gene therapy genetic material is inserted in some target cells, but 
the change is not passed along to the next generation, whereas in germ line gene therapy the 
therapeutic or modified gene will be passed on to the next generation. This difference is of 
importance, since current legislation allows gene therapy only on somatic cells71, which will 
be also the focus of this section.  
I-2-2.Therapeutic genes 
The concept to use genes as drugs for the treatment of human diseases was fist conceived 
around 1970s, owing to the fast growing knowledge in gene function and advancement of 
technologies for DNA delivery into mammalian cells. Plasmid DNA is most commonly found 
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in bacteria as small (compared with chromosomal DNA), circular, double-stranded DNA 
molecules. When specific sequences encoding for therapeutic proteins (e.g. growth factors, 
cytokines) is inserted into the plasmid, this artificial plasmid can be used as vectors in 
molecular cloning, driving the expression of recombinant DNA sequences within host 
organisms. Progress in molecular biology has led to the availability of other therapeutic genes 
and shorter nucleic acid sequences, in particular anti-sense oligonucleotides (AS-ODN) and 
small interfering RNA (siRNA). Nevertheless, these molecules with relatively large size and 
negative charge can not penetrate the cell membrane efficiently and are also susceptible to 
degradation by nucleases, particularly the single stranded AS-ODN. Consequently, the 
delivery of these macromolecules should be mediated by carriers and vectors. DNA and 
oligonucleotides must be transported into the nucleus, while RNA (siRNA, miRNA and 
mRNA) act in the cytoplasm at the level of protein synthesis, as shown in Figure I-10. 
New generation of therapeutic genes provides more precise way to repair disease-
causing genes is needed.1 mRNA and DNA encoding gene editing systems including 
sequence-specific zinc-finger nuclease (ZFPs), TALEs (transcription activator-like effector 
nuclease) and CRISPR–Cas (clustered regularly interspaced short palindromic repeat) 
systems can carry out precise gene correction and insertion in genome. Therefore, this 
strategy offers great potential for personalized medicine. 
In brief, although substantial progress has been made in gene therapy over the past three 
decades (Table I-4), DNA-based drugs are faced with greater delivery and safety challenges 
than other nucleic acid therapeutics owing to their large molecular sizes, the difficulty 
crossing the nuclear barrier and the risk of mutagenesis. In this regard, further clinical 
progress is needed to bring insights into the key steps limiting effective delivery and 
structure–function relationships for vector design. Generally speaking, gene delivery vectors 
are classified into viral and non-viral vectors. Their applications in clinical trials are shown in 
Figure I-11 and introduced in details in the following subsections. 
 
 
 
 
 
 
Figure 1-10 : Gene delivery processes 
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Figure I-10. Overview of the gene delivery process ; Table I-4. Different categories of 
therapeutic genes 
 
 
 
Figure I-11: Graphical presentation of different vectors that have been addressed by gene 
therapy in clinical trials (n=2206), 2015, The Journal of Gene Medicine, Wiley and Sons 
(http://www.abedia.com/wiley/index.html) 
Types Characteristics Function site 
DNA  Double stranded, 
Several kbps, 
Upgrade target protein 
expression 
Nucleus  
mRNA Single-stranded, 
Alternative to DNA,  
Reduced immunogenicity 
Cytoplasm, 
Ribosome 
siRNA Double-stranded, 
Chemically synthesized, 
19–21 bp in length, Downgrade 
target protein expression 
Cytoplasm, 
RNA-induced 
silencing 
complex 
miRNA Similar to siRNA, 
Endogenously synthesized, 
18–25 nucleotides in length,  
Promote mRNA degradation 
and/or translational inhibition 
Cytoplasm, 
RNA-induced 
silencing 
complex 
AS- 
ODN 
single-stranded DNA molecules, 
13-25 nucleotides in length, 
Promote mRNA degradation 
and/or translational inhibition 
Cytoplasm 
Gene 
editing 
system 
mRNA or DNA encoding ZFPs, 
TALEs, CRISPR-Cas 
Nucleus 
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I-2-3. Viral vectors- a natural system 
Viral vectors are so far the most efficient vectors for gene delivery, adopted by 66.6% of 
current clinical trials for gene therapy (Figure 1-11). Adenoviral (AV), retroviral/lentiviral 
(RV/LV), and adeno-associated viral (AAV) vectors are the major ones used in gene therapy 
(Figure I-12). They are generally below 100 nm and AAV with the size of 20 nm is the 
smallest viral vector. Despite their remarkable transduction efficiency, both clinical trials and 
laboratory experiments have suggested that viral vectors have inherent shortcomings for gene 
therapy, including limited loading capacity, immunogenicity, genotoxicity, and failure to 
support long-term adequate transgenic expression. In order to learn the mechanisms of high 
transfection from the natural system, this subsection will only cover the intracellular process 
of viral vectors and strategies to overcome the disadvantages mentioned above. 
 
Figure I-12: Main viral vectors for gene delivery and their load capacity (liposome adopted 
here as typical non-viral vector for comparison) 72 
Viral vectors usually consist of viral capsids and viral genome. When considering for 
gene delivery, the virus have to undergo several modifications and meet some prerequisites.73 
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First, most genes encoding for viral proteins, especially pathogenic ones, should be removed 
from viral genome. Meanwhile, sequences of the viral genomes required for viral replication 
should be maintained. Expression of viral proteins required for viral replication within the 
virus-producing cells (called packaging cells) should also be kept. Finally, the therapeutic 
gene cassette could be inserted into the viral genome to replace the native genes by 
recombination or introduced into the viral vector as episomal genes. 
In general, viral vectors fall into one of the main categories: integrating vectors (e.g. 
gamma-RV, LV), which insert themselves into the recipient’s genome, while non-integrating 
vectors (e.g. AV, AAV) usually form an extra chromosomal genetic element. Integrating 
vectors, such as gamma-retroviral vectors and lentiviral vectors, are generally used to 
transfect actively dividing cells, as they are stably inherited. Non-integrating vectors, such as 
adenoviral vectors and adeno-associated virus (AAV) vectors, can be used to transfect 
quiescent or slowly dividing cells, but they are quickly lost from cells that divide rapidly. 
There are two mechanisms for cellular uptake of viral vectors. AV (binding with coxsackie 
and adenovirus receptor, CAR) and AAV (binding with heparansulphate proteoglycan, 
HSPG) can bind specific receptors on cell membrane and then enter the cellular cytoplasm via 
clathrin-mediated endocytosis. Genome is then transported to the nucleus through the nuclear 
pore, where the association of the AdV genome with nuclear matrix initiates the transcription. 
For RV/LV, membrane fusion is the main mechanism whereby enveloped viruses deliver 
their genomes into cells. 
 
Figure I-13: Viral vectors engineering to reduce toxicity and immunogenicity74 
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Many modification strategies have been implemented for all three vector types as shown 
in Figure above (Figure I-13) with the goal to reduce the side effect of viral system. To start 
with, viral vector with high transfection as well as high toxicity can be pseudotyped with an 
envelope protein (EP) from a different virus with lower toxicity (Figure I-13A). More 
sophisticated hybrid viral vectors have recently been developed and reviewed in details by 
Huang et al.75  
An alternative strategy relies on modification virus with target ligand. On the one hand, 
viral vectors can be coupled with a receptor-ligand fusion (Figure 1-13B). Adaptors are 
molecules with dual specificities: one end binds the viral attachment protein and the other 
binds the receptor on the target cell. The advantages of this approach are its great flexibility, 
as different adaptors can readily be coupled to the same vector, and the fact that it does not 
require changes in vector structure that could be detrimental to vector production or gene 
transfer. On the other hand, this could be achieved by genetic fusion of a targeting ligand 
(Figure 1-13C). Despite being more technically challenging than the use of adaptors, such 
single component systems provide homogenous retargeted vector particles, unlike adaptor-
based approaches. Muench and co-workers modified the capsid of AAV with ligands specific 
for Her2/neu, EpCAM or CD4 receptors that are expressed on tumor cells.76 Vector targeted 
to the tumour antigen Her2/neu was sufficient to track 75% of all tumour sites. CD4-targeted 
AAVs hit human CD4-positive cells present in spleen of a humanized mouse model, while 
other off-target organs remained unmodified. EpCAM-AAV detected single tumour cells in 
human blood opening the avenue for tumour stem cell tracking. Thus, ligand engineered viral 
vectors could deliver genes to target cell types of choice with high specificity. 
To end with, the virus are naturally optimized in essential processes for gene delivery, 
including targeting of specific receptors (e.g. CAR for AV, HSPG for AAV), internalization, 
delivering of nucleic acids to nucleus and, in some cases, permanent modification of the host 
cell genome. Imitating some of these features will contribute to progress in the field towards 
broader and more successful gene therapy. 
I-2-4. Non-viral vectors - learning from nature 
To overcome the limitations of viral systems, namely limited load capacity and toxicity, a 
variety of vectors have been developed to deliver therapeutic nucleic acids to their site of 
actions, including lipids and liposomes, polymers (linear and branched polymers, dendrimers 
and polysaccharides), polymersomes, cell-penetrating peptides77 and inorganic nanoparticles. 
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These synthetic vectors have lower immunogenicity, higher load capacity and easy 
fabrications. Specifically, nucleic acids can be delivered through physical encapsulation or 
electrostatic attraction. Among the non-viral systems, cationic vectors occupy the 
overwhelming percentage, taking advantage of the high charge density to compact and protect 
therapeutic genes.  
I-2-4-1. Barriers to non-viral gene delivery 
 
Figure I-14: Extracellular and intracellular barriers for non-viral gene delivery 
 
(i) Stability 
The presence of endo-nucleases in physiological fluids and extracellular space pose threat on 
the stability of therapeutic genes (Figure I-14). Thus, the vectors should allow the nucleic 
acids from degradation and elimination by RES system. 
(ii) Cellular uptake 
Cell internalization of DNA complexes is generally size-dependent. For exemple, polyplexes 
be internalized by cells via multiple mechanisms, including clathrin-mediated endocytosis 
(CME, for endocytic vesicles with a size of ~100–150 nm), caveolae-mediated endocytosis 
(~50–80 nm), micropinocytosis (~90 nm) and macropinocytosis (~500–2000 nm). Surface 
charge and ligand conjugation are another two factors affecting cellular uptake. Positive 
charge can strengthen the affinity DNA complexes with cell membrane and therefore 
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facilitate internalization. Modificaiton with ligand that can bind specific receptors on cell 
membrane can also lead to higher cellular uptake. 
(iii) Endosomal escape 
When DNA complexes are internalized by phagocytosis or endocytosis, they will be 
sequestered in a membrane-bound vacuole, which is subsequently acidified and fused with a 
lysosome containing acid hydrolases. Therefore, some mechanism must be included to allow 
the nucleic acid to escape from the endosome before it is degraded. 
In case of lipoplexes, a model for local endosomal membrane destabilization was 
proposed for smooth escape from endosomes (Figure I-15, left panel). Specifically, 
electrostatic interactions between cationic lipids and endosomal membrane induce the 
replacement of anionic lipids from the cytoplasm–facing monolayer of the endosomal 
membrane, by means of the so-called flip-flop mechanism. The formation of a neutral ion pair 
between anionic lipids present in the endosomal membrane and the cationic lipids of the 
vector will then result in decomplexation of the DNA and its release into the cytoplasm. 
Moreover, the neutrally charged helper lipid will facilitate membrane fusion and help 
destabilize endosomal membrane. 
The most popular although challenged hypothesis for endosomal escapes of polyplexes 
is the so-called “proton sponge” effect78 (Figure 1-15, right panel). The core of this theory is 
that different amines on polymer chains can be further protonated inside endolysosomes, 
leading to an influx of counter ions (Cl−) and an increase of osmotic pressure inside so that 
the endolysosomes are finally burst. Recently, conjugation of endosome disruptive peptides to 
polyplexes79 and co-administration with week base (e.g. chloroquine) become other options 
for their capacity to induce endosomal escapes.  
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Figure I-15: Hypothesis of endosomal escape of lipoplexes and polyplexes gene delivery 
systems.80 
(iv) Vector unpacking 
This process is widely assumed to be indispensible for gene expression, but the extent and the 
timing effect on transfection efficiency remains unclear. In some studies, vectors have high 
capacity to complex DNA were found to have low transfection efficiency, indicating the 
unpacking is somewhere indispensible for gene expression. 
 
I-2-4-2. Lipid-based systems 
Lipid-based DNA vectors accounts for more than 1/3 of all non-viral vectors applied in 
clinical trials (Figure I-11). The concept of “lipofection” was advanced by Felgner et al.81 
Small liposomes, formed from DOPE and DOTMA (available as Lipofectamine®), were 
mixed with DNA and the resulting “lipoplexes” were able to condense the linear and plasmid 
DNA into a complex. Many other cationic lipids have been developed, including DOTAP, 
DOGS, DC-cholesterol (Figure I-16a). These lipids are usually mixed with a “helper” lipid, 
such as DOPE or cholesterol that improves their stability and overall transfection efficiency. 
The net positive charge of the complexes is probably responsible for their high toxicity and 
also promotes the adsorption of plasma protein that leads to their rapid elimination.  
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Figure 1-16. Chemical structures of cationic and neutral lipids (a) and selected polymeric 
vectors (b) that are commonly used in gene delivery studies and clinical trials. 
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The surface therefore is modified by the addition of anionic lipids or by the inclusion of 
PEGylated lipids. 
To increase the circulation half-life of liposomal nucleic acids, they should have a near-
neutral surface charge (Figure I-17) Two approaches have been used to achieve this: the 
formation of coated cationic liposomes (Figure D-F) and the use of ionizable lipids. Ligands 
are needed for specific binding and internalization (Figure G). Efficient endosomal release 
following internalization is needed for therapeutic activity, and this can be provided by 
ionizable cationic lipids with optimized bilayer destabilizing capacities and pKa. Lee and co-
workers have newly reported a PCR-based nanofactory mediated with neutral lipid as a 
potential gene delivery system (Figure H).82 Plasmid DNA can be amplified by PCR inside 
liposomes about 200 nm in diameter, and the quantity of loaded genes highly increased by 
more than 8.8-fold after PCR reation. Moreover, good biocompatibility was obtained owing 
to free of positive charge. Therefore, this novel system offers new possibility to address both 
efficiency and toxicity issues simultaneously. 
 
 
 
Figure I-17. Versatility of liposomes as drug/gene delivery carriers (A-G), symbols in 
different shapes and colours represent different therapeutics, e.g. drug, protein or nucleic 
acids. PCR-based nanofactory system mediated with neutral lipid (H). 
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I-2-4-3.  Cationic polymer-based systems 
Polymers are alternative competent candidates for gene delivery, largely due to the chemical 
diversity and functionality. They can be classified by surface charge at physiological pH 
(caitionic, neutral or ionic), or by resources (natural or synthetic). As cationic polymers play a 
predominant role in polymer-based gene delivery system, this subsection only covers their 
versatility as gene vectors. 
Cationic polymers can bind DNA molecules to form nanometer-sized complexes known 
as polyplexes. Parameters including the amount and type of amine groups, charge density and 
hydrophilic and hydrophobic contents have been found to direct impact on the transfection 
efficiency of polyplexes.78 Polyplexes have some advantages compared to lipoplexes such as 
small size, narrow distribution, etter protection against enzymatic degradation, higher 
stability, and easy control of the physical factors. However, like cationic lipid-based system, 
cationic vectors share the same challenge in balancing transfection efficiency and cytotoxicity 
due to the excessive positive charge. 
Poly(L-lysine) (PLL) and polyethylenimine (PEI) are among the oldest and most 
commonly used polymeric gene vectors. To improve safety and efficacy, numerous other 
polymers have been studied for gene delivery, including methacrylate-based polymers such as 
poly[(2-dimethylamino) ethyl methacrylate] (pDMAEMA), carbohydrate-based polymers 
such as chitosan and β-cyclodextrin-containing polycations, polyamidoamine (PAMAM) 
dendrimers and degradable poly(β-amino ester) polymers.     
(i) PLL (Poly-L-lysine)  
PLL is a homopolypeptide of the basic amino acid lysine, and its ability to condense DNA has 
been recognized since the 1960s. The biodegradable nature of PLL is advantageous for in 
vivo applications. Pioneering studies in the late 1980s indicated that PLL conjugated to the 
asialoorosomucoid glycoprotein could potentially be applied in non-viral liver-targeted gene 
delivery. In general, in the absence of a lysosomal disruption agent such as chloroquine, PLL 
has fairly poor transfection activity, presumably due to low capacity for endosomal buffering 
and lysis. Numerous modified variants of PLL with enhanced gene delivery properties have 
been reported. One example includes PLL covered with the hydrophilic polymer PEG, which 
is designed to minimize nonspecific interaction with serum components and thereby increase 
circulation time. The clinical potential of PEGylated PLL was investigated as a vector to treat 
cystic fibrosis.1 
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(ii) Polyethylenimine (PEI )  
PEI and its variants are among the most studied polymeric materials for gene delivery. PEI 
has a high charge density at a wide range of pH values with a nitrogen atom at every third 
position along the polymer chain. This attribute of PEI has been postulated to aid in 
condensation of DNA and endosomal escape. The ability of PEI to promote gene transfection 
in vitro and in vivo was first demonstrated in 1995.83 Soon after, it was shown that the 
transfection efficiency and cytotoxicity of PEI strongly depend on its structural properties, 
especially with respect to molecular weight and the linear versus branched forms. Higher 
molecular weight and branched structures generally result in high transfection as well as high 
cytotoxicity. Examples to balance efficiency and safety include PEGylation, degradable 
disulphide-crosslinking, alkylation and ligand conjugation of PEI.84 Adding low molecular 
weight PEIs onto biocompatible polymers (e.g. cyclodextrin, chistosan, dextrans) can 
significantly improve the biocompatibility of PEIs. Hydrophobic segments such as alkyl 
chains of fatty acids and cyclic hydrophobic molecules are also used for PEI modifications, 
based on the principles that acylation reduces the basicity and availability of free amine 
groups. 
(iii) Dendrimers 
They are three-dimensional polymers with spherical, highly branched structures. Frequently 
used dendrimers are polyamines, polyamides, or polyesters, among which polyamidoamine 
(PAMAM) is the most commonly used. The primary amine groups promote DNA cellular 
uptake because of their participation in DNA binding but the buried tertiary amino groups act 
as a proton-sponge break down the endosomes and facilitate the translocation of DNA into 
nucleus. Emanating from the core, dendrimer is constituted of repeat units having at least one 
branch junction, whose repetition is organized in a geometrical progression that results in a 
series of concentric layers called “generations”. It’s well defined that with the increase of 
generation number, transfection efficiency as well as toxicity increase in the same trend. 
Dendrimers displays a pH-dependant relase profile, and in low pH it adopts an extended 
conformation which facilitate the release of genes or drug.85 Moreover, the presence of 
numerous peripheral functional groups on hyperbranched dendrimers affords efficient 
conjugation of targeting ligands and biomarkers that can recognize and bind to receptors 
overexpressed on specific cells for active targeting. 
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(iv) More intelligent polymeric systems have been proposed. Surface shielding with PEG and 
other moieties often leads to a dilemma. It’s necessary for long circulating time and reduction 
of toxicity of cationic polymers wheras it often results in decreased transfecition. One 
possible solution will be PEGylation with different chain length, in which longer PEG chains 
are bonded with cleavable linkers (Figure I-18A). In this way, PEG detaches from polyplexes 
upon cellular uptake and polyplexes could maintain sponge effect for endosomal escape 
 
Figure 1-18: Schematic illustration showing the combined use of a targeting ligand and an 
endosome-disrupting component, providing dual functionality. (A) The system equipped with 
varying lengths of detachable poly(ethylene glycol) (PEG) chains with the detachability. (B) 
The system equipped with a protected endosome-disrupting component containing primary 
amines.86 
Alternatively, the introduction of targeting ligand molecules can be adopted to facilitate 
selective accumulation of polyplexes in the target tissue/cells. So far, a variety of ligand 
molecules have been introduced onto the surface of nanoparticles including polyplexes. For 
instance, asia loorosomucoid, lactose, galactose, and their derivatives have been utilized for 
targeting the liver, while transferrins (Tfs) and folate have been used for targeting cancer 
cells. Furthermore, peptides and antibodies have been utilized for targeting specific tissues. 
Moreover, fine-tuning of polycationic structures can substantially enhance their acidic 
pH sensitivity to induce endosome-selective destabilization without compromising cell 
viability and functions. Furthermore, degradable nature of polycations can reduce the 
cumulative toxicity of repeated transfection and also can allow the easier release of pDNA 
from polyplexes for effective transcription to mRNA in nucleus.  
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I-2-4-4. Solid nanoparticles-based system 
(i) Organic nanoparticles  
They are generally prepared from bio- (collagen, gelatin, elastin, fibronectin, silk, albumin, 
etc)87 or synthetic (PEG, PCL, PLGA, etc) polymers88. As they are neutrally charged at 
physiological conditions, they are generally applied as “non-condensing vector”. 
Consequently, therapeutic genes are generally incorporated in the polymer matrix by physical 
encapsulation, in which multiple genes could be loaded simultaneously. The as-formed 
particles can be further conjugated with moieties stimulating receptor-mediated endocytosis, 
the bioactivity of the encapsulated genes could be maintained by preventing digestion by 
nucleases. Synthetic polymers such as Poly (d,l-lactide-co-glycolide) (PLGA) have been 
extensively investigated for sustained and targeted/localized delivery plasmid DNA. Although 
this kind of system suffers from the low transfection efficiency and low encapsulation 
efficiency, higher transfection was observed in vivo compared with liposomes. Further, gene 
transfection was observed for up to 28 days, suggesting the application of nanoparticles for 
sustained gene expression.  
(ii) Inorganic nanoparticles and hybrid nanosystems 
Silica nanoparticles, carbon nanotubes (CNTs), magnetic nanoparticles, calcium phosphate 
nanoparticles, gold nanoparticles, and quantum dots (QDs) have been widely evaluated as 
gene delivery carriers. Compared with organic nanoparticles, they are not subjected to 
microbial attack and also show good storage stability. These nanoparticles possess many 
advantages in gene delivery such as facile fabrication and surface functionality. However, 
surface modification with cationic amine group is indispensible to compact the negatively 
charged nucleic acids. Consequently, a hybrid nano-system consisting both organic and 
inorganic moieties have emerged to maximize to advantages of the two components89. More 
specifically, the inorganic part in the core, with tunable size, shape, porosity, provides a 
variety of possibilities for gene loading. At the same time, organic part over the surface is 
responsible for charge tuning, biomolecules conjugating, surface shielding and targeting 
delivery. Specially, silica nanoparticles will be introduced in details in the following section 
as hybrid nanovectors for drug and gene delivery. 
 
I-2-5. Scaffold-based gene delivery systems for tissue engineering 
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Local strategies evolved from repair and replacement tissues and organs, then to sustained 
delivery of recombinant cytokines and now reached an epoch for sustained delivery of 
plasmid. Local plasmid-based gene transfer technology is known as gene activated matrix 
(GAM). Studies over the past two decades suggest that GAM may serve as a platform for 
local gene delivery in the wound bed of various tissues and organs, such as acutely injured 
tendon, ligament, bone, muscle, skin and nerve. Fast catabolism of DNA in the blood stream 
avoids systematic toxicities. Additional advantage includes that plasmid DNA is stable and 
flexible compared with protein, thus more likely to be compatible with established sustained 
delivery systems. 
 
Figure I-19: Schematic overview of protein expression in scaffold based gene delivery90 
 
An important assumption was that, following gene transfer, the recombinant cytokines will 
be expressed at more nearly physiological levels but for prolonged period of time by wound 
healing cells. As shown in the Figure I-19, nDNA (1) is released from the scaffold through 
either hydrolysis or cellular migration (2) and internalized into the endosome (3). The 
endosome matures changing its oxidation and acidity resulting in endosomal escape of nDNA 
(4 and 5). nDNA can enter the nucleus (7) to be unpacked (8) or be de-coupled in the cytosol 
(6) for nuclear entry (7), where transcription and translation occurs (9) for protein expression. 
Growth factors or other bioactive signals can be used to induce intracellular signaling 
pathways that prime cells for transfection (10).  
Although naked DNA has been reported to achieve therapeutic effects, the research interest 
now is focused on the delivery of compacted DNA (nDNA) with the help of either viral or 
non-viral (mainly cationic lipid, polymer and inorganic nanoparticles) vectors, due to greater 
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potential for high transfection efficiency.90 The release profile of vectors largely depends on 
the interactions between the matrix and DNA complexes. nDNA can be either encapsulated 
into the system either during matrix fabrication or deposited to the wall surface of the 
fabricated matrix by immersion in nDNA solutions or pipeting. The latter has the advantage 
to avoid the harsh preparation conditions and aggregation of DNA complexes. Yet, it may 
suffer from burst release due to the week interaction with the matrix. Consequently, covalent 
bonding is necessary to achieve stronger affinity and therefore more sustained release. 
As scaffold-based gene delivery involves complex participation of matrix and DNA 
vector and cells, there are therefore different classifications for scaffold-based delivery 
systems. Herein, the systems are classified into 3 types based on the nature of matrix 
(degradability, pore size, stiffness), the source of cells (encapsulated or infiltrated), the 
presence of biochemical molecules (growth factors, cytokines, peptides, etc). In all cases, 
nDNA can be incorporated in the matrix by all the method mentioned above. 
Type 1. Matrix-oriented delivery 
This type of system is characterized by controlled release of DNA to neighbouring cells or 
tissues, with the belief that sustained release of the transfection vector achieves prolonged 
transgene expression over burst-released vectors. The release of DNA generally relies on the 
degrability of the matrix, and therefore, biodegradable polymers such as PLGA, PEG and 
PCL, are of first choice for the system design.  
Type 2. Cells-oriented delivery 
In this case, cells play a central role for the gene delivery. Therapeutic genes are generally 
immobilized in the system and thus difficult to be released out of the matrix. Therefore, cell 
transfection could only happen when cells infiltrated and colonized in the matrix. Hydrogel 
scaffold such as fibrin, collagen, peptide crosslinked hyaluronic acid and peptide crosslinked 
PEG are often chosen for matrix design. 
Interestingly, this type of matrix can combine cell therapy and gene therapy for 
successful tissue engineering when cells encapsulated in the scaffold. On the one hand, the 
cells can act as bioreactors for the continuous production of therapeutic proteins. On the other 
hand, the cells introduced can help tissue regeneration when the host cells are unable to repair 
the defect or deficiency alone to disease, age, or excessive trauma. 
Type 3. Biochemical cues meditated delivery 
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This type of system is aimed to prime cells for transfection by encapsulation of biochemical 
cues such as ECM components (e.g. fibronectin, glycosaminoglycan), growth factors (e.g. 
FGF), peptide (e.g. RGD). The presence of biochemical cues can influence proliferation, 
migration, internalization, intracellular trafficking and gene expression. For example, 
glycosaminoglycans (GAGs) in the native ECM are known to play an important role in 
sequestering biomolecules within the matrix based on their degree of sulfatation and 
structural variations in their carbohydrate backbone. Biomaterials incorporating GAGs have 
increasingly been explored as a strategy to transiently regulate growth factor availability91.  
A potential problem of single gene therapy is that simply increasing the concentration 
may not promote all phases of wound healing. A single growth factor cannot counteract all 
the deficiencies of a burn wound, nor control the complexities of chronic wound healing. 
Lynch et al. demonstrated in a partial thickness wound healing model that the combination of 
PDGF and IGF-I was more effective than either growth factor alone, while Sprugel et al. 
found that a combination of PDGF and FGF-2 increased the DNA content of wounds in the 
rat better than any single growth factor. The efficacy of KGF nDNA in combination with 
IGF-I nDNA was compared to the same genes individually. Noticeably, this combination 
accelerated re-epithelization, increased proliferation, and decreased skin cell apoptosis 
compared to the single construct alone. The re-epithelialization in the burn model was over 
twice that of the untreated control with a significant improvement in cell survival. 
Transfection of multiple growth factor genes at strategic time points of wound healing 
(sequential growth factor therapy) is therefore the next logical step in augmenting wound 
healing. 
Slow-release matrices and gene-delivering gel matrices are used for prolonged 
transgenic expression. The concept of a genetic switch is another exciting development, 
where transgenic expression in target cells can be switched ‘on’ or ‘off’, depending on the 
presence of or absence of a stimulator such as tetracycline. Biotechnological refinements, 
such as wound chamber technique, may also improve the efficacy of gene delivery to wounds. 
These new techniques need further studies to define their efficacy and clinical applicability. 
More studies are also needed to define growth factor and cytokine levels in different phases of 
wound healing and to elucidate the timing of gene expression or down-regulation required for 
better wound healing. 
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I-3. SILICA NANOPARTICLES – VERSATILE DELIVERY PLATFORMS 
I-3-1. The chemistry of silica nanoparticles 
I-3-1-1. Non-porous silica nanoparticles  
Plain silica particles have been developed at the industrial scale for many years. They are 
currently used as additives in a wide range of applications, including pharmaceutical 
formulations, foodstuff and toothpaste.  
Three main methods exist for the preparation of silica nano- and microparticles 
(Figure I-20) 
(i) the aqueous route: 
This method uses water glass solutions. Water glass is obtained by the dissolution of siliceous 
sand in highly concentrated sodium (or potassium) hydroxide solutions. The resulting 
solutions have a MxSiyOz.nH2O general formula (M = Na, K). They consist of silicate 
oligomers in very alkaline solutions (pH > 12). To obtain silica particles, these solutions are 
dropped down in an aqueous acidic solution (usually H2SO4). The size of the particles is 
controlled by the concentrations of the two reagents as well as other processing parameters 
(addition rate, stirring rate, temperature, etc…) 
(ii) the sol-gel route: 
In 1968, Stöber and Fink reported a simple synthesis of monodisperse spherical silica 
particles by means of hydrolysis/condensation of a dilute solution of tetraethyl orthosilicate 
(TEOS) in ethanol in the presence of ammonium hydroxide.115 Uniform amorphous silica 
spheres whose sizes ranged from 10 nm to 2 µm were obtained simply by changing the 
concentrations of the reagents. This Stöber method was later improved by many others and 
appears to be the simplest and most effective route to monodispersed silica spheres. 
(iii) the microemulsion route: 
The emulsion route has been widely developed to design silica capsules for 
microencapsulation.116 These particles can be prepared by water-in-oil W/O or oil-in-water 
O/W processes, mainly depending on the hydrophilic or hydrophobic character of the 
molecule to encapsulate (Figure I-20). If the molecule is hydrophilic, it is first dissolved in 
the water phase in the presence of the hydrolyzed silicon alkoxide and a surfactant. This 
aqueous phase is then dispersed in the oil phase (W/O). If the molecule is lipophilic, it is 
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dissolved in an organic solvent together with the un-hydrolyzed alkoxide. This oily phase is 
dispersed in the surfactant-containing water solution. 
 
Figure I-20. Microemulsion route to doped silica particles: (left panel) water-in-oil W/O, 
(right panel) oil-in-water O/W.116 
 
It must be noticed that the obtained particles have some porosity in the micropore range 
(a few angströms in diameter). However, these pores are too small to serve as host cavities for 
the loading of molecules by impregnation routes. This is the reason why they are usually 
termed as plain or non-porous, in contrast to the mesoporous particles described in the next 
section.  
I-3-1-2. Mesoporous silica nanoparticles (MSN)  
Since their discovery in 1992, mesoporous materials have attracted extensive attention due to 
the unique physical and chemical features including large specific surface area and pore 
volume, ordered pore channels and great potentials across a wide variety of fields such as 
catalysis, biomedicine, optics and so on.117 The synthesis of MSNs is typically relying on co-
operative self-assembly of supramolecular surfactant assemblies, acting as structure directing 
agents, and oligomeric silica species (Figure I-21). Furthermore, controlled nucleation and 
growth allows for tailoring of particle size (10–1000 nm). By tuning the synthesis conditions 
and/or by variation of the reactants elongated MSNs with tunable aspect ratios can be 
synthesized, providing yet another method for optimization of the particle technology for 
biological applications. Mesoporous nanoparticles are obtained after removal of the structure-
directing agent leading to opening of the porosity. MSNs typically have a high specific 
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surface area (600–1000 m2.g-1) and a large pore volume (0.6–1.0 cm3.g-1) that allow for high 
levels of drug loadings to be achieved.  
Typical pore dimensions of MSNs are 2–4 nm, but recent advances have made it 
possible to synthesize MSNs with pore dimensions as large as 50 nm, which are generally 
referred as large-pore MSNs (LPMSN).118,119 Several synthetic methods have been proposed 
to enlarge the pore sizes of MSNs including post-enlargement by introducing a swelling agent 
(e.g., 1,3,5-trimethylbenzene) into the core part of micelles or using large molecular weight 
block copolymers (e.g., F127, P123, and PS-b-PEO) with long organic molecular chains as 
mesopore template. Although these approaches are effective in enlarging the pore sizes of 
MSNs, the obtained MSNs unfortunately usually suffer from the over large particle sizes 
(typically > 100–300 nm), irregular morphologies, and a severe tendency to aggregate. 
 
Figure I-21: Schematic illustration of the formation mechanism of ordered large-pore silica 
nanospheres. A. Pore structure tuning achieved by modifying surfactant concentration: (a) 
lamellar, (b) hexagonal and (c) cubic.118 B. Pore expansion with benzene derivatives.119 
For biomedical applications, precise control over particle size, shape, pore size, and pore 
geometry is very important. Totally, the pore size and its orientation are mainly determined 
by the nature of surfactant templates. The particle size and morphology can be controlled 
from sphere-, rod-, to wormlike structures by tailoring the molar ratio of silica precursors and 
surfactants, pH control using base catalysts, addition of co-solvents or organic swelling 
agents, and introduction of organoalkoxysilane precursors during the co-condensation 
reaction (Figure I-22). 
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Figure I-22. Versatile structures of silica nanoparticles: a-l92, m93, n. dendrimer-like120 and o. 
cone-shaped121 pores silica nanoparticles 
I-3-1-3. Surface functionalization 
Three methods can be used to modify the external and, for MSN, internal surface of silica 
particles: 
(i) Surface adsorption 
The isoelectric point of amorphous silica is around pH 2-3, which means that in the absence of 
specific ion adsorption, the silica surface is negatively charged under biologically conditions. 
Therefore, electrostatic adsorption of positively-charged species is an attractive technique for 
simple surface modification of silica particles. This approach has been largely explored for the 
coating of SiNPs with biopolymers.122 A major issue of this strategy is that the surface-sorbate 
interactions are highly dependent on the physico-chemical conditions of the medium (pH, ionic 
strength) 
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(ii) Post-grafting 
The surface of silica particles exhibits 3-5 silanol groups per nm2. This provides readily 
available moieties for surface modification via silanization reaction involving the 
condensation of trifunctional organosilanes (SiR’(OR)3) in an organic solvent (Figure I-23). 
The organic group R’ of the silane is usually selected so as to provide a reactive site for 
further interaction/binding with functional (bio)-molecules 
To restrict or bias the deposition to the exterior surface of the MSN, the modification can 
be performed prior to extracting the templating agent. The templating agent can then be 
removed, and the protected, unreacted silanol groups in the pore interiors can be further 
modified.  
 
Figure 1-23: Silanization of ceramic surfaces. (A) Organo-functional silane molecule basic 
structure: an organic hydrolyzable group (OR) and an organo-functional group (F). (B) 
Chemical structures of mostly used silane precursors for surface functionalization of ceramic 
materials.123 
 
(iii) Co-condensation 
The co-condensation method relies on the formation of the particles from a mixture of 
hydrolyzed alkoxysilanes with organosilanes, resulting in an hybrid network.  In this case, the 
amount of organic functions on the particle/pore surface should be the same as within the 
silica network. In order to favor the localization of these groups on the pore surface, it is 
possible to use amphiphilic organosilanes that serve as cosurfactants and are incorporated into 
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the templating micelle.124 Here again, the principle is to introduce organic groups that may 
further interact with functional molecules. 
I-3-2. Silica nanoparticles in drug delivery 
I-3-2-1. Overview 
There are two main methods by which drugs can be loaded in particles: encapsulation (i.e. 
incorporation of the drugs during particle synthesis) or adsorption/grafting on the 
external/internal surface. In the case of non-porous silica nanoparticles, only the two first 
methods are available. The microencapsulation method has been used successfully for the in 
situ incorporation of drugs.125 Recent results from our group concerning antibiotics 
encapsulation within Stöber nanoparticles have shown that this approach allowed to achieve 
significant drug loadings but that the amount of incorporated drugs was highly dependent on 
their interactions with the silica precursors.94 
When adsorption/grafting is considered, MSNs with high specific surface area are by far 
more advantageous. Consequently, the main research on drug delivery applications of silica 
nanoparticles are based on porous silica nanoparticles.126 In 2001, Vallet-Regí firstly reported 
the application of MSNs as a drug delivery system for ibuprofen release.127 Later, drugs of 
different hydrophobic/hydrophilic properties, molecule weights, and biomedical effects such 
as ibuprofen, doxorubicin, camptothecin, cisplatin have also been loaded in the mesopores to 
enhance high bioavailability or to balance efficacy and toxicity.128 Moreover, MSNs systems 
allow the delivery of protein drugs, which are fragile structures of large molecular weight.129 
MSNs can well protect these biomacromolecules from premature degradation, thanks to their 
porous structure and stable nature.  
More recently, Brinker and co-workers fused supported lipid bilayer onto MSNs to 
construct a “protocell”.130 The organic-inorganic nanocomposites can synergistically combine 
the advantage of MSNs with extraordinarily high drug loading capacity, and liposome with 
enhanced lateral bilayer fluidity. They enable targeted delivery and controlled release of high 
concentrations of multicomponent cargos within the cytosol of cancer cells. The hybrid 
nanocomposites were used to deliver drugs and drug cocktails, siRNA cocktails and protein 
toxins. The killing effect of protocells on multidrug resistant cells of was 106 times higher 
over that of liposomes when delivering a cocktail of DOX, 5-fluorouracil and cisplatin. Nano-
based drug co-delivery systems have been designed for targeting the ATP-dependent trans-
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porters concurrently delivering chemo-drugs for increasing intracellular drug concentration. It 
is also possible to co-deliver cytotoxic drugs and genes targeting non-pump resistant related 
molecules including Bcl-2, transcription factor NF-κB and hypoxia-inducible factor alpha 
(HIF-1α). 
“On-demand” release systems have also emerged as intelligent delivery platforms. They 
can respond to a range of endogenous or exogenous stimuli, including redox, pH or 
temperature, enzymes, competitive binding and photo-irradiation, thus more controllable 
release profiles can be achieved.95 This kind of system requires stimuli-responsive caps over 
the mesopores, ranging from polymers (e.g. PEI, β-CD) to nanoparticles (e.g. Au, tiO2)96. 
Moreover, multiple stimuli-responsive systems were also developed (one example is shown in 
Figure I-24). Nevertheless, very few studies of these systems are performed in vivo. 
 
  
Figure I-24: (Left panel) Release of guest molecules from the pores of DNA-capped MSPs 
upon a) heating and b) treatment with DNase I.95 (right panel) (A) Functionalization protocol 
of the MSN; (B) drugs loaded MEMSN under physiological condition; (C) removal of PASP 
protection layer in response to MMP at a tumor site; (D) cell uptake through RGD-mediated 
interaction; (E) glutathione-triggered drug release inside the cell; and (F) apoptosis of tumor 
cells.131 
The current trend is this area is to incorporate more and more functions within a single 
particle to obtain multifunctional platforms. In particular, the association of magnetic, 
fluorescent and photothermal properties allows simultaneous bioimaging and drug delivery 
for nanotheranostics (Figure I-25).132 
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Figure I-25: Cargo loading possibilities of silica nanoparticles.132 
 
I-3-2-2.Silica nanoparticles for gene delivery 
 
 
Figure I-26: The state-of-art of silica nanoparticle-based gene delivery system. Non-porous 
SiNP(a-c) and porous SiNP. Yellow layer represents fuctionalization of particle surface (d-e) 
and red dots indicate co-delivery with drugs (d). 
Nonporous silica nanoparticles were used for the first time as inorganic nonviral gene 
delivery carriers by Kneuer et al., in 200097. However, this study and most of the following 
ones focus on particle surface modification and adsorption of model plasmids by electrostatic 
interactions. Very recently, Paunescu et al., proposed a method for encapsulating DNA into 
amorphous silica spheres to mimic the protection of nucleic acids within ancient fossils98. 
DNA encapsulation was achieved by electrostatic adsorption and the following formation of 
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silica shell. This interesting work may not only be applied in medical field such as gene 
therapy and gene storage, but also in products tagging and tracing in the market. 
 
Particle 
type 
Gene 
location 
Modification Gene 
type 
Results  
Outer 
surface 
AH-APTESa 
AE-APTESb 
pDNA SiNP:DNA(w/w) of 30 was 
sufficient for complexation; 
absorbed DNA was protected 
from enzymatic degradation by 
DNase I. 
101 NSN 
Interface 
between 
Core and 
shell 
TMAPSc DNA Loaded DNA high temperature 
and radical oxygen species;  
DNA can be further extracted 
intact 
98 
Outer 
surface 
APTES pDNA Optimal ratio for transfection is 
TEOS: APTES 1:10  
102 MSN 
Pores 
(3 nm) 
Outer surface 
with PEI cap 
and KALA 
peptide  
short 
salmon 
DNA 
and 
siRNA 
Successful downgrading of 
EGFP and VEGF in vitro; 
System loaded with VEGF-
siRNA inhibited the growth of 
tumor over a month 
103 
 Outer 
surface 
PEI, PEG and 
anti-HER2 
antibody 
siRNA HER2 protein levels reduced by 
60%; 
Multiple intravenous injections 
over 3 weeks significantly 
inhibits tumor growth 
104 
LPMSN Pores (20 
nm) 
APTES, PLL Oligo 
DNA-
Cy3 
PLL-modified MSN showed a 
higher reduction of cellular 
viability of cancer cells at 30% 
105 
 Pores (23 
nm) 
APTES siRNA 
targeting 
EGFP 
and 
VEGF 
GFP expression level decreased 
to 12% in vitro and 42% in 
vivo; tumor weight was 20% of 
control group 
106 
 Pores (20 
nm) 
PDMAEA siRNA Controlled release of siRNA 
mediated by self-catalyzed 
hydrolysis of PDMAEA 
107 
 Pores (inside 
6 nm, 
opening ~10 
nm) 
PEI and TAT 
peptide 
 
pDNA Nucleus targeting, 
High transfection (36.5%) was 
obtained, substantially higher 
than that by LPMSN-PEI 
(13.5%) and MSN–PEI-TAT 
(4.97%) 
121 
aN-(2-aminoethyl)-3-aminopropyltrimethoxysilane(AE-APTES) 
bN-(6-aminohexyl)-3-aminopropyltrimethoxysilane(AH-APTES) 
cN-trimethoxysilylpropyl-N,N,Ntrimethylammoniumchloride (TMAPS) 
Table I-5: Typical silica nanoparticles-based gene delivery systems 
Mesoporous silica nanoparticles (MSNs) have extensive potential in gene delivery due to 
the large surface area, versatile functionality and excellent biocompatibility. However, the 
loading of DNAs or RNAs inside the mesopores of MSNs seems a challenging mission and in 
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most reports therapeutic genes were only adsorbed on the outer surface mainly due to poor 
availability of the mesopores. Therefore, optimization of loading conditions99 and 
enlargement of mesopores were two most promising solutions to enhance the adsorption of 
genes inside the MSNs. 
Considering the large size of nucleic acids, more promising gene delivery system will be 
SiNP with large pore size (10-50 nm), which will provide better protection for instable 
therapeutic genes and more functionality, such as targeting and stimuli-responsive moieties, 
for more intelligent delivery and release. Wu et al. has newly reported a LPMSN based 
targeting delivery system for transport of the therapeutic genes into the nucleus, where 
nucleic acids can be exactly and efficiently expressed.100 High transfection was obtained due 
to the combined proton sponge effect of PEI grafted on the particle walls and the nuclear 
localization signal of TAT peptide on the surface. Small particle size (~30 nm) and large pore 
size (6-10 nm) was found to be responsible the readily uptaken and pDNA protection 
respectively. As summarized in Table I-5, positive charge generation is still the predominant 
strategy for the gene loading to SiNP. 
 
I-3-3. Silica-collagen nanocomposites 
I-3-3-1. Collagen 
Collagens are the most abundant proteins in the mammalian body, accounting for 20–30% of 
the total protein. Collagens form a large family of triple helical molecules with about 28 
different types described, with types I, II, III and IV being the most commons.133 All 
collagens share the same triple-helical structure where three parallel polypeptides, α-chains, 
coil around each other forming a right handed triple helix chain (collagen type I as an 
example, Figure I-27). In animals these collagen triple helices are known as tropocollagen 
and its hierarchical organization into more complex structures generates the fibers and 
networks in tissues such as bone, skin and tendons (Figure I-28). The primary functions of 
type I collagen are to provide mechanical support and to control cell adhesion and migration. 
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Figure 1-27: Chemical structure of collagen type I. (a) Primary amino acid sequence, (b) 
secondary left-handed helix and tertiary right-handed triple-helix structure and (c) staggered 
quaternary structure.134 
 
 
Figure I-28: Hierarchical structure of collagen type I leads to specific functions and 
characteristics across length scales.109 
 
The abundance, non-antigenicity, biodegradability, biocompatibility and plasticity make 
collagen a promising biopolymer for medical applications. Collagen scaffolds have been 
extensively used for soft tissue repair, vascular and dermal tissue engineering, bone repair and 
as a carrier for the delivery of drugs and biologically active molecules.135 Many of them are 
commercially available in diverse forms that include gels, pads, particles, pastes, powders, 
sheets or solutions. 
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Thanks to the above-mentioned characteristics, collagen is frequently used to prepare 
wound dressings. However, collagen-based materials suffer from uncontrolled degradation 
and low mechanical strength, which necessitate the chemical and physical modifications of 
the collagen. Composite collagen hydrogels obtained from introducing other natural (e.g. 
elastin, hyaluronan) or synthetic (e.g. PEG) polymers109 and particulates (e.g. calcium 
phosphate particles, silica nanoparticles) have been widely used to add strength and 
functionality to the system. Another efficient approach is through chemical (e.g. 
carbodiimides, glutaraldehde) and physical (e.g. UV light, gamma radiation) modification.  
Raftery et al. studied collagen-based scaffolds for localized gene delivery, where 
chitosan-DNA was loaded by surface adsorption.44 The scaffolds used in the study include a 
collagen scaffold and collagen-hydroxyapatite (CHA) scaffold for bone repair, and a 
collagen-hyaluronicacid (CHyA) with properties optimized for cartilage regeneration. 
Sustained gene expression from MSCs seeded on the scaffolds was maintained for up to 28 
days and interestingly the composition of the scaffold had an effect on transfection efficiency. 
These results demonstrate that by simply varying the scaffold composition and the gene 
chosen, the system has potential for a myriad of therapeutic applications. 
I-3-3-2. Silica-collagen nanocomposites 
 
Figure 1-29: Overview of silica–collagen materials. Starting components, conditions of 
composite formation, main characteristics and potential applications.110 
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The ease to prepare collagen hydrogel facilitates the incorporation of other ingredients 
(e.g. cell culture medium, bioactive proteins, drugs), which makes collagen-based materials 
appealing candidates for bioactive wound dressing fabrication. However, fast release of 
biomolecules and limited mechanical strength remains drawbacks of this system.136 In this 
context, it has been suggested that the combination of collagen hydrogels with silica could 
improve their performance.137 Various silica species have been reported for silicification of 
soluble collagen, fibrils, fibers, films, gels or scaffolds for different medical applications 
(Figure 1-29).110 Increasing studies are being carried out on silica-collagen hydrogels for 
tissue engineering, including nerve regeneration111, bone repair112, artificial cornea113 and 
wound healing114. Preliminary biocompatibility studies by subcutaneous implantation in rats 
showed the absence of significant inflammation, infiltration of fibroblast cells and initiation 
of vascularization.138 
Compared with other silicification approaches, the physical incorporation of silica 
nanoparticles within collagen hydrogel should allow to take full advantage of their drug 
delivery potential. By tuning particle size, surface chemistry and porosity, it may be possible 
to achieve controlled release kinetics. Whether this strategy can be applied to gene delivery 
systems is the central question that has motivated this work. 
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Résumé 
Nous avons développé des matériaux nanocomposites associant des complexes formés par 
l’association de nanoparticules de silice, de polyethylèneimine et d’ADN avec des hydrogels 
de collagène colonisés par des fibroblastes 3T3. Grâce à la modulation de la taille de la 
particule de silice et de la masse moléculaire du polymère, il a été possible de réaliser la 
transfection des fibroblastes au sein du gel, permettant l’expression génique pendant une 
semaine. Des configurations alternatives consistant en l’addition des particules à des gels 
cellularisés ou impliquant la culture des cellules sur la surface d’hydrogels contenant les 
complexes ont aussi été étudiées. Ces études montrent que l’encapsulation des particules 
limite la dissémination du plasmide et de la silice hors de l’hydrogel. Elles montrent aussi le 
rôle clé joué par la prolifération et la migration cellulaire sur l’efficacité de la transfection.  
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II-1. INTRODUCTION 
In this work, collagen-based nanocomposite hydrogels integrating plain silica nanoparticles 
were evaluated as gene delivery systems to favour tissue repair. We hypothesized that the 
integration of plasmid-PEI-SiNP complexes within collagen hydrogels would allow for a 
sustained gene release. We show here that PEI-coated silica nanoparticles with optimal size 
and polymer molecular weight are efficient plasmid vectors when they are entrapped within 
cellularized collagen networks, allowing for a prolonged gene expression. We demonstrate 
that the transfection efficiency depends on both particle diffusion and cell 
proliferation/migration within the hydrogel. The encapsulation of the vectors within the 
collagen scaffold also has the advantage to avoid rapid dissemination of the plasmids and the 
particles, providing a safe solution for the development of biofunctional medical dressings 
favouring tissue regeneration. 
 
II-2. EXPERIMENTAL SECTION 
II-2-1. Preparation and Functionalization of Silica Nanoparticles 
Silica nanoparticles (SiNP) with diameter d varying from 50 nm to 400 nm were synthesized 
by the Stöber method using ammonia, ethanol and tetraethylorthosilicate (TEOS) (Table II-1) 
Particle size d 
(nm) 
TEOS (mL) 25% NH4OH  
(mL) 
EthanoL 
(mL) 
H2O 
(mL) 
50 7.6 9.6 200 - 
100 7.4 7.3 200 5.7 
200 7.6 9.7 200 6.0 
400 7.0 16.0 200 11.0 
Table II-1. Conditions for preparation of SiNP with different particle sizes 
The as-synthesized particles were dialyzed against distilled water for 2 days, 
recovered by centrifugation and resuspended in 10 mM Phosphate Buffer Saline (PBS) (pH= 
7.4). For PEI-SiNP particle preparation, 200 mg of branched PEI with different molecular 
weights (1.8 kDa, 10 kDa, 25 kDa, Sigma-Aldrich) was dissolved in 20 mL of 10 mM PBS 
(pH 7.4). Silica nanoparticles suspension (20 mL) with the same concentration was then 
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added dropwise into the PEI solution under stirring. The mixtures were further stirred for 48 h 
after which particles were recovered by centrifugation, washed 3 times in 10 mM PBS and 
finally resuspended in the buffer solution. Particle sizes and zeta potential (ζ) were measured 
in 10 mM PBS solution using a ZetaSizer Nano (Malvern Instruments Ltd., Worcestershire, 
UK). Particles were also imaged using Transmission Electron Microscopy (TEM) on a JEOL 
1011 instrument. The amount of adsorbed PEI was determined by thermogravimetric analysis 
(TGA) and elemental analysis (C,H,O,N).  
II-2-2. pDNA-PEI and pDNA-PEI-SiNP Complexation 
 Reporter plasmid pCMV-GLuc (pGluc) encoding Gaussia Luciferase (New England 
BioLabs, Ipswich, MA) was used for transfection experiments. This plasmid was amplified by 
one shot® BL21(DE3) pLysS kit (InvitrogenTM, Life technologies), extracted by one 
PureLink® HiPure Plasmid kit (InvitrogenTM, Life technologies) and finally stored in Tris-
EDTA buffer at -20 oC. pDNA-PEI complexes were prepared at weight ratio of 1:2. pDNA-
PEI-SiNP complexes were prepared at various pDNA:PEI-SiNP weight ratios. Complexes 
formation was examined by agarose gel electrophoresis. Briefly, 1 µL of pDNA solution (0.1 
µg. µL-1) were mixed homogeneously with a total volume of 9 µL of PEI-SiNP suspension or 
PEI solution (PBS 1x) by vortexing in a microcentrifuge tube. The resulting mixtures were 
left at room temperature for 2 h to achieve complete complexation, before being loaded onto 
0.7% agarose gel with ethidium bromide (0.1 µg.mL-1) and running with TAE buffer at 100 V 
for 40 min. DNA retardation was observed by irradiation with ultraviolet light. 
II-2-3. Fibroblast Cell Culture 
3T3 mouse fibroblasts were cultured in complete cell culture medium (Dulbecco’s Modified 
Eagle’s Medium (DMEM) supplemented with 10% fetal serum, 100 U.mL-1 penicillin, 100 
µg.mL-1 streptomycin and 0.25 µg.mL-1 Fungizone). Tissue culture flasks (75 cm2) were kept 
at 37 °C in a 95 % air: 5 % CO2 atmosphere. Before confluence, fibroblasts were removed 
from culture flasks by treatment with 0.1% trypsin and 0.02 % EDTA. Cells were rinsed and 
resuspended in the above culture medium before use.  
II-2-4. Preparation of Collagen-Based Nanocomposites 
 Collagen type I was purified from rat tails and the concentration was estimated by 
hydroxyproline titration, as previously described.1 Tubes separately filled with collagen 
solution (2 mg.mL-1 in 17 mM acetic acid), whole cell culture medium, and 0.1 M NaOH 
were kept in ice bathes for 1 h before preparation to slow down the gelling kinetics of 
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collagen. Complexes were formed by adding 1 µg of pDNA to 25 µL of a solution containing 
PEI or PEI-SiNP in order to achieve the pDNA:PEI (or pDNA-PEI-SiNP) ratio obtained from 
gel electrophoresis. Three models were proposed in our study: particles on top of cellularized 
hydrogels (model 1), co-entrapped particles and cells (model 2), and cells beneath free-
floating nanocomposites (model 3) (Figure II-1). For model 1, 500 µL of collagen solution 
and 400 µL of culture medium were added to a 1.5 mL tube and vortexed vigorously. After 
addition of 30 µL of 0.1 M NaOH and strong vortexing, 125 µL of the cell suspension at a 
density of 106 cells.mL-1 was added and mixed homogenously. Then 0.9 mL was sampled 
from the mixture and deposited into a 24-well plate. The plate was then incubated at room 
temperature for 10 min for complete gelling of collagen. After this delay, 25 µL of the 
complexes solution was added onto the surface of the materials. For model 2, a similar 
procedure was followed except that the 25 µL of complexes was mixed with 100 µL of the 
cell suspension before gel formation. Model 3 was similar to model 2 except that the cell 
suspension was replaced by culture medium and the hydrogels were left free-floating in the 
culture medium of plate-seeded cells (5.103 cells.mL-1).  
 
 
Figure II-1. Schematic representation of the three models  
 
II-2-5. Cell Transfection and Cell Viability 
Transfection efficiency of pDNA-PEI and pDNA-PEI-SiNP were evaluated by luciferase 
expression of pGLuc by 3T3 fibroblast cells in cell culture medium. To perform cell 
transfection in 2D, 3T3 mouse fibroblasts were plated at a density of 5.104 per well in a 24-
well plate. pDNA-PEI or pDNA-PEI-SiNP complexes (25 µL, prepared as described above) 
were added to the cell culture medium. After 4 h, the supernatant was removed, the well was 
refreshed with 1 mL medium and the cells were then cultured for another 44 h in complete 
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medium for the expression of luciferase. To perform cell transfection in 3D, pDNA 
complexes were added on the top of the hydrogel (model 2) or mixed with the collagen 
solution (model 1 & 3). 1 mL of whole medium was then added in each well. At selected time 
points over a 1-week period, 0.5 mL of the culture medium was collected from the wells and 
replenished with equal volumes of fresh medium. For measurements of luciferase activity, a 
BioLux Gaussia Luciferase Assay Kit (New England Biolabs) was used and transgene 
expression of luciferase was reported as relative light units (RLU). Control groups were under 
the same culture conditions as the experiment groups except for the absence of DNA 
complexes. 
Internalization of nanoparticles in 3T3 mouse fibroblasts was studied using 
fluorescence microscopy. For cells cultured in 2D, the pDNA-particle complexes along with 
cell culture medium were removed after 24 h incubation, rinsed 3 times with PBS and fixed 
with 4% paraformaldehyde for 1 hour at RT. The cell nucleus was then stained with DAPI 
(4',6-diamidino-2-phenylindole dihydrochloride, Life technologies, 300 nM in PBS) for 10 
min and rinsed with PBS before observation. For cells immobilized in collagen hydrogels, 
gels were incubated for 48 h, rinsed 3 times with PBS and fixed with 4% paraformaldehyde 
overnight. Next, the fixed samples were dehydrated in ethanol and butanol and incorporated 
in paraffin to obtain 10 µm histological sections with a manual microtome. Before 
observation, the as-obtained samples were immersed in toluene, ethanol and then water for 
rehydration. The cell nucleus was stained with DAPI for 10 min and rinsed with PBS before 
observation. Model 2 was also studied by scanning electron microscopy (SEM). Collagen 
hydrogels were fixed using 3.63% glutaraldehyde in a cacodylate/saccharose buffer (0.05 
M/0.3 M, pH 7.4) for 1 hour at 4 °C. Following fixation, samples were washed three times in a 
cacodylate/saccharose buffer (0.05 M/0.3 M, pH 7.4) and dehydrated through successive 
increasing concentration ethanol baths from 70% to 100% alcohol. Thereafter, samples were 
dried in a critical point dryer and gold sputtered (20 nm) for analysis. Samples were observed 
with Hitachi S-3400N SEM operating at 10 kV. 
Cell viability was monitored using the Alamar Blue test. For the 2D model, cell 
culture medium was removed for luciferase activity test and 200 µL of the Alamar Blue 
solution (10% in cell culture medium) was added. The cells were then incubated at 37 °C with 
5 % CO2 for 4 h. The supernatant in each well was then collected, diluted with 800 µL water, 
and its absorbance was measured at λ = 570 nm and 600 nm. Cell viability was calculated and 
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reported as a percentage of the control group (n = 6). For the 3D model, cell viability was 
assessed in the same way except that the 800 µL water was first added to the collagen gel for 
0.5 h at room temperature to extract the Alamar blue solution trapped in the gel and then 
collected for the absorbance measurements. To further understand the proliferation of cells in 
the collagen gel (1 mg/mL) over one week, cell viability was evaluated with Alamar Blue test 
as described before after 2, 5 and 7 days and was calculated as the percentage of that of 2 
days. 
II-2-6. Statistical analysis 
Graphical results are presented as mean±SD (standard deviation). Statistical significance was 
assessed using one-way analysis of variance (ANOVA) followed by Tukey (compare all pairs 
of groups) or Dunnett (compare a control group with other groups) post-hoc test. The level of 
significance in all statistical analyses was set at a probability of P< 0.05.  
II-3. RESULTS AND DISCUSSION 
II-3-1 Silica particle characterization 
Plain silica nanoparticles SiNPd with diameters ranging from 50 nm to 400 nm were obtained 
using the Stöber reaction, as indicated by DLS measurements in water (Table II-2) and 
confirmed by TEM observation (Figure II-2). Zeta potential (ζ) values were constant over the 
particle size variation and significantly negative (-25/-35 mV), as expected for silica near 
neutral pH. After contact with PEI25, all particles have a positive ζ value in PBS, in agreement 
with the surface deposition of the polycation polymer. The amount of adsorbed PEI was 
maximum for SiNP50 and SiNP200 particles (ca. 15 w%) and lower for SiNP100 and SiNP400. 
DLS studies indicate that particles with intermediate sizes have a good stability in PBS 
whereas the smallest and largest ones show a tendency towards aggregation. 
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Figure II-2. TEM image of SiNP with different particle sizes 50 nm- 400 nm (×11,000) 
bare particles  after coating  
dH2O 
[nm] 
ζH2O 
[mV] 
 dPBS 
[nm] 
ζPBS 
[mV] 
PEI 
[wt%] 
50 ± 10 - 28 ± 12  140 ± 70 + 18 ± 8 15 
120 ± 20 - 27 ± 11  150 ± 40 + 19 ± 6 10 
210 ± 10 -26 ± 8  250 ± 40 + 19 ± 6 15 
390 ± 40 -35 ± 7  420 ± 150 + 20 ± 9 5  
Table II-2. Diameter (d) and zeta potential (ζ) and PEI amount for silica nanoparticles before 
and after coating with PEI-25kD 
 
II-3-2. Cell transfection properties of silica nanoparticles in 2D 
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In a first step, the complexation ability of the different PEI25-coated SiNPd was studied by 
electrophoretic mobility shift assays of pDNA (Figure II-3). The optimal plasmid :particle 
weight ratio ensuring full retention of pDNA by particles was 1:30 w/w% for SiNP400 and 
SiNP200 and 1:10 w/w% ratio for SiNP100 and SiNP50. 
 
Figure II-3. Agarose gel electrophoresis showing the particle size effect on pDNA 
complexation by PEI25SiNPd. A constant amount of DNA was complexed with silica particles 
at different weight ratios 1:10, 1:30 and 1:50. 
The cell transfection ability of these complexes was studied on 3T3 fibroblast cells 
seeded in 24-well plates (2D configuration). Luciferase expression, indicative of successful 
internalization and transport to the nucleus of the pDNA, was observed for all systems 
(Figure II-4).  
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Figure II-4. Transfection of 3T3 mouse fibroblasts after 4 h incubation with free and silica-
associated PEI25 expressed in Relative Light Units (RLU) (n=3). Variance of the luciferase 
expression among group PEI25-SiNP50, PEI25-SiNP100, PEI25-SiNP200 and group PEI25-SiNP400 
was determined by one-way ANOVA with Tukey post-hoc test (*P<0.05, ** P<0.01). 
Importantly, PEI25, pDNA and SiNPd alone gave no significant signal. The PEI25 
polymer alone was the most efficient transfecting agent whereas its adsorption on SiNP 
decreases its transfection ability by one order of magnitude regardless of the nanoparticle 
size. This may be attributed to the fact that a fraction of the positively-charged ammonium 
groups of PEI is interacting with the silica surface and is therefore no longer accessible for 
DNA complexation. Another explanation is related to the size of the complexes that can be 
less adequate for cell internalization by fibroblasts than PEI alone. Fibroblasts are able to 
internalize particles by endocytosis in a size dependent manner, with smaller particles being 
more rapidly engulfed by cells than larger ones. Noticeably, internalization of nanoparticles 
with a diameter larger than 500 nm is observed only in exceptional cases. PEI25 on its own has 
the best ability to compact DNA and generate 100 nm complexes suitable for cell uptake. In 
contrast, after PEI adsorption, SiNPs have diameters in the 150-420 nm range. This can 
explain why the largest PEI25-SiNP400 exhibited the lowest transfection efficiency.  
Considering the effect of particle size in more detail, it is worth pointing out that  
adsorption of cationic polyelectrolytes on silica surface is a complex phenomenon where 
transitions from flat to extended configurations are observed as a function of polymer 
concentration. The particle size also has a major influence on the adsorption process from 
different points of view: it controls the density of silanol groups, and therefore particle surface 
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charge; it dictates the available surface for adsorption per particle; it defines the maximum 
packing density of polymers via its radius of curvature. Here a reliable comparison must be 
made from the PEI density on the particle surface rather the amount of PEI sorption per g of 
silica. Such a density can be estimated by the product of PEI wt% by particle radius, leading 
to PEI density decreasing as SiNP200 > SiNP400 > SiNP100 > SiNP50. It illustrates the fact that 
the decrease in available surface per particle with increasing size is compensated by the 
increase in maximum PEI packing density. Interestingly, electrophoresis data indicates that 
PEI25-SiNP100 and PEI25-SiNP50 bind more DNA than PEI25-SiNP200 and PEI25-SiNP400. 
However higher transfection is obtained for PEI25-SiNP50 and PEI25-SiNP200. This strongly 
suggests that transfection efficiency is not directly related to PEI amount nor to particle size. 
A more relevant parameter is DNA compaction that depends on PEI conformation. Here 
SiNP50 and SiNP200 have similar transfection efficiency although SiNP50 has lower PEI 
density but binds more DNA than SiNP200. That is to say, the PEI chains on SiNP50 are more 
effective to bind DNA than the PEI chain on SiNP200. As mentioned above, this can be 
explained considering that for small radius of curvature (i.e. large particles), PEI can adopt a 
flat configuration that is not favorable for DNA compaction. As the radius of curvature 
increase (i.e. the particle size decrease), PEI chains can adopt a more compact configuration 
to optimize their packing on the surface, a situation that is more favorable for DNA 
compaction  
 
II.3.3 Effect of PEI Molecular Weight on Fibroblast Transfection in 2D 
Taking into account their limited tendency to aggregate and high PEI loading, the SiNP200 
particles were selected for the following investigations. For these SiNP200 particles, 
decreasing the PEI molecular weight from 25 kDa to 10 kDa led to an increase of particle size 
polydispersity and an increase in the amount of adsorbed polymer (Table II-3). For short PEI 
chains (MW = 1.8 kDa), submicronic aggregates were detected by DLS in PBS whereas the 
amount of adsorbed PEI was similar to that of PEI25. Large branched PEI chains are known to 
adopt compact conformation whose dimensions decrease with decreasing MW.2 This allows 
for a higher density of PEI molecules on the surface, explaining the higher rate of adsorption 
of PEI10 compared to PEI25. However, when decreasing further the polymer MW, short chains 
can adopt a more linear conformation and a flat configuration on the surface, leading to a 
lower density and therefore lower amount of adsorbed PEI. The observation of a significant 
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aggregation of the PEI1.8-SiNP200 confirms this hypothesis as flat PEI chains are less effective 
in improving colloidal stability via steric repulsion compared to extended conformations.3  
MW 
[kDa] 
dPBS 
[nm]a 
ζPBS 
[mV] 
PEI 
[wt%]b 
1.8 > 1000 + 20 ± 12 15 
10 310 ± 100 + 19 ± 8 25 
25 250 ± 40 + 19 ± 6 15 
 
Table II-3. Diameter (d) and zeta potential (ζ) and PEI amount for 200 nm-silica 
nanoparticles after coating with PEI of different molecular weight MW 
 
Agarose gel experiments performed on pDNA-complexed PEI-coated particles 
showed that the optimal plasmid:particle weight ratio was 1:30 w/w% independently of the 
PEI molecular weight, in agreement with the fact that a similar ζ value of + 20 mV was found 
for all PEI-SiNP200 particles (Figure II-5) 
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Figure II-5. Agarose gel electrophoresis showing the PEI molecular weight influence on PEI-
Si200/pDNA complexation. A constant amount of DNA was complexed with silica particles at 
different weight ratios 1:3, 1:5, 1:10, 1:30 and 1:50. 
Transfection assays in 2D revealed an interesting phenomenon (Figure II-6). When 
PEI polymers alone were used as complexation reagents, an increase in transfection efficiency 
with increasing molecular weight was observed, in agreement with the literature.4-6 When 
PEI-SiNP200 systems were used, the optimal transfection was achieved with PEI10. Moreover, 
the particles showed a higher transfection efficiency than the polymer alone. This beneficial 
influence of PEI adsorption was further evidenced at lower molecular weight since PEI1.8 
alone did not show any transfection capability whereas expression of luciferase was 
detectable for PEI1.8-SiNP200. 
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Figure II-6.  Transfection of 3T3 mouse fibroblasts after 4 h incubation with free and SiNP200 
coated with PEI of various molecular weights (n=6). Variance of the luciferase expression 
between group PEI10, PEI25-SiNP200, PEI1.8-SiNP200 and group PEI10-SiNP200 was determined 
by one-way ANOVA with Dunnett  post-hoc test (*** P<0.001). 
Whereas the higher amount of adsorbed PEI10 compared to PEI25 may, at least 
partially, account for the behavior of the corresponding particles, the observed improvement 
of transfection efficiency of shorter PEI upon coating suggests that another parameter should 
be considered. Importantly, the decrease in transfection efficiency of PEI chains with lower 
molecular weight was attributed to their decreased ability to compact DNA, a pre-requirement 
to its internalization. Thus, based on our observation of particle aggregation upon plasmid 
addition, it is possible to assume that several particles are conjointly involved in the 
compaction of one pDNA chain, allowing for its better compaction. Noticeably, such an 
aggregation process is known to be responsible for the transfection capabilities of cationic 
liposomal formulations (lipofection).7 
To clarify the transfection pathway of PEI-coated SiNPs, FITC-containing silica 
nanoparticles were prepared and their internalization after complexation with pDNA by 
fibroblasts cells was followed by fluorescence microscopy. As shown in Figure II-7, the 
presence of silica particles (green fluorescence) within the cells and accumulating near the 
nucleus (blue fluorescence) was ascertained. Noticeably, significant particle aggregation was 
observed for PEI1.8-Si200, in agreement with the DLS data. Bare SiNP200 nanoparticles put in 
contact with pDNA were also used as controls, showing a similar uptake as PEI-coated ones, 
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in agreement with the literature.8 Therefore it is not possible to determine whether internalized 
particles bear PEI and pDNA or not.  
 
Figure II-7. Fluorescence microscopy images showing internalization of (a) pDNA-SiNP200, 
(b) pDNA-PEI25-SiNP200, (c) pDNA-PEI10-SiNP200, (d) pDNA-PEI1.8-SiNP200 complexes by 
3T3 fibroblasts after 24 h of incubation. Green fluorescence corresponds to FITC-labeled 
particles and blue to DAPI nuclei staining (scale bar = 20 µm). 
However, solutions containing the pDNA-PEI-Si200 particles were regularly 
centrifuged and the absence of luciferase expression using the supernatant was checked. This 
evidences that transfection is not due to soluble pDNA-PEI complexes that may have been 
desorbed from the silica particle surface (Figure II-8). 
 
Figure II-8. Control transfection experiments with particle supernatant. Supernatant-P 
denotes the supernatant of PEI25-SiNP200 while Supernatant-P-DNA refers to the supernatant 
of DNA-PEI25-SiNP200 complexes..The former was further complexed with pDNA before 
transfection test. No luciferase expression was detected using neither of the supernatant as 
transfection reagent.  
 91 
Altogether, these data indicate that PEI-coated silica nanoparticles ca. 200 nm in 
diameter are well-suited for plasmid delivery to fibroblast cells in 2D. Importantly, they 
reveal to be even more effective than PEI alone when using low molecular weight polymers. 
This is a very interesting result as the cytoxicity of PEI is know to increase with its molecular 
weight due to higher cationic charge. Here, for all experiments carried out, cells showed good 
viability even when PEI alone was used as the pDNA carrier (Figure II-9).  
 
 
 
 
 
 
 
 
 
 
 
Figure II-9. Cell viability in 2D as influenced by different sizes of SiNP and different 
molecular weight of PEI. Cell viability was assessed after 4 h of contact with Alamar Blue 
test and calculated in the percentage of control (n=6).  
This is probably due to the small amount of PEI (2 µg/mL) used in these experiments 
together with the fact that 3T3 mouse fibroblast is a robust cell line. To study this point 
further, the viability of fibroblasts after 4 h of contact with PEI and PEI-coated SiNP200 
particles as a function of dose (0-100 µg/mL) was studied (Figure II-10). PEI25 showed 
significant cytotoxicity (i.e. cell viability < 80 %) above a 10 µg/mL concentration. This toxic 
dose increased to 50 µg/mL for PEI10 while no significant cytotoxicity was observed for 
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PEI1.8 in the studied concentration range. Strikingly, PEI25-SiNP200 and PEI10-SiNP200 showed 
a very limited impact on cell viability (> 90 %) at all investigated doses. This clearly 
demonstrates the beneficial effect of PEI adsorption on the silica nanoparticle surface on its 
cytotoxicity. As indicated earlier, this can be attributed to the fact that the apparent positive 
charge of the PEI chain is decreased by interaction of some of the protonated amine groups 
with the silica surface. 
 
Figure II-10: Impact of PEI and PEI-coated SiNP200 nanoparticles after 4 h of contact 
as monitored by the Alamar Blue viability test. 
II-3-4. Cellularized collagen hydrogels as models for 3D transfection 
 Cellularized collagen hydrogels can be considered as good model of dermis to evaluate 
biomolecules effects in more physiologically-relevant 3D conditions. pDNA-PEI-SiNP200 
particles were placed onto hydrogels to assess their diffusion through the collagen network 
and their ability to transfect immobilized 3T3 fibroblasts, using pDNA-PEI polyplexes as 
controls (model 1). For PEI25-based polyplexes, an efficient transfection was detected from 
day 2 until the end of the experiment. In contrast, no luciferase expression was detected at day 
2 when PEI25 was absorbed onto SiNP200. The transfection became significant after day 5 only 
and was enhanced after day 7 but remained one order of magnitude lower than the pDNA-
PEI25 polyplexe alone. (Figure II-11) A similar trend was observed for PEI10 except that after 
day 7, the particles showed a level of luciferase expression similar to the polyplexes. In the 
case of PEI1.8, a weak transfection was detected at day 7 but only for particles. Overall, 
similar transfection efficiencies were obtained in these 3D models compared to 2D 
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configuration, except for a delay in luciferase expression. This is in good agreement with our 
recent study showing that silica nanoparticles with sizes ranging from 10 nm to 200 nm can 
diffuse through cellularized hydrogels, with the diffusion rate decreasing with increasing 
particle size.9 Moreover, these particles could be internalized by immobilized fibroblasts. 
Interestingly, these data also suggest that the particles aggregates that were suggested to be 
responsible for pDNA compaction are preserved during diffusion. 
 
Figure II-11. Transfection of 3T3 mouse fibroblasts immobilized in collagen hydrogels after 
2, 5 and 7 d of contact with diffused free and Si200-associated PEI of various molecular weight 
(model 1, n=6). Variances among the cumulative luciferase expression on 7 d of PEI10, PEI25-
SiNP200 and PEI10-SiNP200 were determined by one-way ANOVA with Tukey post-hoc test ( 
*P<0.05, ** P<0.01). 
II-3-5. Evaluation of Cellularized Nanocomposites as Cell Factories 
Two different configurations for the use of plasmid-loaded particles associated with collagen 
hydrogels can be envisioned. The first strategy relies on the implantation of cellularized 
scaffolds incorporating the functional nanoparticles (model 2, Figure II-12(a)). The 
advantage of this configuration is that DNA cargos can rapidly transfect cells encapsulated in 
the implant. Cells start to produce the biomolecules of interest in a short range of time. With 
this strategy, we can produce a cell factory to promote wound healing. In addition, the 
implantation of collagen hydrogels in the wound bed limits the risk of infection while 
preventing dehydration.10-11 However, in this situation, it is important to check that particle 
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internalization by the cells is still possible within the hydrogel. For this purpose, collagen 
hydrogels encapsulating both 3T3 fibroblasts and pDNA-PEI-Si200 were prepared. Using 
fluorescent carriers, it was possible to observe the accumulation of particles within 
immobilized cells (Figure II-12(b)-(d)).  
 
Figure II-12. (a) SEM image of nanocoposites, displaying SiNP and fibroblast immobilized 
in collagen scaffold. Fluorescence microscopy image showing internalization of (b) pDNA-
PEI25-Si200, (c) pDNA-PEI10-Si200, (d) pDNA-PEI1.8-Si200 complexes by 3T3 fibroblasts 
within collagen hydrogels after 48 h of incubation, in which green fluorescence corresponds 
to FITC-labeled particles and blue to DAPI nuclei staining  (scale bar = 20 µm). 
Transfection assays performed in collagen hydrogels encapsulating both 3T3 
fibroblasts and p-DNA-PEI or pDNA-PEI-Si200 also confirm internalization and gene 
expression (Figure II-13). The luciferase expression followed similar trends in terms of the 
effect of PEI chain length, both as such or associated with Si200 particles, compared to the 
complexes in solution. The main difference between the two systems lies on the lower 
expression rate for encapsulated complexes, suggesting that more vectors can enter in contact 
with the cells upon diffusion than after immobilization.  
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Figure II-13. Transfection of 3T3 mouse fibroblasts co-immobilized with free and Si200-
associated PEI of various molecular weight in collagen hydrogels after 2, 5 and 7 d of 
incubation (model 2, n=6). Variance among the cumulative luciferase expression on 7 d of 
PEI10, PEI25-SiNP200 and PEI10-SiNP200 was determined by one-way ANOVA with Tukey 
post-hoc test  ( *P<0.05, ** P<0.01). 
It was previously shown that silica nanoparticles entrapped within the fibrillar 
collagen network are in close interaction with protein fibrils.12 As a consequence, 
nanoparticles are expected to have a restricted mobility. The alternative possibility is that 
cells proliferate and migrate within the collagen network, meet complexes and internalize 
them.13-14 This assumption is supported by the measured proliferation of fibroblasts within the 
hydrogels (Figure II-14) The time needed for cell proliferation and migration can explain the 
observed delay in luciferase expression compared to the 2D situation. Nevertheless, the trends 
obtained for these nanocomposites as a function of PEI molecular weight and adsorption are 
in good agreement with that obtained for 2D transfection as well as for particle diffusion 
assays (model 1). This indicates that the pDNA-PEI-Si200 complexes preserve their integrity 
upon encapsulation. 
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Figure II-14. Proliferation of cells in a particle-free collagen gel (1 mg/mL) evaluated with 
Alamar Blue test and presented as cell viability, which is calculated in the percentage of 2d 
(n=3). Significant increase of viability was detected for 5d and 7d vs 2d determined by one-
way ANOVA with Tukey post-hoc test (*** P< 0.001). 
Importantly, no evidence for cytotoxicity was observed for model 1 (particle diffusion 
through cellularized gels) and model 2 (co-immobilized particles and cells) after 24 h of 
contact with PEI and PEI-coated particles during transfection experiments (Figure II-15). 
Increasing the dose to 50 µg/mL showed high cytotoxicity for PEI25 and PEI10 whereas coated 
silica nanoparticles had a limited impact on cell viability. 
(a) 
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(b) 
 
(c) 
 
Figure II-15. Cell viability as assessed with Alamar Blue test and calculated in the 
percentage of control (n=6). (a) model 1 and (b) model 2 configurations after 24 h of contact 
in the conditions of cell transfection. (c) model 2 after 24 h of contact with a 50 µg/mL dose. 
II-3-6.Evaluation of Nanocomposites as Gene Delivery Systems. 
We then studied a second situation where the collagen scaffolds incorporating functional 
nanoparticles could act as a medicated dressing to deliver genes to tissue cells at the site of 
implantation. To test this configuration, hydrogels containing p-DNA-PEI or pDNA-PEI-
Si200 were left free-floating in the culture medium covering 3T3 cell-seeded well plates 
(model 3). As shown in Figure II-16, significant level of luciferase expression was only 
observed for pDNA-PEI25 after 5 days, but this level remains one order of magnitude below 
the transfection efficiency achieved in model 2. This strongly support the hypothesis that 
entrapped vectors have a very limited mobility within the collagen hydrogels so that 
internalization is possible only if cells can migrate inside the protein network. One important 
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outcome of this study is that complexing DNA with PEI-SiNP provides an efficient method to 
confine gene expression within the scaffold and avoid plasmid and silica particles 
dissemination in the surrounding tissue, at least before colonization of the material by host 
cells. 
 
Figure II-16. Transfection of 3T3 mouse fibroblasts in contact with free-floating collagen 
hydrogels containing free and Si200-associated PEI of various molecular weight after 2, 5 and 
7 d of incubation (model 3, n=3). 
II-3-7. Implication in Gene Delivery and Tissue Engineering 
Coupling PEI with plain spherical SiNP seems to be a very interesting strategy for targeted 
cell transfection. The cytocompatibility of SiNPs has been widely studied and discussed in the 
literature.  Dissolution of silica nanoparticles into silicic acid has been demonstrated both in 
cells and in animals.9, 15 The spherical shape of SiNPs is also an important factor. Although 
needles or rods have the most appropriate shape to be engulfed by fibroblasts, they are more 
cytotoxic as they inflict mechanical damage when they penetrate biological membrane.4, 16-17 
Moreover spheres are more suitable to favour gene expression as they approach the nucleus 
more rapidly than elliptical particles.17 Noticeably, most previous attempts to use silica 
nanoparticles as gene carriers have been made using mesoporous nanoparticles (MSNs). 
Regular MSNs are not good carriers of plasmidic DNA because of their small pores (2 nm), 
that prevent internal plasmid diffusion and compaction.18 As a consequence, pDNA is stuck at 
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the surface and is not protected against cellular nucleases. To overcome this problem, MSN 
with ultra-large pores (23 nm) have been prepared.19-20 These particles were able to pack 
pDNA and succeeded in transfecting cells. Alternatively, MSNs loaded with an anticancer 
drug were coated with PEI allowing for DNA SiRNA conjugation and delivery.4 Our 
approach has the advantage of technical simplicity and short reaction time. Moreover, the 
possibility to encapsulate active drugs within Stöber particles has already been demonstrated 
so that combination of drug and gene delivery using such plain SiNPs appears feasible.12 
 Considering the applications of the here-described nanocomposites, it is first 
important to point out that tissue repair involves the formation of new healthy tissue in the 
wound site requires several phases well-orchestrated to guide the tissue formation. 
Inflammation is crucial for the debridement of necrotic tissue and to kill bacteria. In absence 
of modulation, a chronic inflammation can occur.21 The incorporation of a therapeutic gene 
modulating inflammation such as IL-10 within collagen nanocomposites could be useful to 
promote wound healing. In addition inflammatory cells that infiltrate the implant could be 
directed towards a wound healing phenotype instead of an inflammatory one. Synthetic 
matrices made from biodegradable polymers such as PLGA or Polycaprolactone were 
previously evaluated for gene delivery.22-23  DNA/PEI complexes are mixed with the polymer 
in solution before matrix synthesis. In this case, polyplexes are encapsulated within material 
walls. This allows for a controlled and sustained delivery of polyplexes but requires a large 
porosity for cell infiltration. Moreover, synthetic polymers are not the natural support of 
fibroblasts and are not remodelled by cells. Alternatively, several collagen based-materials 
have been developed.  Most of them are cross-linked collagen sponges rehydrated with a 
polyplexes solution (Transfecting reagent/pDNA). Polyplexes are therefore adhering to the 
sponge wall and easily detached under flow. As a consequence a rapid diffusion of polyplexes 
occurs preventing a precise spatio-temporal control of the gene delivery process.24 In this 
perspective, the silica-collagen materials combine several advantages. As demonstrated 
earlier, the stiffness of collagen hydrogels at 1 mg.mL-1 promote fibroblast proliferation over 
one week and favour cell infiltration thanks to a pore size of ca. 5 µm.1 This is highly 
beneficial to the target application as proliferating cells are more willing to be transfected 
than quiescent ones.25 The other major advantage of the nanocomposites approach is that the 
DNA-loaded particles cannot diffuse out of the hydrogel. Therefore, in the first period after 
implantation, the delivery of plasmids to the immobilized cells would allow for the 
production and release of proteins. In a second phase, silica-collagen hydrogels will be 
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colonized by inflammatory and connective cells.26 Our data suggest that cells from the host 
organism could also be transfected during implant infiltration. Overall, it should allow for a 
prolonged production and delivery of active proteins at the implantation site and in its 
surrounding, favoring neotissue formation. 
II.4 CONCLUSION 
We have demonstrated that PEI-coated plain silica nanoparticles are able to deliver 
therapeutic genes in a controlled and sustained manner within collagen hydrogels. The gene 
delivery properties of these particles were evidenced when they are transported through pre-
formed cellularized hydrogels or co-entrapped with fibroblasts, whereas no transfection was 
observed for cells external to the material. This offers various and safe options to combine 
silica and collagen to design gene delivery systems promoting wound healing.  
These results lead to two important questions. One of more fundamental nature is related to 
the mechanisms of the transfection process when silica particles are used as vectors. In fact 
we have observed that best transfection levels were obtained for free PEI25 and that the 
highest transfection efficiency for silica-based systems was at least one order below these 
values. One possible approach to address this important question is to modifiy the mode of 
association between the silica particles and PEI, which should impact on the intracellular 
process of plasmid delivery. The second point that needs to be addressed is related to the 
possible applications of these materials. Above-described results were obtained using 
immortalized mouse fibroblast cells, which constitute a robust and easy-to-work model. 
However, if medical applications are foreseen, the technology has to be transferred to human 
cells. Therefore it was of primary importance to study the transfection efficiency of the 
silica@PEI vectors in primary skin cells, both in 2D and 3D configurations. 
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CHAPITRE III 
Influence de la chimie des particules de silice et du type 
cellulaire sur l’efficacité de la transfection 
 
 
Résumé 
Dans ce chapitre, nous avons exploré plus avant les capacités de transfection des 
particules de silice. Nous avons tout d’abord tenté de moduler l’efficacité de transfection en 
changeant la nature de l’interaction silice-PEI. Pour cela, des groupements sulfonates et 
chlorure d’alkyle ont été introduits en surface. Les particules non modifiées ont montré une 
quantité maximale de PEI adsorbé et une efficacité de transfection optimale. La présence de 
sulfonates diminue ces deux paramètres malgré un ratio optimal particule:ADN similaire aux 
particules nues. La liaison covalente a un impact négatif sur l’ensemble des propriétés. Ces 
résultats indiquent que le renforcement des interactions silice-PEI peut être défavorable à la 
transfection. Ceci suggère que le détachement du complexe PEI:ADN de la particule dans les 
endosomes est une étape clé de ce processus. Dans un deuxième temps, nous avons étudié la 
transfection de cellules humaines primaires, en vue d’applications in vivo. Nous montrons 
que la transfection en 2D par des particules silice-PEI est possible avec des fibroblastes et des 
keratinocytes humains et en 3D avec les fibroblastes, mais avec des efficacités moindres que 
pour les cellules 3T3. Ceci est attribué au plus faible taux de prolifération des cellules 
primaires. 
 
En révision dans Langmuir 
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III-1. GENERAL INTRODUCTION 
Despite the success of our strategy based on collagen-based nanocomposite hydrogels, further 
steps were required before being able to propose a fully functional biomaterial. First, the 
performances of PEI-coated silica particles in terms of transfection efficiency were 
significantly smaller than PEI (25 kD) alone. We hypothesized that the modulation of the 
silica-PEI interactions may impact on the plasmid loading, complex internalization and/or 
transfer to the cell nucleus. As shown hereafter, varying the strength of interaction between 
the particle surface and the polymer indeed has a deep impact on the transfection efficiency. 
This study also provides interesting insights on the intracellular mechanism of transfection. 
The second point to be addressed was related to the extension of our approach from 
immortalized fibroblasts to human primary cells, a necessary step if cellularized dressings are 
targeted. The study illustrates the cell-dependent efficiency of the transfection, particularly 
emphasizing the relationship between the cell proliferation rate and the protein expression 
efficiency. 
 
III-2. IMPACT OF POLYETHYLENEIMINE CONJUGATION MODE ON 
CELL TRANSFECTION EFFICIENCY OF SILICA NANOPARTICLES  
III-2-1. Preparation and Functionalization of Silica Nanoparticles 
In order to study the influence of the conjugation mode of PEI on the transfection efficiency 
of the silica nanoparticles, we have prepared three different particles : naked particles SiO2, 
particles grafted with propylsulfonate moieties SiO2-SO3, both of which can adsorb PEI via 
electrostatic interactions, and particles grafted with propylchloride moieties, allowing for its 
covalent grafting. Naked silica nanoparticles SiO2 (200 nm) and PEI (25 kD)-coated 
SiO2@PEI were prepared following the procedure described in section II-2-1.  
For SiO2-SO3@PEI particle preparation,1 the SiNP was first functionalized with thiol 
groups by silylation with 3-mercaptopropyltrimethoxysilane (MPTMS). Typically, 1 g of 
silica was dispersed in a mixture of 100 ml ethanol and 2.2 ml ammonium hydroxide solution 
before addition of 1 ml MPTMS. The mixture was stirred for 40 min at room temperature. 
Subsequently, the reaction mixture was heated to 80 °C and the total volume was reduced by 
2/3 by distillation of ethanol and ammonia at ambient pressure. Then, the mixture was cooled 
back to room temperature, centrifuged, washed 3 times with ethanol and dried at 60 °C.  
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The amount of –SH was determined by Ellman test.2 For this test, a phosphate buffer 
(0.2 M, pH = 7.3) was prepared and labeled as solution A. Solution B (10 mM EDTA) was 
produced by dissolving 372 mg of EDTA in 100 mL of solution A, and solution C (6 mM 5-
(3-Carboxy-4-nitrophenyl)disulfanyl-2-nitrobenzoic acid -DTNB) was prepared by dissolving 
238 mg of DTNB in 100 mL of solution A. Several vials were filled with a mixture of 8 ml of 
solution A, 1 mL of solution B and 1 mL of solution C. A series of masses of SiO2-SH, less 
than 50 mg, were measured and then each dispersed into a vial mixture solution. 
Simultaneously, several known quantities of thiol (obtained from a solution of MPTMS) were 
also introduced in the same mixture solution to determine the molar extinction coefficient by 
linear regression. After 45 minutes of stirring, the particle dispersion is filtered through a 
syringe filter. The absorbance of the filtrate and standard MPTMS solutions are determined 
by spectrophotometry. The absorbance of the solutions MTPMS can be traced back to the 
value for the experience of the molar extinction coefficient of NTB2- by linear regression.  
Then 0.9 g of the thus-obtained SiO2-SH was suspended in 45 mL hydrogen peroxide 
(H2O2 35%, Acros Organics) under stirring at RT for 48 hours. The solid product was washed 
by centrifugation with distilled water before addition of 35 mL of concentrated sulfuric acid 
(H2SO4 95.0-98.0%, Sigma Aldrich) and stirred for 2 hours at RT. Finally the as-synthesized 
SiO2-SO3 particles were washed with water, suspended in PBS and coated with PEI as 
described above.  
For SiO2-Cl@PEI particle preparation, 400 mg of SiO2 nanoparticles was dispersed in 20 
mL of dried toluene, and 1.3 mL of chloropropyltriethoxysilane (Cl-PTES) was added to the 
suspension, that was further kept under reflux for 24 h. The product was washed thoroughly 
with toluene and ethanol, and dried at room temperature. Then, 200 mg SiO2-Cl was 
dispersed in 20 ml ethanol, and 0.8 g of PEI was added to the suspension. The suspension was 
refluxed for 24 h. The final solid product was recovered by washing with ethanol and dried at 
room temperature. The as-synthesized SiNP-Cl@PEI was suspended in 10 mM PBS (pH 7.4) 
before use. 
III-2-2. Particle characterization 
Silica nanoparticles SiO2 were synthesized by the Stöber method and obtained with a low 
size dispersity (210 ± 20 nm, from TEM with a polydispersity index PDI = 0.005) (Figure 
III-1).  
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Figure III-1. TEM images of SiO2, SiO2-SO3, SiO2-Cl before(A-C) and after (D-F) 
modification with PEI 25 kDa  
 d 
(nm) 
ζ 
(mV) 
Cl:Si 
(wt%) 
N:Si 
(wt%) 
PEI 
(wt%) 
silane/ 
particle 
amine/ 
particle 
SiO2 214 ± 17 -15 ± 6 - - - - - 
SiO2@PEI 188 ± 68 +20 ± 7 - 11.0 12.7 - 5106 
SiO2-SO3 233 ± 38 -21 ± 8 - - - 1.5104a - 
SiO2-SO3@PEI 221 ± 20 +21 ± 9 - 3.8 4.2 NDb 1.5106 
SiO2-Cl 518 ± 308 -13 ± 6 2.7 - - 1.7106  
SiO2-Cl@PEI 806 ± 642 +18 ± 9 1.1 3.1 3.4 NDb 106 
afrom Ellman titration; bND= not determined 
Table III-1. Hydrodynamic diameter (d), zeta potential ζ in PBS, elemental analysis and 
calculated composition of the particles 
 
After coating with PEI, the particle hydrodynamic diameter (d) in PBS was not 
significantly modified but the PDI significantly increased to 0.127. The zeta potential (ζ) 
value turned from negative to positive in PBS, in agreement with the deposition of a cationic 
polymer (Table III-1). In the case of sulfonated SiO2-SO3 particles, neither surface 
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functionalization nor PEI sorption significantly impacted on the colloidal size distribution. 
The mean ζ value of SiO2-SO3 particles was slightly more negative than for bare silica, due to 
the presence of acidic sulfonate moieties, but the ζ value after PEI coating was similar for 
both particles. The SiO2-Cl nanoparticles showed a high tendency to aggregate, as such and 
after PEI conjugation, with high PDIs in both situations. However, the ζ values were not 
significantly different from the two previous systems (Table III-1).  
Elemental analysis allowed for the quantification of grafted moieties and amount of surface 
PEI (Table III-1). From the Cl:Si weight ratio, it was possible to estimate grafting density per 
particle of ca. 1.5x106 silanes for SiO2-Cl. For SiO2-SO3, the S content was below 0.1 wt% so 
that the silane density was obtained by the Ellman test, yielding to a grafting density per 
particle of ca. 1.5x104 groups. The Cl:Si ratio decreased from 2.7:100 to 1.1:100 upon reaction 
with PEI, supporting the occurrence of a nucleophilic substitution reaction between the 
propylchloride moiety and some amine groups of the polymer. In parallel, the highest amount 
of bound PEI was obtained for SiO2@PEI (12 w%) while the two other systems had a 
significantly lower binding capacity (4 wt% for SiO2-SO3@PEI and 3 wt% for SiO2-Cl@PEI). 
Surface modified particles before PEI sorption were studied using 29Si solid-state magic 
angle spinning (MAS) NMR measurements. These experiments, and all other NMR studies 
reported hereafter, were performed by S. Masse and G. Laurent (LCMCP) on a Bruker Avance 
III 300 MHz equipment.   
 
Figure III-2. 29Si MAS NMR spectra of (blue line) SiO2-SO3 and (green line) SiO2-Cl. 
Experiments were carried out using a single-pulse technique and high power 1H decoupling 
(HPDEC) at a 5 kHz spinning rate with 30° pulses and a recycling delay of 60 s with 720 and 
840 scans, respectively  
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As seen on Figure III-2, three main peaks at ca. -110 ppm, -100 ppm and  -90 ppm are 
obtained for both SiO2-Cl and SiO2-SO3. These resonances correspond to Q4 (Si(OSi)4), Q3 
(Si(OSi)3OR) and Q2 (Si(OSi)2(OR)2) silicon atoms (where R can be an organic group or an 
hydrogen atom). The predominance of Q4 species indicates that the particles have a high 
degree of condensation. When SiO2-Cl and SiO2-SO3 are compared, the former has a higher 
relative amount of Q3 and Q2 compared to the latter, in agreement with the larger grafting 
density. 
More information about the grafting reaction was obtained using 29Si-{1H} cross-
polarization (CP) MAS experiment.3 This technique allows to enhance the signal of silicon 
species that are in close proximity to hydrogen atoms. As seen on Figure III-3, two additional 
signals of weak intensity are present of the spectra of SiO2-SO3 at ca. -65 ppm and -57 ppm. 
They are more clearly evidenced of the spectra of SiO2-Cl, together with another signal at - 48 
ppm. These signals correspond to T3 (SiR’(OSi)3), T2 (SiR’(OSi)2OR) and T1 
(SiR’(OSi)(OR)2) silicon species, respectively, where R’ is an organic group covalently bound 
to Si. Although these species have long been attributed to organosilanes that are individually 
attached to the silica surface by 1 to 3 Si-O-Si bonds, it is now well-accepted that silanization 
of silica particle surface leads to more complex situations where pre-condensed short chains of 
silanes are formed before grafting.4  
 
 
 
Figure III-3. 29Si-{1H} CP MAS NMR spectra of (blue line) SiO2-SO3 and (green line) SiO2-
Cl. Experiments were carried out with a recycling delay of 1 s, a 1 ms contact time with 4096 
scans for both samples  
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The surface composition of the particles was studied by X-Ray Photoelectron 
Spectroscopy in collaboration with C. Méthivier, Laboratoire de Réactivité de Surface. The 
surveys of uncoated and coated particles, together with pure PEI are shown in Figure III-4, 
together with the relative abundance (in atom %) of each element. Detailed spectra for each 
region are provided at the end of this chapter, except for N1S provided as Figure III-5. 
For PEI, carbon and nitrogen elements are identified in a C:N atomic ratio of 70:30, in 
fair agreement with the overall C2H5N formula of ethylene imine. The C1s data show an 
asymmetric peak in the 284-288 eV region, corresponding to the overlap of C-C (285 eV) and 
C-N (287 eV) signals.5 The N1s signal consists of a single peak centered à 399 eV that can be 
attributed to primary/secondary/tertiary amines. For SiO2, the typical peaks of amorphous 
silica are observed at 103 eV (Si2p) and 534 eV (O1s).6 A weak C1s signal is also obtained that 
can be attributed to carbon surface contamination as well as possible unhydrolyzed Si(OC2H5) 
moieties. 
The XPS spectrum of SiO2@PEI particles combines the Si, O and C peaks of SiO2 and PEI. 
However, the N1S data showed two populations at 399 eV and 401 eV in a 56:44 intensity ratio, 
the latter corresponding quartenary amines (Figure III-5).7 The presence of sulfonate groups 
could be ascertained by the presence of a S2s signal at 232 eV for SiO2-SO3.8 Compared to 
SiO2, the C1s region showed an additional signal near 289 eV that can be attributed to the C-S 
bond. PEI coating did not significantly modify the C, O, Si and S signals. At the N1s level, the 
399 eV and 401 eV peaks are again identified but with an intensity ratio of 64:36. For SiO2-Cl, 
the Cl2p peak near 200 eV confirms the successful grafting of Cl-PTES.9 Similarly to SiO2-
SO3, the C1s signal shows a high energy contribution corresponding to C-Cl bond. For SiO2-
Cl@PEI, the Cl2p signal was still clearly evidenced but a slight decrease of the Cl:Si ratio was 
found, in qualitative agreement with the elemental analysis results. The signal at the N1s level 
indicates a unprotonated:protonated amine ratio of 72:28, the highest value in this series. 
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Figure III-4. XPS  survey spectra of PEI (top image) and particles before (left hand column) 
and after (right hand column) reaction with PEI.  
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Figure III-5. XPS spectra at the N1s level and their deconvolution for pure PEI and PEI-
coated particles.  
 
Attempts were made to further characterize PEI immobilized on the particle surface using 
13C NMR. Although the main idea was to compare the 13C-{1H} CP-MAS NMR spectra of 
the polymer before and after sorption, the problem was faced that pure PEI is a liquid. 
Therefore the CP-MAS approach cannot be applied to this sample and the only spectra that 
could be recorded was the 13C High Power Decoupled (HPDec)-MAS spectra. This spectrum 
is shown on Figure III-6 and compared to the 13C-{1H} CP-MAS NMR spectra of 
SiO2@PEI. As expected, PEI in the liquid state shows well-defined narrow resonance peaks 
in the 35-60 ppm region. In contrast, adsorbed PEI shows two broad bands in the same region 
due to its low mobility. It is clear from this comparison that it is not possible to draw any 
conclusion on the chemical or structural modification of PEI after sorption from this 
technique.  
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Figure III-6 Blue line: 13C HPDec spectra of PEI (Recycle time: 3s@30°; NS: 280; 
rotation: 300 Hz); green line: 13C-{1H} CP-MAS NMR of SiO2@PEI (Recycle time: 1s; 
contact time: 1ms; NS: 4096; rot: 5 kHz) 
The possibility to focus on the grafted moieties rather than PEI itself was then studied. This 
allows for the comparison of these functions before and after PEI reaction in the solid state. 
The drawback is that, based on the chemical composition of the particles, the intensity of the 
resonances belonging to the grafted groups were expected to be smaller than that of PEI and 
that some overlap may exist between the peaks of the two systems. This happened to be the 
case for SiO2-SO3 that was not further studied. In contrast, for SiO2-Cl (that has a significantly 
higher amount of grafted moieties compared to SiO2-SO3), some resonances of high intensity 
could be observed outside the chemical shift region of PEI (Figure III-7). However, although 
a comparison between the two spectra shows some modifications of the relative intensities of 
the peaks, it is still difficult to draw any useful conclusion from these spectra. 
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Figure III-7 13C-{1H} CP-MAS NMR of (blue) SiO2-Cl and  (green) SiO2-Cl@PEI 
(Recycle time: 1s; contact time: 1ms; NS: 4096; ro: 5 kHz). 
 
It was then hypothesized that the covalent binding of the propylchloride chain to PEI may 
have an effect on the propyl chain mobility. To check this, an inversion recovery cross 
polarization (IRCP) approach was used.10 This technique allows for the discrimination of 
elements of different mobilities in a single system but also to compare the mobility of different 
systems. This mobility can be estimated from the inversion time ti at which a given NMR 
signal turns from positive to negative. The IRCP-MAS NMR spectra of SiO2-Cl is shown in 
the upper part of Figure III-8. Resonances at 10 ppm, 28 ppm and 48 ppm correspond to the 
propyl chain whereas the peaks at 17 ppm and 59 ppm correspond to unhydrolyzed ethoxy 
groups of TEOS. Focusing on the 48 ppm signal corresponding to the C atom in α position of 
the Cl atom, its inversion time lies in the 200-300 µs range. The lower part of Figure III-9 
shows the IRCP-MAS NMR spectra of SiO2-Cl@PEI. In this case, ti can be estimated in the 
50-70 µs range. Such a decrease in inversion time is correlated with an increase of the cross-
polarization rate and therefore a decrease in mobility of the Cα atom, supporting the 
occurrence of a strong interaction between the end of the propyl chains and PEI. 
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Figure III-8. 13C Inversion recovery cross polarization (IRCP)-MAS NMR spectra of (a) 
SiO2-Cl and (b) SiO2-Cl@PEI. Main acquisition parameters used for the IRCP exp.: Recycle 
time: 1s; contact time: 1ms; NS: 4096; ro: 5 kHz; inversion time ti (from top to bottom): 5, 10, 
20, 30, 50, 70, 100, 200, 300, 500, 700, 1.000, 3.000, 5.000, 10.000 µs.  
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III-2-3. Transfection experiments 
Protocols used in the following section were the same as those described in Chapter II, 
except for the additional use of primary normal human keratinocytes (NHK) that were 
cultured in keratinocytes growth medium 2 (Promocell) supplemented with CaCl2.   
In a first step, the optimal p-Gluc:particle ratio was determined by gel electrophoresis 
using the procedure described in section II-2-2 (Figure III-9). Full retention was achieved for 
pGLuc:SiO2@PEI and pGLuc:SiO2-SO3@PEI: weight ratios of 1:30 whereas a 1:50 ratio was 
optimal for pGLuc:SiO2-Cl@PEI. These ratios were used to evaluate the potential of 
particles@PEI systems to deliver G-Luc plasmids into 3T3 fibroblasts and human primary 
keratinocytes. 
 
 
 
Figure III-9. Agarose gel electrophoresis showing the influence of PEI conjugation mode on 
pGLuc complexation. A constant amount of pGLuc (1)g) was complexed with particles at 
1:3, 1:10, 1:30 and 1:50 weight ratios. 
 
Delivery of therapeutic genes from PEI-coated silica nanoparticles requires the particles 
uptake by cells. Particle internalization within mouse 3T3 fibroblasts was checked using 
fluorescent FITC-silica nanoparticles after 48 h of contact. Observations by fluorescence 
microscopy evidenced the accumulation of colloids near the cell nucleus for SiO2@PEI and 
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SiO2-Cl@PEI (Figure III-10A). Bleaching of the FITC probes during sulfonate particle 
preparation hindered their intracellular observation. Cytotoxicity of uncoated and PEI-coated 
particles was also studied on 3T3 fibroblasts. This study consisted in the measure of cell 
viability of fibroblasts incubated with increasing doses of particles (Figure III-11B). For 
particle@PEI systems, cell viability was always higher than 80 %, indicating the absence of 
significant cytotoxicity up to 50 µg.mL-1 in PEI. In contrast, PEI alone was detrimental to cell 
viability at a dose > 5 µg.mL-1. Uncoated particles were evaluated using the same silica 
weights, showing no visible cytotoxicity effect.  
 
            
Figure III-10. (A and B) Fluorescence microscopy image showing internalization of 
pGLuc:particle@PEI by 3T3 fibroblasts after 48 h of incubation (green: FITC-labeled 
particles, blue : DAPI nuclei staining, scale bar = 20 µm) ; (C) Impact of PEI, particles and 
particle@PEI systems on 3T3 cell viability at the end of transfection experiments as 
monitored by the Alamar Blue test. Bar: 50)m. 
The transfection efficiency of the particles was evaluated in 3T3 mouse fibroblasts and 
primary human keratinocytes using a plasmid encoding for Luciferase (pG-Luc) (Figure III-
11). Quantities of polymers used in this experiment were not toxic for cells with the aim of 
comparing the abilities of transfection of the different systems. The ability of transfection was 
first analyzed on immortalized 3T3 fibroblasts (Figure III-11A). Among particles, the 
highest bioluminescence level was obtained with SiO2@PEI, that was one order of magnitude 
below that of PEI alone. The efficiency of SiO2-SO3@PEI particles was ten times lower than 
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that measured with SiO2@PEI. Last, a very weak luciferase activity was observed with the 
SiO2-Cl@PEI system.   
 
 
Figure III-11. Transfection of mouse 3T3 fibroblasts (A) and human primary keratinocytes 
(B) after a 4 h incubation period with pGLuc :particle@PEI systems. Variance of the 
luciferase expression among particle groups was determined by one-way ANOVA with 
Tukey posthoc test (*** P < 0.001) 
 
Indeed, the luciferase activity was only the double of the basal level quantified in controls 
samples (without pG-Luc). The potential of PEI@particles to delivery genes was also 
investigated on primary normal human keratinocytes (Figure III-11B). The bioluminescene 
levels measured after incubation with the different systems of particles revealed the same 
profiles of transfection as those observed in 3T3 cells. The best ability of transfection was 
obtained with SiO2@PEI. The transfection efficiency was three times lower with SiO2-
SO3@PEI particles and that measured with the SiO2-Cl@PEI system was very low. 
Compared with the performance of the different particles@PEI systems on 3T3 cells, the 
bioluminescence levels measured with keratinocytes were two times lower.  
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III-2-4. Discussion 
 
III-2-4-1. Influence of conjugation mode on PEI attachment 
These data indicate that the conjugation mode impacts on PEI content, charge and plasmid 
binding ability. For SiO2@PEI, using a particle radius of 100 nm and a silica density of 2 g.cm-
3, the total amount of amine groups per particle can be estimated to ca. 5.106 from elemental 
analysis (Table III-1). The ammonium/total amine ratio obtained by XPS is ca. 45 % (i.e. ca. 
2.2x106 ammonium per particle). As a comparison a 30 % value was reported for PEI in a 
buffer solution (pH 7.4), suggesting that partial PEI protonation occurred during the adsorption 
process.11 A density of 3-5 silanol per nm2 was reported for amorphous silica surfaces, i.e. 4-
6x105 SiOH for 200 nm particles, with 20 % of acidic (pKa = 4.5) and 80 % of basic (pKa = 
8.5) groups.12 The increase in PEI protonation may therefore arise from an acid-base reaction 
with the silanol groups. Comparing 5x105 SiOH with 2.2x106 N+ per particle, the 
silanol:ammonium ratio is 1:4-5 so that the positive charge of PEI is not balanced by the 
negative charge of silica, explaining the positive ζ value of these systems.  
For SiO2-SO3@PEI, the protonation degree of PEI is closer to the reported value in buffer 
(36 % vs. 30 %). Sulfonate groups are fully deprotonated at pH 7 so that proton exchange with 
PEI was not expected. The fact that the silanol groups do not significantly interact with the 
polymer suggests that PEI is kept apart from the silica surface. Interestingly, combined 
elemental analysis and XPS indicate that there are 5x105 ammonium groups per particle to be 
compared with 1.5x104 sulfonate groups. This observation can be compared with a recent 
study devoted to the sorption of collagen triple helices on the surface of silica particles.1 For 
bare particles, a large amount of collagen was readily adsorbed, suggesting that the protein 
adopts a flat configuration on the particle surface. In contrast, sulfonate-bearing particles could 
adsorb less collagen but the proteins had a more ordered organization. It was suggested that the 
sulfonate groups could act as anchoring points for the protein chains that protrude out of the 
surface rather than laying flat, so that the amount of sorbed collagen was limited by the steric 
constraints of the triple helices packing. A similar situation can be reasonable assumed for the 
present system (Figure III-12). Noticeably, naked particles have a lower initial negative 
charge, bind more PEI with a higher degree of protonation than sulfonated ones, so that it was 
expected that they exhibit a higher positive surface charge after coating. However the two 
systems show close ζ values. This can be explained considering that silanol groups of the 
surface can contribute to the overall particle charge for SiO2 whereas these moieties are 
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screened by the sulfonate/PEI layer, strengthening our model of a flat vs. compact organization 
of the polymer in the two systems.  
 
 
Figure III-12. Schematic representation of the different conjugation modes of 
polyethyleneimine (PEI) with silica particles and proposed PEI configuration: non-specific 
adsorption on silica particles (SiO2@PEI), strong electrostatic interactions with sulfonate-
modified silica particles (SiO2-SO3@PEI) and covalent bond with propylchloride-grafted 
silica particles (SiO2-Cl@PEI). 
 
For SiO2-Cl@PEI, the protonation degree of PEI is similar to its free form in buffer and the 
number of amines per particle is ca. 106. This value is in the same range as the initial density of 
propylchloride groups (1.5x106). Elemental analysis indicate that one half of the Cl atoms are 
no longer present after reaction with PEI. Taken together these data suggest that an important 
fraction of the PEI amine groups have reacted with the propylchloride moieties. It is therefore 
possible to assume that each PEI chain is bound to the particle surface by several anchoring 
points, decreasing its conformational flexibility and therefore its maximum packing density on 
the surface, resulting in a low PEI loading (Figure III-12). Noticeably, SiO2-Cl@PEI has a 
similar ζ value to SiO2@PEI, which can be explained considering that the less negative surface 
charge of the chlorinated surface compared to bare particles is compensated by lower PEI 
loading and lower PEI protonation. 
Considering the optimal plasmid:PEI ratio, it depends on the positive charge of PEI, as the 
PEI-plasmid system is a polyelectrolyte complex, as well as on the PEI flexibility, that 
determines its ability to wrap and compact DNA.13,14 The amount of PEI per particle must also 
be considered for the optimal plasmid:particle ratio. SiO2@PEI and SiO2-SO3@PEI particles 
have a similar optimal pGLuc:particle@PEI ratio although the former has a higher polymer 
loading with a larger proportion of ammonium groups than the latter. As pointed out earlier, 
the ζ value is not a suitable parameter to compare the complexing ability of the systems as it 
can include a contribution of the silica particle surface that is not involved in the DNA 
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wrapping process. Rather PEI conformation has to be considered (Figure III-8). For SiO2, the 
extended conformation of the polyelectrolyte is not favorable for DNA wrapping whereas the 
local anchoring of PEI on the surface of Si-SO3 should better preserve its structural flexibility. 
For SiO2-Cl, as mentioned earlier, its flexibility should be limited by the high density of 
covalent bonds, resulting in a low pG-Luc:particle@PEI ratio. 
 
III-2-4-2. Influence of conjugation mode on transfection efficiency 
Despite their extensive study, the exact mechanisms driving cell transfection by non-viral 
vectors are still controversial.15 Yet the main steps of the process have been identified. First, 
the DNA complex must be internalized by endocytosis, a process that depends on its size and 
charge. Here, the three particles exhibit similar positive charges compatible with 
internalization. SiO2@PEI and Si-SO3@PEI particles have similar dimensions (ca. 200 nm) in 
PBS whereas SiO2-Cl@PEI dispersions show a tendency to aggregate into larger species (ca. 
800 nm). Nevertheless fluorescence images suggest the successful internalization of a fraction 
of SiO2-Cl@PEI particles. This could be explained by the de-aggregation of SiO2-Cl@PEI, 
allowing the uptake of individual particles. A second hypothesis relies on the polydispersity 
of SiO2-Cl@PEI particles. According to the results obtained by DLS, a small fraction of 
particles possesses the appropriate size (less than 400 nm) to be engulfed by cells. Despite the 
fact that the uptake abilities are cell dependent, it is generally admitted that particles larger 
than 500 nm are not likely to be internalized by endocytosis in mammalian cells.16,17 This 
could explain the very low level of transfection. The question of the particle size, rather the 
covalent bonding seems to a crucial parameter for cellular uptake of SiO2-Cl@PEI. Several 
groups have functionalized PEI by covalent attachment on mesoporous silica nanoparticles or 
on hyaluronic acid chains. They obtained particles:DNA complexes with a limited 
aggregation (less than 350 nm), thereby permitting cellular uptake and transfection.18-20 In 
addition, some of these particles were functionalized with mannose facilitating the 
engulfment by receptor-mediated endocytosis.19 Last, the studied cells were macrophages that 
are cells with high efficiency of engulfment.  
In a second step, DNA must be released in the cytoplasm. This is possible via endosome 
acidification leading to endosomal membrane disruption. The plasmid carrier can play a role 
both in the destabilization of the endosome via the proton sponge effect and in the protection 
of DNA against acidic degradation. The first effect increases with the amount of PEI and 
should therefore be more favorable with SiO2. The protecting effect depends on the PEI 
quantity, its conformation and flexibility. The ratio PEI:DNA for SiO2@PEI , Si-SO3@PEI,  
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SiO2-Cl@PEI were 3.8, 1.2 and 1.7, respectively. According to the results of cell viability, 
these ratios were not associated with any cytotoxicity.  It is well-admitted that the transfection 
capabilities increase when the PEI:DNA ratio rises.21 Hence, the quantity of PEI on SiO2 
particles could explain in part its higher transfection ability because of its impact on DNA 
compaction and protection against nucleases. Nevertheless, the conformation of PEI at the 
surface also plays an important role and is expected to be optimal for the Si-SO3@PEI system.  
In a following step, the released plasmid must diffuse to the nucleus and enter, either during 
mitosis or via the nuclear import machinery. Importantly, the stage at which PEI and DNA are 
dissociated is still a matter of debate.15 However, focusing on the particle-PEI interactions, it 
is interesting to note that in the acidic conditions of the endosomes, an important fraction of 
the silanolate groups of the bare silica particles become protonated. This decreases the 
negative charge of the carrier, favoring PEI desorption. On the opposite, sulfonate functions 
should remain negatively-charged, preserving their attractive interactions with PEI. Finally, 
for SiO2-Cl, the existing covalent bonds are not expected to be cleaved, limiting the possibility 
for complexes to escape. These trends in PEI detachment from particles nicely follow the 
measured transfection efficiencies, suggesting that such a release is a relevant event in the 
plasmid delivery process.  
Surprisingly, the performance of PEI alone was not better than that of the SiO2@PEI 
system for keratinocytes, in contrast to the results obtained with 3T3 cells. The highest cell 
transfection observed with PEI compared to particles on immortalized cells could be 
explained by the particle size and the metabolic activity of 3T3 fibroblasts. PEI/DNA 
complexes measure about 100 nm in diameter.22 These complexes are rapidly uptaken by 
cells via the chlatrin-mediated endocytosis. In contrast, larger particles@PEI systems are 
more internalized by the caveolin-mediated endocytosis.23 Therefore the chlatrin pathway 
seems to be more efficient in 3T3 fibroblasts to engulf complexes. Second, 3T3 cells 
proliferate rapidly, facilitating plasmid transfer by disruption of the nuclear membrane during 
cell division. Thus it can be proposed that PEI complexes are rapidly uptaken, transported to 
the nucleus and that protein expression occurs at a very high rate thanks to fast proliferation. 
In contrast, the uptake of particles being less efficient, there is a delay required for sufficient 
plasmid accumulation before significant protein expression is achieved. In the case of primary 
cells such as keratinocytes, the cells proliferate at a lower rate. Therefore the overall protein 
expression rate is slower for both systems. Moreover, in these conditions, it is possible for 
silica particles to accumulate in a higher quantity between two cellular division event, so that   
the protein expression level becomes comparable to that of PEI.  
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III.2.5 Conclusion 
One of the starting hypothesis of this study was that enhancing the interactions between the 
silica surface and PEI would allow to immobilize more polymer on the particle so as to 
complex more DNA and possibly enhance transfection efficiency. However, our study 
showed that the opposite situation occurs. The naked silica surface offers an open area of 
silanolate groups available for unspecific adsorption of extended PEI chains. The introduction 
of well-defined moieties provides a smaller number of binding sites leading to a decrease in 
the amount of immobilized PEI. Moreover, the persistence of significant interactions between 
the silica surface and PEI in the acidic conditions of the endosomes appears detrimental to the 
gene delivery. Yet data obtained with sulfonated particles suggest that this situation leads to a 
more favorable PEI conformation. Therefore it would be interesting to change the nature of 
the grafted moiety, for instance using carboxylate groups whose pKa is closer to endosomal 
pH, and also to achieve a better control of the grafting density. In parallel, our hypothesis 
concerning PEI:DNA detachment has to be supported by further experiments. In particular, 
the use of fluorescence resonance energy transfer (FRET)24 techniques would be particularly 
useful to monitor the fate of SiO2:PEI:DNA complexes in the intracellular media. 
 
III.3 IMPACT OF CELL TYPE ON THE TRANSFECTION EFFICIENCY OF 
POLYETHYLENEIMINE-COATED SILICA NANOPARTICLES  
III-3-1. Cell Culture and Experimental Conditions 
In this study, human primary dermal fibroblasts and epidermal keratinocytes were selected as 
they are relevant cells in the pathophysiology of cutaneous chronic wounds. Human primary 
fibroblasts culture was performed using the same protocol than that for 3T3 cells.  For 
keratinocytes, the protocol was also similar except for the culture medium as described in the 
section III-2-2. The protocols used for collagen-silica hydrogels preparation and transfection 
experiments in 2D and 3D were the same as those described in Chapter II, except when noted. 
 
III-3-2. Human Primary Dermal fibroblasts 
III-3-2-1. 2D experiments 
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Transfection studies were performed with dermal fibroblasts seeded in culture wells and bare 
silica nanoparticles 200 nm (SiNP) in diameter coated with PEI 25 kDa and 10 kDa.  Pure PEIs 
of same molecular weight were evaluated in parallel. As shown in Figure III-13, the 
transfection efficiency follows a similar trend as found for 3T3 cells (see Figure II-6 in 
previous chapter). When coated on silica nanoparticles, PEI10 exhibited a higher ability to 
deliver plasmidic DNA compared to its soluble form. Interestingly, silica nanoparticles coated 
with PEI10 and PEI25 showed the same performance of transfection. However some differences 
were found between immortalized and primary fibroblasts. First the RLU values for human 
primary fibroblasts are at least one order of magnitude below that of 3T3, the difference 
reaching two orders of magnitude for PEI25. Second, PEI10 is significantly less efficient than 
PEI25-coated particles for human cells.  
 
Figure III-13. Transfection of human fibroblasts after 4 h incubation with free and SiNP 
coated with PEI of various molecular weights (n=3).  
The cytotoxicity of the different systems towards human fibroblasts was also evaluated 
after 4 h of contact using the Alamar Blue test (Figure III-14), evidencing no significant 
impact on cell viability. 
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Figure III-14. Human fibroblast viability in 2D as influenced by different molecular weight 
of PEI without or with SiNP. Cell viability was assessed after 4 h of contact with Alamar 
Blue test and calculated in the percentage of control (n=3).   
III-3-2-2. 3D experiments 
These experiments were performed by co-encapsulation of human fibroblasts and plasmid-PEI 
or plasmid-SiNP@PEI complexes in 1 mg.mL-1 hydrogels. In order to optimize plasmid 
content, a first series of experiments was performed with PEI25 only with pGLuc content 
between 2 and 8 µg/gel and a pGLuc:PEI weight ratio of 1:2. As seen on Figure III-15, 
maximum transfection was observed over 7 days for the intermediate plasmid content (4 µg) 
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Figure III-15. Transfection of human fibroblasts co-immobilized with pGluc-PEI25 
complexes in collagen hydrogels after 3, 5 and 7 d of contact, using 2, 4 and 8 µg of plasmid 
/gel 
Viability tests performed over the same period showed that the system containing the 
highest plasmid content has a significant but limited cytotoxicity, that can correspond to the 
associated high concentration of PEI (Figure III-16). Hence the observation of an optimal 
value at 4 µg can be attributed to the achieved compromise between low plasmid content (2 
µg) and cytotoxicity of PEI (8 µg). 
 
Figure III-16. Cell viability of human fibroblasts co-immobilized with pGluc-PEI25 
complexes in collagen hydrogels after 7 days, using 2, 4 and 8 µg of plasmid /gel in collagen 
as evaluated with Alamar Blue test and calculated as the percentage of the control (n=3). 
 
Transfection experiments using co-immobilized PEI-coated silica nanoparticles were 
therefore performed with a 4 µg plasmid content per gel (1 mL each). In these conditions, it 
was observed that the transfection efficiency of particles was much lower than that of free 
PEIs (Figure III-17). However, compared to the control, significant bioluminescence levels 
could be observed from day 5 to 12 for the two PEI-coated systems. At day 12, the RLU 
values were two orders of magnitudes higher than that measured in the control samples 
(Figure II-13). Nevertheless, the luciferase expression obtained with dermal fibroblasts was 
one order of magnitude below the values obtained with 3T3 cells. Some differences were 
observed in terms of profile of transfection between the different conditions. For instance, 
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PEI-coated systems did not have the same performance of transfection compared to the free 
PEI 10 kDa.  
 
 
 
Figure III-17. Transfection of human fibroblasts co-immobilized with p-GLuc-PEIx and 
pGLuc-PEIx-SiNP complexes in collagen hydrogels after 3, 5, 7 and 12 days of contact, 4 µg 
of plasmid /gel. Bottom graph focuses on the silica particle systems (n =3).  
Viability tests indicated that these differences could not be attributed to cytotoxic 
effects of the plasmid carriers (Figure III-18) 
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Figure III-18. Cell viability of human fibroblasts co-immobilized with p-GLuc-PEIx and 
pGLuc-PEIx-SiNP complexes in collagen hydrogels after 7 days as evaluated with Alamar 
Blue test and calculated as the percentage of the control (n=3). 
 
III-3-3.  Human keratinocytes 
III-3-3-1. 2D experiments 
In a first step, transfection experiments were performed using a pGluc:PEIx-SiNP ratio of 
1:30, similar to previous studies. However, in these conditions, very low transfections 
efficiencies were obtained that could be correlated with high cytotoxicity. Lower 
plasmid:particle weight ratios (from 1:5 to 1:20 at constant plasmid content) were therefore 
evaluated. As shown on Figure III-19, the cytotoxicity of the particles could efficiently be 
lowered by decreasing their concentration. The ratios used in these experiments are lower 
than the optimal ones. Hence it is possible than a small quantity of pDNA has not been 
complexed.  
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Figure III-19. Human keratinocyte viability as influenced by different molecular weight of 
PEI and different plasmid:particle ratio. Cell viability was assessed after 4 h of contact with 
Alamar Blue test and calculated in the percentage of control (n=3).   
 
The transfection efficiency of these different systems was also studied (Figure III-20). 
Here again, the bioluminescence levels were lower than for 3T3 cells. This can be in part due 
to the lower plasmid:particle ratios used. Moreover PEI-coated particles had very similar 
efficiency to free PEI. The optimal conditions for particle systems resulted from a 
compromise between a low plasmid:carrier ratio that corresponds to a larger fraction of 
pGLuc interacting with the particles and therefore being able to be uptaken, and a high 
plasmid:carrier ratio that corresponds to a lower particle concentration and therefore lower 
cytotoxicity.  
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Figure III-20. Transfection of human keratinocytes after 4 h incubation as influenced by 
different molecular weight of PEI and different plasmid:particle ratio (n=3).  
 
III-3-3-2. 3D experiments 
Contrary to fibroblasts, keratinocytes do not survive within collagen hydrogels. Therefore a 
pseudo 3D model was used where the complexes, being pGLuc-PEI or pGLuc-SiNP@PEI, 
are immobilized in the collagen hydrogel and keratinocytes are seeded on its surface. 
In these conditions, only free PEI25 led to a bioluminescence level that was statistically 
different from the control (Figure III-21). Again these differences could not be attributed to 
toxicity effects (Figure III-22). These results are in good agreement with the data obtained 
for 3T3 cells (see Figure II-16) and suggest that only the pGLuc-PEI25 complex can migrate 
out of the hydrogel. 
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Figure III-21. Transfection of keratinocytes seeded on collagen hydrogels containing p-
GLuc-PEIx and pGLuc-PEIx-SiNP complexes after 3, 5 and 7 d of contact.  
 
Figure III-22. Cell viability of human keratinocytes seeded on collagen hydrogels containing 
p-GLuc-PEIx and pGLuc-PEIx-SiNP complexes after 7 days of contact as evaluated with 
Alamar Blue test and calculated as the percentage of the control (n=3). 
 
 
III-3-4. Discussion and conclusion 
The efficiency of transfection depends on the ability of cells to uptake polyplexes. In addition, 
gene delivery and transgene expression is facilitated when the cells have a high proliferative 
rate. When used in their soluble form, the performance of PEI 25 KDa and PEI 10 KDa, is 
much lower than that observed with 3T3 cells. To reach the same amplitude of transfection, it 
 135 
was necessary to increase the quantity of DNA by 4. This can be explained by the doubling 
time of primary cells that is much longer than immortalized cells. Fontana et al have shown 
that several micrograms of polyplexes were required to efficiently transfect adipose stem cells 
encapsulated in HA/collagen microgels.25 However, the results obtained with primary cells 
are in agreement with the general scheme of cell transfection in 3D systems.  
Unlike 3T3 cells, free forms of PEI are always more effective on dermal fibroblasts 
than the PEI-coated systems. Primary dermal fibroblasts do not have the same ability of 
migration as 3T3 cells. When immobilized in a 3D collagen gel, fibroblasts stop migrating 
after a few days. Then, they differentiate into myofibroblasts and acquire contractile 
faculties.26,27 They contract the collagen network and their abilities to proliferate drastically 
decrease28. This weak proliferation could explain why gene delivery is less effective when the 
cells are encapsulated in a 3D collagen hydrogels compared to 2D conditions. Immortalized 
cells do not behave this way as they are unable to contract a 1 mg.mL-1 collagen gels and keep 
their migratory faculties. When they move they can be in contact with particles and uptake 
them. In the case of primary fibroblasts, this is not possible. Cells pull on collagen fibrils to 
bring them closer and contract the collagen network.26,27 This mechanism permits the 
interaction between the particles stuck on collagen fibrils and the cellular membrane. 
However, this mechanism is less effective to uptake particles compared to cell migration. This 
explains why the free forms of PEI are more effective to deliver genes because they can 
diffuse rapidly in the pores of the collagen network, encounter fibroblasts and transfect them. 
Transfection of collagen-entrapped complexes put in contact with keratinocytes also 
gave similar trends than 3T3 cells concerning the influence of PEI molecular weight and the 
influence of the silica particles. Only the free form of PEI is able to transfect keratinocytes 
seeded on the surface. This evidences one more time the confinement of PEI-coated silica 
nanoparticles within the collagen network.  
Noticeably, the viability of keratinocytes is more affected by the presence of silica 
particles than that of the primary fibroblasts. As a consequence, the ratios used in the 
experiments of transfections were lower. This result is surprising as the cytotoxicity of 
submicronic silica nanoparticles has not been described. Nabeshi et al have shown that 300 
nm SiNPs do not present any toxicity on keratinocytes until a1 mg.mL-1 dose is reached29. 
This dose is much higher than that used in this study.  However comparison between different 
sets of experiments is often difficult due to variations in particle size, structure, surface 
functionality, etc. Its understanding would require a much deeper study of the cellular 
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response to the silica particles. One particularly interesting observation is the difference in 
particle toxicity between keratinocytes and fibroblasts. As a matter of fact we could not find 
any explanation for this difference in the literature. Noticeably, such studies may be 
particularly valuable in the field of biomaterials for wound healing as one of the current 
material in the market, Apligraf®, combines these two kinds of cell associated with collagen 
30.  
 
III.4 CONCLUSION 
We have demonstrated that the mode of conjugation of PEI with the silica particle surface has a 
deep impact on the transfection efficiency of the inorganic carrier. Our data suggest that this 
impact is related to both PEI conformation and stability of the silica-PEI interface in the 
intracellular medium. We have also shown that silica-PEI particles have the ability to transfect 
human cells, although to a lower extent than immortalized fibroblasts. This difference in 
transfection efficiency was attributed to the lower proliferation rate of the primary cells. 
From a fundamental point of view, these studies have brought novel and important 
information about the mechanisms of gene delivery mediated by PEI-silica nanoparticles. 
From an application point of view, these results are rather disappointing as these carriers are 
significantly less effective than pure PEI25 in most situations. It is therefore important at this 
point to remind the advantages of the composite approach: (i) the SiO2@PEI particles are less 
cytotoxic than PEI alone at high doses, (ii) once immobilized within the collagen gels, they do 
not release complexed plasmids outside the material, (iii) silica particles may be loaded with 
an additional drug, allowing the design of medicated dressings delivering two bioactive 
molecules.  
On this basis, we decided to go a step further towards the design of a biofunctional 
nanocomposite material by evaluating the possibility to use silica-PEI particles as vectors for 
the delivery of a plasmid inducing the expression of IL-10, a protein relevant for our targeted 
application in chronic wound healing.   
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Résumé 
Dans ce dernier chapitre, nous avons exploré la capacité des nanocomposites à réguler 
l’inflammation en utilisant les particules de silice modifiées par le PEI comme vecteur d’un 
plasmide permettant l’expression de l’Interleukin-10 (IL-10). Dans un premier temps, la 
production d’IL-10 par des cellules 3T3 en culture 2D après transfection a été démontrée. Un 
modèle de macrophages activés par les LPS (lipopolysaccharides) a ensuite été mis au point. 
La réponse de ces cellules à l’IL-10 produites par les fibroblastes a été démontrée par la 
mesure par PCR quantitative de la décroissance du niveau d’expression du facteur TNF-α. 
Dans un deuxième temps, la production de l’IL-10 par les cellules 3T3 co-immobilisées avec 
les complexes au sein des hydrogels de collagène a été démontrée. Malgré les quantités 
élevées d’IL-10 produites au sein des nanocomposites, il n’a pas été possible d’observer 
l’impact de cette protéine sur les macrophages activés. Ce résultat nécessitera néanmoins 
d’être vérifié et l’expérience devra être étendue à des macrophages immobilisés dans les 
matrices de collagène.   
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IV-I INTRODUCTION  
Wound healing is a multi-cellular process which occurs after an injury, with the aim of 
restoring the integrity of skin. The phases of normal wound healing involve a range of growth 
factors and cytokines which act at different stages of tissue repair. Consequently, many of 
these bioactive proteins such as VEGF1, PDGF-BB2, TGF-β3 and IL-10 have been studied as 
therapeutic drugs to promote the healing process. Among them, IL-10 has received a 
particular attention as potent anti-inflammatory biomolecule. This cytokine can inhibit the 
action of NO and the synthesis of a variety of inflammatory cytokines including IL-1β and 
TNF-α. More generally, IL-10 allows for the repolarization of pro-inflammatory macrophages 
into regulatory macrophages. These cells have a crucial role in the modulation of 
inflammation, thereby promoting cutaneous wound healing. IL-10 is also a product of glia 
(astrocytes and microglia) and leukocytes such as macrophages and dendritic cells, which 
express IL-10 receptors. Therefore, IL-10 delivery have been widely investigated to treat 
inflammation in central nervous system4, lung (e.g. pneumonia5), joint (arthritis6), heart 
fibrosis, liver7, colon 8 and even cancer9.  
Several trials of protein therapy have been attempted by injection of cytokine in the 
cutaneous wound bed. Unfortunately, these strategies have failed because of the rapid 
diffusion and their short half-life due to their degradation19. Hence, gene therapy represents an 
interesting alternative. Current strategies for IL-10 gene delivery rely on the systematic 
delivery or the local injection. Moreover, this was predominantly achieved by viral vectors 
such as (adeno-associated virus) AAV5, 10, (adenovirus) AV11 and (lentivirus) LV12 . A few 
attempts have been carried out with non-viral vector such as dendrimer13, PEI, alginate 
nanoparticles6, PAGA14 and PLGA microparticles15. For example, Jain et al. have developed 
a gene delivery system for the treatment of rheumatoid arthritis. In this study, pDNA 
encoding for IL-10 (pIL-10) was immobilized within alginate nanoparticles. Subsequently, 
particles were modified with tufstin peptide in order to target macrophages.6 This targeting 
system was found to be capable of repolarizing macrophages from inflammatory M1 
phenotype to anti-inflammatory M2 phenotype. Moreover, animals treated with the particles 
retained their mobility as a result of IL-10 expression. 
Scaffold-based delivery systems create a space for tissue growth and provide a support 
for cell adhesion and migration. More importantly, spatio-temporal control over bioactive 
molecules release can achieve the optimal efficacy while averting side effects. Gower et al. 
loaded Lentivirus carrying pIL-10 in porous PLGA scaffold. The main advantage observed 
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was a decreased inflammation following the scaffold implant. IL-10 delivery was found to 
decrease leucocyte infiltration in the implanted scaffold by 50%. Thus, this system has the 
potential to improve the therapeutic effect with minimal inflammatory response. Combination 
of gene and cell delivery is a promising approach to achieve optimal therapeutic efficacy. On 
the one hand, implanted cells can replace the damaged tissues and produce growth factors to 
favor tissue repair. On the other hand, the transfected cells can act as bioreactors to produce 
therapeutic proteins to promote tissue regeneration. However, few attempts have been made 
for the co-delivery of cells and genes. Holladay et al co-delivered stem cells and plasmid IL-
10 (pIL-10) in collagen sponges for the treatment of myocardial infarction.13 The complexed 
plasmids were adsorbed within the pre-formed collagen scaffold and stem cells were seeded 
on top of the sponges. The produced IL-10 downregulated the inflammatory response, thereby 
improving the survival of the transplanted stem cells. 
As shown in Chapter II, silica-collagen nanocomposties co-encapsulated with 
fibroblasts and plasmidic DNA gave promise for the local and sustained release of proteins 
using pGluc as a gene model. Herein, we further explored the possibility for the delivery of 
plasmid encoding IL-10 and measured the anti-inflammatory effect of IL-10 on LPS activated 
macrophages. More specifically, we evaluated our model as gene delivery system to down-
regulate the expression of pro-inflammatory cytokines such as TNF-α.  
IV-2. MATERIALS AND METHODS 
IV-2-1. Production of plasmid encoding human IL-10 (phIL-10) 
The phIL-10 plasmid purchased from Origene (USA) is obtained from the pCMV6-XL5 
plasmid in which the ORF cDNA sequence encoding for Human Interleukin 10 has been 
inserted. This plasmid was amplified by one shot BL21(DE3) pLysS kit (Invitrogen, Life 
technologies), extracted by one PureLink HiPure Plasmid kit (Invitrogen, Life technologies), 
and finally stored in Tris-EDTA buffer at −20 °C. 
IV-2-2. phIL-10-PEI and phIL-10-PEI-SiNP Complexation. 
The phIL-10-PEI complexes were prepared at weight ratio of 1:2. Silica nanoparticles 200 nm 
in diameter and coated with PEI 25 kDa or 10 kDa were used as vectors. The phIL-10-SiNP 
complexes were prepared at various phIL-10:PEI-SiNP weight ratios. Complex formation was 
examined by agarose gel electrophoresis. Briefly, 2 µL of phIL-10 solution (0.1 µg.µL−1) was 
mixed homogeneously with a total volume of 8 µL of PEI-SiNP suspension or PEI solution 
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(PBS 1×) by vortexing in a microcentrifuge tube. The resulting mixtures were left at room 
temperature for 2 h to achieve complete complexation, before being loaded into a 0.7% 
agarose gel with ethidium bromide (0.1 µg.mL−1) and running with TAE 1X (Tris acetate 
EDTA) buffer at 100 V for 40 min. DNA retardation was observed by irradiation with 
ultraviolet light. 
IV-2-3. Mouse fibroblast and macrophage Cell Culture 
3T3 mouse fibroblasts were cultured in complete cell culture medium as previously described 
in Chapter II. The mouse macrophage cell line (RAW264.7 cells) was purchased from 
Sigma Aldrich. The cells were grown and maintained in the same medium as 3T3 cells. These 
cells were harvested by scratching, centrifugation and suspended in a fresh medium. Cell 
counts were measured using a standard trypan blue cell counting technique. 
IV-2-4. Preparation of Silica-Collagen Nanocomposites 
Complexes were formed by adding 5 µg of phIL-10 to 125 µL of a solution containing PEI or 
PEI-SiNP in order to achieve the optimal phIL-10:PEI (or phIL-10-PEI-SiNP) ratio identified 
gel electrophoresis. 500 µL of a type I collagen solution was mixed with 245 µL of culture 
medium and he complexes were added to the mixtures After addition of 30 µL of 0.1 M 
NaOH and vortexing, 100 µL of the cell suspension at a density of 1.5×106 cells.mL−1 was 
added and mixed homogeneously. Last 0.9 mL was sampled from the mixture and deposited 
onto a 24-well plate. The plate was then incubated at room temperature for 10 min for 
complete gelling of collagen.  
IV-2-5. Cell Transfection and Cell Viability 
Transfection efficiency of phIL-10-PEI and phIL-10-PEI-SiNP was evaluated by the titration 
of the protein hIL-10 secreted in the cell culture medium using an Elisa-kit for hIL-10 
(Novex, life technologies). 
To perform cell transfection in 2D, 3T3 mouse fibroblasts were plated at a density of 5 
× 104 per well in a 24-well plate. phIL-10-PEI or phIL-10-PEI-SiNP complexes (25 µL, 
prepared as described above) were added to the cell culture medium. After 4 h, the 
supernatant was removed, the well was refreshed with 1 mL medium, and the cells were then 
cultured for another 44 h in complete medium for the expression of hIL-10. Last media from 
each well were collected and frozen until analysis.  
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For 3D experiments, silica-collagen nanocomposites were incubated with 1 mL of 
fresh medium. The ability of nanocomposites to produce and secrete hIL-10 was analyzed 
over one week. At day 2, 5 and 7, 500 µL of the culture medium was collected from the wells, 
frozen and replaced with an equal volume of fresh medium. Control groups were under the 
same culture condition as the experiment groups except for the absence of DNA complexes.  
Cell viability was monitored using the Alamar Blue test. For the 2D model, cell 
culture medium was collected after 2 days and replaced by 200 µL of the Alamar Blue 
solution (10% in cell culture medium). Cell viability was calculated and reported as a 
percentage of the control group as described in Chapter II (n = 3). Cell viability was assessed 
at day 7 in the 3D models (using the same procedure, except that 800 µL water was first 
added to the collagen gel for 0.5 h at room temperature to extract the Alamar blue solution 
trapped in the gel and then collected for the absorbance measurements. 
IV-2-6. Macrophage activation with LPS 
Mouse macrophages RAW 264.7 were seeded at a density of 105 and cultured overnight 
before activation with LPS (Sigma). A volume of a LPS stock solution (100 µg/mL) in PBS 
was added to each well to reach the final concentration of 1µg/mL or 0.1 µg/mL. At different 
incubation time, 1 h, 3 h and 6 h, cells were treated with Trizol (Invitrogen, Carlsbad, CA, 
USA) and then stored at -80 oC before RNA extraction. 
IV-2-7. Total RNA extraction and RT-PCR 
All studies were carried out in a designated PCR clean area. RNAs were extracted using 
RNeasy mini-kit (Qiagen, France) according to the manufacturer’s recommendations. To 
eliminate the contamination with genomic DNA, a DNase digestion was performed for 15 
min. First-strand cDNA was synthesized at 37°C by M-MLV reverse transcriptase 
(Invitrogen, France). With the aim of testing the primers, PCR amplification reactions of 
TNF-α, 18S and GAPDH were carried out using a pool of cDNA (see the primers sequences 
below). Cycling conditions were: initial denaturation at 94°C for 5 min, followed by 50 cycles 
consisting of a 30 s denaturation at 94°C, a 30 s annealing at 59°C and a 45 s elongation at 
72◦C. PCR products were analyzed after migration in a 1% agarose gel with 0.01 µg/ml 
ethidium bromide using the Gel Doc analyzer (Biorad, France).  
 
TNF-α C1 (couple 1)  
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F1 : AAG CCT GTA GCC CAC GTC G TA GCA,  
R1: GCA GCC TTG TCC CTT GAA GAG AAC CT) 
TNF-α C2 (couple 2) 
F2: CGG GGT GAT CGG TCC CCA AAG 
R2: GGA GGG CGT TGG CGC GCT GG 
18S 
F: GTG GAG CGA TTT GTC TGG TTA,  
R: CGG ACA TCT AAG GGC ATCA 
GAPDH 
F: CTT CAC CAC CAT GGA GAA GGC 
R: GGC ATG GAC TGT GGT CAT GAG. 
IV-2-8. Measurement of gene expression by real time PCR (Q-PCR) 
Real-time quantitative PCR amplifications were carried out in a Light Cycler 480 detection 
system (Roche, France), using the Light Cycler Fast Start DNA Master plus SYBR Green I 
kit (Roche). The mRNA transcript level of TNF-α was normalized with the housekeeping 
gene GAPDH because its expression is not modified in our conditions. Gene expressions of 
TNF-α were quantified using the absolute quantification method (n= 4). Cycling conditions 
were: initial denaturation at 94 °C for 5 min, followed by 50 cycles consisting of a 10 s 
denaturation at 94 °C, a 15 s annealing at 59 °C and a 15 s elongation at 72 °C. Then, a 
melting curve was obtained for each sample by increasing the temperature from 59 °C to 97 
°C at a rate of 0.11 °C /s. The results were analyzed using the absolute quantification with 
arbitrary values. For this purpose, a standard curve was carried out for each target and 
reference gene. Primer efficiencies were calculated in each experiment from the standard 
curve carried out in the same plate as the quantified samples. For each sample, a ratio target 
gene/reference gene was calculated and compared with a calibrator point. This calibrator 
point was the cDNA obtained from the control samples at day 2 (without Il-10 treatment).  
The value 1 was given to the mean of ratios for the control samples (n= 4). Arbitrary values 
were then calculated for each condition by comparison with the value 1, using the ratios.  
 
IV-2-9. Effect of IL-10 on activated macrophages 
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IV-2-9-1. Dose and time dependent effect of IL-10 on mRNA levels of TNF-α  
IL-10 quantities produced by 3T3 fibroblasts during the 2D cell transfection experiments 
were diluted to a final IL-10 concentration of 0.1, 0.5 and 1.0 ng/mL in cell culture medium. 
Macrophages were seeded on plastic as introduced in IV-2-6. Control group was 
macrophages only treated with the LPS solutions at 0.1 or 1 µg.µL-1. The IL-10 solutions 
were added 1 h before or together with LPS. Then, TNF-α expression was quantified 1 h or 3 
h after LPS activation by real time PCR to determine the anti-inflammatory effect of IL-10.  
IV-2-9-2. Modulatory effect of IL-10 produced from nanocomposites on mRNA level of TNF-α 
Supernatants containing IL-10 produced from 3D nanocomposites (after cell transfection by 
free or SiNP associated PEI) were collected at day 2, 5 and 7. These supernatant were 
incubated with macrophages under the optimal condition determined in section IV-2-9-1. 
IV-2-10. Statistical Analysis. 
Results are presented as mean ± SD (standard deviation). Statistical significance was assessed 
using one way analysis of variance (ANOVA) followed by Tukey (compare all pairs of 
groups) or Dunnett (compare a control group with other groups) posthoc test. The level of 
significance in all statistical analyses was set at a probability of P < 0.05. Prism (Grahpad) 
software was used for all data analysis. 
IV-3 RESULTS AND DISCUSSION 
IV-3-1. Gel electrophoresis 
With a phIL-10:SiNP ratio  of 1:30 (w/w), full inhibition of the plasmid migration was 
achieved for both PEI25-SiNP and PEI10-SiNP (Figure IV-1) The phIL-10 complexation 
abilities of the particles were similar to those observed for pGLuc, as expected from the 
similarity of their size (ca. 5 Kbp). 
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Figure IV-1. Agarose gel electrophoresis of phIL-10 complexation by PEI25-SiNP and PEI10-
SiNP. A constant amount of DNA was complexed with silica particles at different weight 
ratios 1:10, 1:20, 1:30 and 1:50. 
IV-3-2. Production of hIL-10 by 3T3 fibroblasts transfected in 2D 
The quantification of hIL-10 in the culture media evidenced that the PEI-loaded silica 
nanoparticles complexed with phIL-10 were able to transfect 3T3 fibroblasts (Figure IV-2). 
These systems permitted a sustained expression of the phIL-10, the synthesis and the 
secretion of the associated cytokine. The profile of transfection resembled that observed for 
pGLuc, i.e. the free form of PEI25 exhibited the best abilities to induce IL-10 expression. 
However, compared to pGLuc, the variations between the different systems were smaller. The 
production of IL-10 after transfection with PEI10-SiNP represented 40 % of the quantity 
produced by 3T3 cells after transfection with free PEI25. However, such a comparison should 
be taken with care as luciferase quantification is based on the monitoring of its enzymatic 
activity via the generation of luminescent molecules. Since one enzyme can degrade several 
substrates, the resulting signal is amplified compared to the direct quantification of IL-10 
proteins. 
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Figure IV-2 Transfection of 3T3 mouse fibroblasts after 4 h incubation with free or PEIx-
SiNP complexed with phIL-10 (n = 3). Variance of the hIL-10 expression among groups 
PEI10, PEI25-SiNP, PEI10-SiNP was determined by one-way ANOVA with Tukey posthoc test 
(*P < 0.05, ** P < 0.01, ** P < 0.001). 
Therefore, the results obtained with phIL-10 provide a more realistic view of the 
transfection capabilities of the vectors. Interestingly, the IL-10 production obtained with 
PEI10-SiNP is 2 and 3 times higher than that with PEI25-SiNP and free PEI10, respectively. 
Once again the cell transfection and the biomolecule synthesis were not associated with any 
cytotoxicity (Figure IV-3). It has been shown in Chapter II that PEI25 was toxic for doses 
equal or higher than 5-10 µg.mL-1 on 3T3 cells. In contrast, PEI25 and PEI10 were not toxic at 
100 µg.mL-1 when they were associated with SiNPs. Hence, it should be possible to 
counterbalance the lower ability of PEI10-SiNP to produce IL-10 by using higher doses than 
PEI25 
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Figure IV-3 Cell viability of 3T3T mouse fibroblasts after 4 h incubation and 44 h 
transfection as evaluated with Alamar Blue test and calculated as the percentage of the control 
(n=3). 
IV-3-3.Production of hIL-10 from SiNP-Collagen Nanocomposites 
The ability of 3T3 cells to produce IL-10 was evaluated in a 3D context after cell 
encapsulation within a collagen hydrogel to form nanocomposites. Unlike the nanocomposites 
made with pGLuc, the synthesis of IL-10 was already detectable from day 2 regardless of the 
transfection system used (Figure IV-4). The cell transfection was not associated with any 
toxicity for the fibroblasts (Figure IV-5). The IL-10 synthesis reached a maximum at day 5 
with concentrations comparable to those obtained in 2D conditions. This delay of synthesis 
could be attributed to the time for 3T3 cells to migrate within the collagen network and 
encounter transfection systems. The slight decrease of IL-10 concentration at day 7 could be 
due to the IL -10 instability in culture medium 17. 
 
Figure IV-4. Production of hIL-10 by 3T3 mouse fibroblasts encapsulated within silica-
collagen nanocomposites (n = 3). Variance of the IL-10 expression among groups 
PEI25−SiNP, PEI10−SiNP was determined by one-way ANOVA with Tukey posthoc test (*P 
< 0.05, ** P < 0.01). 
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Figure IV-5. Cell viability of 3T3 fibroblasts co-immobilized with phIL-10 complexes in 
collagen hydrogels after 7 days, as evaluated with Alamar Blue test and calculated as the 
percentage of the control (n=3). 
 
IV-3-4. Test of Primers 
The electrophoresis of the PCR products revealed the presence of intense bands for all the 
couples of primers tested (Figure IV-6). The PCR products had the appropriate size 
evidencing the efficiency and the specificity of the reaction. However, this specificity will be 
checked with the melting curve at the end of the real time PCR. For the further experiments, 
we decided to select TNF-α C1 and GAPDH as housekeeping gene.   
 
 
Figure IV-6 Agarose gel electrophoresis for cDNA after reverse transcription for TNF-α C2, 
GAPDH, 18 S and TNF-α C1. 
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IV-3-5. Activation of macrophages by LPS 
The ability of LPS to activate macrophages was evaluated by measuring the expression level 
of TNF-α, a marker of inflammation. In contact with a component of the bacterial outer 
membrane (LPS), macrophages adopt a pro-inflammatory phenotype called M1. Irrespective 
of the dose of LPS used in this experiment, the macrophage activation was maximal one hour 
after LPS addition (Figure IV-7). Then, the TNF-α amount decreased to reach a level closed 
to the basal value of control samples (without activation by LPS) after 6 hours. The value 1 
(one) was given to control samples and the expression of TNF-α was calculated by 
comparison with this basal level.  
 
Figure IV-7 The mRNA level of TNF-α at different time points, determined by qPCR and 
showed in the ratio compared with that of control group (n=2). Variance of the TNF-α 
expression among 1, 3 and 6 h was determined by one-way ANOVA with Tukey posthoc test. 
*P<0.05 
IV-3-6. Anti-inflammatory effect of the synthesized IL-10 in 2D 
Several doses of hIL-10 and different conditions were tested to analyze the effect of this 
cytokine on the TNF-α expression. hIL-10 was used to modulate inflammation because its 
sequence is close to that of mouse IL-10. In addition, it has been shown hIL-10 had an 
activity on mouse cells. The pre-treatment of macrophages with hIL-10 one hour before the 
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addition of LPS clearly impacted the effect of the biomolecule (Figure IV-8). The highest 
degrees of TNF-α downregulation were reached with the hIL-10 pre-treatment. In addition, 
the downregulation was dose-dependent regardless of the delay after LPS activation (1 or 3 
hours). The best results were obtained with an analysis one hour after activation and with IL-
10 pretreatment. The concentration of IL-10 at 0.1 ng.mL-1 inhibited the expression of the 
TNF-α gene by 25%. This inhibition reached 75% when a concentration of 1 ng.mL-1 was 
used. Therefore we decided to select these conditions for the further experiments in 3D with 
nanocomposites; i.e the IL-10 pre-treatment, LPS activation and analysis after 1 h. 
 
 
Figure IV-8 The mRNA level of TNF-α at different time points, determined by qPCR and 
showed in the ratio compared with that of control group. The number before “+” indicates the 
time (0 or 1 h) for pretreatment with IL-10 while the number after indicates incubation time 
for IL-10+LPS (n=3). Variance of the TNF-α expression among all the groups was 
determined by one-way ANOVA with Tukey posthoc test (*P < 0.05, ** P < 0.01, ** P < 
0.001). 
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IV-3-7. Effect of IL-10 produced from silica-collagen nanocomposites on activated 
macrophages 
Supernatants collected from nanocomposites were tested on activated macrophages seeded on 
plastic. The control used in this experiment was the activated macrophages, with the aim of 
analyzing the modulation of their activation. Taking into account the doses of IL-10 released 
from nanocomposites, the downregulation of the TNF-α gene was expected in every 
condition. Indeed, the concentrations of IL-10 produced by nanocomposites were always 
higher than 0.1 ng.mL-1 regardless of the type of transfection systems and the time point 
considered (day 2, 5 and 7). Surprisingly, the inhibition of the TNF-α expression was only 
observed with the PEI10-SiNP systems (Figure IV-9).  
 
Figure IV-9. The mRNA level of TNF-α at different time points, determined by qPCR and 
showed in the ratio compared with that of control group. Variance of the TNF-α expression 
level between control and PEI10-SiNP on 2, 5 and 7 d was determined by non-paired two 
tailed t test, ***P<0.001. 
These results are not logical in regards with our previous data. For instance, the high 
quantity of IL-10 produced with the free form of PEI25 should have dramatically 
downregulated the expression of pro-inflammatory molecules such as TNF-α. This shades 
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serious doubt about the validity of these experiments that will need. These results may be 
explained by the weak activation of macrophages. To verify this point, unactivated 
macrophages should be used as negative controls. Another possibility would lie in the 
unstability of IL-10 in the culture medium. The apparent in vivo half-life of i.p. injected IL-10 
was approximately 2 h in mice.16 Kenis et al studied stability of IL-10 in human serum, and 
the degradation of IL-10 was found both concentration and temperature dependant17. The 
serum concentration of IL-10 samples at 40oC was decreased to 70 % after 1 day’s storage. 
Therefore this point will need to be studied further. 
 
IV-4 CONCLUSIONS AND PERSPECTIVES 
In this study we have shown that collagen-silica nanocomposites are able to produce effective 
doses of IL-10 which inhibit the synthesis of pro-inflammatory cytokines. The system in 
which PEI10-SiNP:DNA complexes are immobilized give the best performance. As the 
secretion of Il-10 increases until day 5, the modulation of inflammation is time lapse 
dependent. As a consequence, nanocomposites could act as spatio-temporal gene delivery 
systems. The nanocomposites could slightly modulate the inflammation to permit the wound 
debridement by macrophages during the first days after the injury. In a second time, the 
inhibition would be more effective to switch towards the proliferative phase of tissue repair. 
Beyond its anti-inflammatory, the delivery of IL-10 is crucial for wound healing as this 
cytokine as an effect on the organization of the extracellular matrix (ECM). Indeed it has been 
shown that transgenic mice exhibited impaired scaring with fragile ECM 18. 
One possible step further in this study would rely on the design of a more complex 
fully 3D in vitro model. As a model of a chronic wound environment, macrophages may be 
encapsulated within a collagen gel and activated by LPS. Collagen-based nanocomposites 
incorporating fibroblasts and phIL-10-PEI-SiNP complexes can be applied onto this gel and 
their effect analyzed over one week. After transfection, fibroblasts would work as a bioreactor 
for the production of IL-10, that can act on macrophages to downregulate the expression of 
pro-inflammatory cytokines. As a consequence, pro-inflammatory macrophages may be 
differentiated into wound healing macrophages (Figure IV-10). 
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Figure IV-10. Towards a fully 3D model to study the ability of silica-collagen 
nanocomposites to modulate inflammation in a model of chronic wound.  
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CONCLUSIONS AND PERSPECTIVES 
 
The objective of this thesis was to develop a wound dressing made of collagen type I 
hydrogel and achieve co-delivery of cells and therapeutic genes to promote healing processes 
in chronic wounds. 
To this end, we first developed a non-viral gene delivery system based on silica 
nanoparticles (SiNP) by optimizing particle size, PEI molecular weight as well as PEI 
conjugation method to achieve a high transfection efficiency while reducing the cytotoxicity 
of PEI. Then, by co-encapsulating mouse fibroblasts and pDNA-PEI-SiNP complexes during 
gelation of collagen hydrogel, a cell factory was constructed for the sustained and localized 
gene delivery over one week.  
By carrying out experiments both in 2D and 3D configurations, we obtained some 
interesting findings for gene delivery systems with or without scaffold: 
1. Surface modification plays a more important role than size variation for efficient gene 
delivery by silica nanoparticles  
Particle size is an important parameter for cellular uptake and generally the ease for cellular 
internalization decrease with the increase of particles size. However, PEI-coated silica 
particles with size from 50 nm to 200 nm showed no significant variation in terms of cell 
tranfection. Furthermore, when 200 nm SiNP were modified with PEI of different MWs, 
different transfection efficiencies were obtained. Surpringly, SiNP coated with intermediate 
size polymers (10 kDa) achieved the highest transfection efficiency Moreover, when we 
modified particles of same size with -SO3 or -Cl before the introduction of PEI, significant 
difference in cell transfection were also observed. More specifically, the transfection of SiO2-
SO3@PEI particles was on order lower than that of SiO2@PEI while no protein expression 
was observed with the SiO2-Cl@PEI system. 
2. Conjugation mode of PEI on silica surface has noticeable impact on cell transfection 
Three methods, i.e. direct adsorption, adsorption mediated by–SO3, and covalent bonding were 
adopted to graft PEI on silica nanoparticles. These particles showed differences in particle 
distribution, PEI content, PEI conformation while sharing similar surface charge and 
closeDNA binding capacity. More importantly, significantly different transfection efficiency 
was obtained in the trend of SiNP@PEI > SiNP–SO3@PEI > SiNP–SO3@PEI. We have 
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proposed that the persistence of significant interactions between the silica surface and PEI in 
the acidic conditions of the endosomes can be detrimental to the intracellular trafficking of the 
plasmid, considering that PEI-DNA should be released from the particle for translocation into 
nucleus.  
3. Silica nanoparticles can alleviate cytotoxicity originating from PEI 
During this work, cytotoxicity studies were performed on mouse fibroblasts with different 
PEIs associated to several types of particles, in a wide range of doses. There is clear trend that 
cytotoxicity increases with the increase of PEI molecular weight, with PEI 25 kDa becoming 
detrimental at 10 µg/ml, PEI 10 kDa at 50 µg/ml while no toxic effect was found for PEI 1.8 
kDa even at 100 µg/ml. Meanwhile, pure particles and particles modified with –SO3 or –Cl 
exhibited no toxicity in the testing range. More interestingly, for all PEI-coated particles, cell 
viability was above 80% throughout all the tests. In conclusion, the association of PEI with 
silica nanoparticles can significantly reduce its cytotoxicity, allowing the increase of the doses 
that can be used for transfection experiments. 
4. Transfection efficiency and cytotoxicity differ among cell lines 
PEI-SiNP particles also showed the ability to transfect human cells, fibroblasts and 
keratinocytes, although to a lower extent than mouse fibroblasts. This difference in 
transfection efficiency was attributed to the lower proliferation rate of the primary cells. 
Furthermore, keratinocytes were more sensitive to PEI-coated particles, requiring to decrease 
the plasmid :particle weight ratio and therefore lowering the maximal transfection efficiency 
5. Silica-collagen nanocomposites can achieve localized and sustained gene delivery 
We have built three 3 D models to better understand the release mechanism from or within 
silica-collagen nanocomposites. Our results indicated that, once immobilized within the 
collagen gels, particles do not release complexed plasmids outside the material. Moreover, 
sustained gene delivery can also be achieved by adding complexes to pre-formed cellularized 
hydrogels. This illustrates that the method used to associate the complexes with the 3D matrix 
is a key factor for scaffold-based gene delivery system. In particular, the migration and 
proliferation of cells within the gel seem to be crucial to obtain an effective transfection. 
In addition, sustained expression of proteins from silica-collagen nanocomposites was 
detected for two plasmids, pGluc and phIL-10, over one week. Noticeably, in the case of 
pGluc, accumulative release of luciferase was presented as luciferase is a very stable protein 
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that can stand a relatively high temperature (37oC) over this period. For IL-10, only temporal 
concentration was shown as it undergoes rapid degradation in experimental conditions. 
6. Silica-collagen nanocomposites have the potential to co-deliver cells and therapeutic 
genes  
It was possible to achieve high levels of production of IL-10 by fibroblasts transfected by 
phIL-10-PEI-SiNP nanoparticles in 2D culture. The expressed protein showed a significant 
ability to reduce TNF-α mRNA levels in LPS-activated macrophages. The sustained release 
of IL-10 from the nanocomposites was also observed. Unfortunately our first evaluation of 
the anti-inflammatory effect of the released proteins was not conclusive and should be 
reproduced. In parallel, developing more realistic 3D models of wound tissues would allow to 
improve the relevance of our in vitro studies.    
Perspectives 
Although silica-nanocomposites exhibited desirable sustained gene delivery in preliminary 
studies, many challenges remain for clinical applications: First, a more efficient non-viral 
gene delivery system should be developed as our particles still exhibited lower transfection 
efficiency than free PEI 25 kDa. Therefore it would be interesting to change the nature of the 
grafted moiety, for instance introducing carboxylic acid groups, for more efficient cell 
transfection. Secondly, our hypothesis concerning PEI-DNA detachment from the particle 
surface has to be supported by further experiments. Mimicking the acidic environment of 
endosomes and neutral cytoplasm could allow to investigate the effect of pH variations on the 
intracellular fate of the vectors.  
From the point of view of applications, a more robust collagen hydrogel must be 
developed. In our study, the used collagen concentration was low, leading to materials that 
can be difficult to handle by surgeons. Increasing collagen concentration or introducing 
another biocompatible polymer could be further explored. However, it will be important to 
keep in mind that cellular proliferation and migration are key phenomena in the transfection 
process. As matrix stiffness is a stimulus for cell proliferation, designing dense matrices could 
favor the transfection 
Last but not least, the anti-inflammation properties of silica-collagen nanocomposites 
are still to be confirmed. The incorporation of other bioactive molecules, such as antibiotics, 
within the hydrogel and/or the silica particles may also be envisioned. This would allow to 
progress further towards a medicated dressing capable of delivering multiple therapeutical 
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agents, and therefore to address the many challenges currently faced to efficiently favor tissue 
repair. 
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Annex: List of abbreviations 
 
AAV Adeno-associated virus 
AV Adenovirus 
AS-ODN Anti-sense oligonucleotides 
Bcl-2 B cell lymphoma-2 
β-CD β-cyclodextrin 
CSF Colony-stimulating factor 
Cl-PTES Chloropropyltriethoxysilane  
CRISPR Clustered regularly interspaced short palindromic repeat 
DAPI 4’,6-diamidino-2-phenylindole dihydrochloride 
DC-cholesterol 3β-[N-(N',N'-dimethylaminoethane)-caramoyl] chelesterol 
DLS Dynamic light scattering 
DOGS Dioctadecylamidoglycylspermine 
DMEM Dulbecco’s Modified Eagle’s Medium 
DOPE Dioleoylphosphatidylethanolamine 
DOTAP 1,2-dioleoyl-3-trimethylammonium-propane 
DOTMA N-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium chloride 
DOX Doxorubicin 
ELISA Enzyme-linked immunosorbent assay 
ECM Extracellular matrix 
EGF Epidermal growth factor 
FGF Fibroblast growth factor 
FITC Fluorescein isothiocyanate 
GAM Gene activated matrix 
GM-CSF Granulocyte/macrophage colony-stimulating factor 
HIF-1α Hypoxia-inducible factor alpha 
IL Interleukin 
IGF-I Insulin-like growth factor-I 
KGF Keratinocyte growth factor 
LPS Lipopolysaccharides 
LPMSN Large pored mesoporous silica nanoparticle 
LV Lentivirus 
miRNA microRNA 
mRNA Messenger RNA 
MSN Mesoporous silica nanoparticle 
MPTMS 3-mercaptopropyltrimethoxysilane 
NF-κB Nuclear factor-κB 
NSN Nonporous silica nanoparticle 
nDNA Compacted DNA 
NMR Nuclear magnetic resonance 
NO Nitric oxide 
PAGA Poly [-(4-aminobutyl)-L-glycolic acid] 
PAMAM Polyamidoamine 
PCL Polycaprolactone 
PCR Polymerase chain reaction 
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PDGF Platelet-derived growth factor 
pDNA Plasmid DNA 
PEI Polyethylenimine 
PEG Polyethylene glycol 
PFA Paraformaldehyde 
pGluc Plasmid encoding secreted Gaussia luciferase 
PHEMA Poly(2-hydroxyethyl methacrylate) 
phIL-10 Plasmid encoding human interleukin-10 
PLGA poly(lactic-co-glycolic acid) 
PLL Poly-L-lysine 
PU Polyurethane 
PVA Poly(vinyl alcohol) 
PVP Polyvinylpyrrolidone 
rhPDGF Recombinant human platelet-derived growth factor 
RLU Relative lighte unit 
ROS Reactive oxygen species 
RV Retroviral 
SEM Scanning electron microscopy 
SiNP Silica nanoparticle 
siRNA Small interfering RNA 
TALEs Transcription activator-like effector nuclease 
TEM Transmission electron microscopy 
TEOS Tetraethyl orthosilicate  
TGA Thermogravimetric analysis 
TNF Tumor necrosis factor 
Tris-HCl Tris(hydroxymethyl)aminomethane hydrochloride 
VEGF Vascular endothelial growth factor 
XPS X-ray photoelectron spectroscopy 
ZFN Zinc-finger nuclease 
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Résumé. Ce travail concerne l’évaluation de nanoparticules de silice associées à la poly-
ethylèneimine (PEI) comme vecteurs de délivrance de gène pour le traitement des plaies 
chroniques de la peau. Des matériaux nanocomposites associant des complexes formés par 
l’association de ces particules hybrides et d’ADN avec des hydrogels de collagène colonisés 
par des fibroblastes 3T3 ont été élaborés. Grâce à la modulation de la taille de la particule et 
de la masse moléculaire du polymère, il a été possible de réaliser la transfection des 
fibroblastes au sein du gel, permettant l’expression génique pendant une semaine. Ces études 
montrent le rôle clé joué par la prolifération et la migration cellulaire sur l’efficacité de la 
transfection. L’efficacité de la transfection a ensuite été modulée en modifiant les interactions 
silice-PEI. Les résultats obtenus suggèrent que le détachement du complexe de la particule 
dans les endosomes est une étape clé de ce processus. La transfection de cellules humaines 
primaires  a aussi été étudiée en vue d’applications in vivo. La transfection a été observée 
avec des fibroblastes et des keratinocytes humains en culture et avec les fibroblastes au sein 
des gels, mais avec des efficacités moindres que pour les cellules 3T3. Ceci est attribué au 
plus faible taux de prolifération des cellules primaires. Enfin la capacité des nanocomposites à 
moduler l’inflammation a été testée sur des macrophages humains activés. Ces systèmes 
permettent la synthèse soutenue d’IL-10 par les fibroblastes et l’inhibition de l’expression de 
TNF-alpha chez les macrophages. 
 
Abstract. This work is devoted to the evaluation of silica nanoparticles associated to poly-
ethyleneimine (PEI) as vectors for gene therapy in the context of skin chronic wounds repair. 
Nanocomposite materials associating complexes formed by the association of these hybrid 
particles and DNA with collagen hydrogels cellularized with 3T3 fibroblasts have been 
prepared. Thank sto the modulation of particle size and polymer molecular weight, it has been 
possible to achieve fibroblast transfection within the gel, allowing for sustained protein 
expression over one week. These studies evidence the key role of cell proliferation and 
migration on transfection efficiency. The transfection process has been further modulated by 
modification of the silica-PEI interactions. The results suggest that the complex detachment 
from the particles within the endosomes is a key step in this process. The transfection of 
human primary cells has also been studied foreseeing in vivo applications. Human fibroblasts 
and keratinocytes have been successfully transfected in culture and, in the case of fibroblasts, 
within collagen hydrogels, but with lower efficiency than with 3T3 cells. This has been 
attributed to the lower proliferation rate of primary cells. Finally the ability of 
nanocomposites to modulate inflammation has been evaluated on activated human 
macrophages. These systems have allowed for the sustained production of IL-10 by 
fibroblasts and the inhibition of TNF-alpha expression by macrophages. 
 
 
